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 ... shake off all the fears of servile prejudices under which weak minds are servilely 
crouched. Fix reason firmly in her seat, and call to her tribunal for every fact, every opinion. 
Question with boldness even the existence of a god because, if there be one, he must more 
approve of the homage of reason than that of blindfolded fear. You will naturally examine 
first the religion of your own country. Read the bible then, as you would read Livy or 
Tacitus. The testimony of the writer weighs in their favor in one scale, and their not being 
against the laws of nature does not weigh against them. But those facts in the bible which 
contradict the laws of nature, must be examined with more care, and under a variety of 
faces. Here you must recur to the pretensions of the writer to inspiration from god. Examine 
upon what evidence his pretensions are founded, and whether that evidence is so strong as 
that it's [sic] falshood [sic] would be more improbable than a change of the laws of nature 
in the case he relates.... Do not be frightened from this enquiry by any fear of its [sic] 
consequences. If it ends in a belief that there is no god, you will find incitements to virtue in 
the comfort and pleasantness you feel in it's [sic] exercise, and the love of others which it 
will procure you. If you find reason to believe there is a god, a consciousness that you are 
acting under his eye, and that he approves you, will be a vast additional incitement. If that 
there be a future state, the hope of a happy existence in that increases the appetite to deserve 
it; if that Jesus was also a god, you will be comforted by a belief of his aid and love. In fine, I 
repeat that you must lay aside all prejudice on both sides, and neither believe nor reject any 
thing because any other person, or description of persons have rejected or believed it. Your 
own reason is the only oracle given you by heaven, and you are answerable not for the 
rightness but uprightness of the decision....  
 
 
(Thomas Jefferson, letter to his young nephew Peter Carr, August 10, 1787) 
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The Utilization of Enzymes in the Synthesis and Modification of Natural and Non-
Natural Compounds:  A Chemo-Enzymatic Approach to Enantiomerically Pure 
Compounds  
 
Jason A. Carr 
ABSTRACT 
  
The employment of enzymes and whole cells has been important in many industries 
for centuries. However, it is only in the last 30 years that the use of enzymes for the 
synthesis of high-value fine chemicals has enjoyed increasing popularity. In fact, esterases 
and lipases are used almost routinely these days to provide optically active building blocks 
for the construction of imaginative new routes to chiral target molecules. The major topic of 
this work describes the utilization of enzymes (namely lipases) in the synthesis and 
modification of natural and non-natural compounds.  
Chapter 1 outlines the strengths and weaknesses of the most widely used enzyme 
systems and a description of a brief summary on the state of the art of biotransformations 
with special emphasis on the general applicability and reliability of various reaction types is 
described. 
 Chapter 2 describes the enzymatic resolution of various 3-acetoxy-4-aryl-substituted 
azetidin-2-ones. Following screening of enzymes, such as Novozym-435, PS-30, PPL and 
AYS the best conditions were a phosphate buffer with PS-30 as the enzyme. The resulting 
products were the (3S, 4R)-3-hydroxy-4-aryl-substituted azetidin-2-ones and the unreacted  
xv 
(3R, 4S)-3-acetoxy-4-aryl-substituted azetidin-2-ones. Reactions generally occurred with 
high conversion and high selectivity.  
In Chapter 3, the regioselective transesterifications and hydrolysis of peracylated 
sophorolipid (SL) derivatives catalyzed by lipases was investigated.  It was confirmed from 
the detailed spectral analysis of the products that transesterification failed to furnish any free 
hydroxyls on the sophorose ring. Instead, transesterification took place on the methyl ester 
located at the carboxylic end of the 17-hydroxyoctadecenoic acid chain attached to the C-1′ 
position of the sophorose ring.  
In Chapter 4, the chemo-enzymatic syntheses of enantiomerically pure R and S 
imperanene from vanillin are described. The key step entails the asymmetrization of a 
prochiral diol using lipase PS-30. The resulting monoacetate has enantiomeric excesses of 
>97%. 
Biocatalysts represent a new class of chiral catalysts useful for a broad range of 
selective organic transformations. It is stating the obvious to say that biocatalysis is not a 
panacea for synthetic organic chemistry. However, advances over the past thirty years mean 
that it would be a serious mistake not to consider the employment of a biocatalyst, in, 
perhaps, the key step in a sequence of transformations that turn a cheap starting material into 
an expensive fine chemical. 
 
 
 
 
xvi 
CHAPTER ONE 
INTRODUCTION & BACKGROUND 
1.1 General Introduction 
The use of enzymes for the biotransformation of non-natural organic compounds 
is not at all new as they have been used for about a century 1. What has changed, 
however, is the objective; that is, ‘biocatalysis’ has evolved as a trend-setting segment of 
organic synthesis since the mid-eighties thus providing a powerful tool to the arsenal of 
modern organic synthesis. Whereas most of the early studies were directed towards the 
elucidation of biochemical pathways and enzyme mechanisms, the enormous potential 
for employing enzymes to transform non-natural organic compounds was only realized 
relatively recently, i.e. during the late 1980´s.  
 
Fig. 1-1 Annual publications on the biocatalytic transformation of non-natural organic 
compoundsa
                                                 
a Data obtained from database Faber, ~8000 entries (05/1997). 
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 As a result of this intense research, enzymes have been secured an important place in 
contemporary organic synthesis2-14. A testament to the importance of biocatalysis in 
synthetic organic chemistry is illustrated when an entire issue (Tetrahedron, Vol 60, Issue 
3, 2004) was dedicated to synthetic biocatalysis. 
Much of the early research was impeded by a tacitly accepted dogma which stated 
that enzymes are Nature´s own catalysts developed during evolution for the regulation of 
metabolic pathways. This narrow definition implied that man-made or non-natural 
organic compounds cannot be regarded as substrates. However, once this pedagogic 
problem was attacked by non-traditionalists15, it was quickly shown that the substrate 
tolerance of enzymes is much wider than believed. An impressive number of biocatalysts 
have been shown to possess a wide substrate tolerance by keeping their exquisite 
catalytic properties with respect to chemo-, regio- and, most importantly, enantio-
selectivity.16 For many of these enzymes, the natural substrates - if there are any - are not 
known. As a consequence, the frequency of use of a particular enzyme is not evenly 
distributed among the various types of biocatalysts but follows a pattern shown in Fig. 1-
2. Herein, a description of a brief summary on the state of the art of biotransformations17 
with special emphasis on the general applicability and reliability of various reaction types 
is described.     
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 Fig. 1-2 Frequency of use of enzymes in biotransformations; (i) Ester formation, -
aminolysis, -hydrolysis; (ii) ester hydrolysis; (iii) ester and amide hydrolysis, peptide 
synthesis; (iv) nitrile hydrolysis; (v) hydrolysis of epoxides, halogens, phosphates, 
glycosylation; (vi) reduction of aldehydes, ketones and enoates; (vii) biohydroxylation, 
sulfoxidation, epoxidation, Baeyer-Villiger oxidation, dihydroxylation; (viii) cyanohydrin 
formation, acyloin and aldol reaction; (ix) glycosyl transfer; (x) Claisen-type 
rearrangement, isomerization of carbohydrates, racemization and epimerization.  
 
 
1.2 Hydrolases 
Reactions catalyzed by various types of hydrolases are predominant among 
biotransformations. The lack of sensitive cofactors, which have to be recycled, makes 
them particularly attractive for organic synthesis. Consequently, they account for about 
two thirds of all reactions reported. In particular, reactions involving the cleavage (or 
formation) of an amide- or ester bond are most easy to perform by using lipases, esterases 
and proteases, respectively. Other types of hydrolysis reactions involving phosphate 
esters, epoxides, organo-halogens and nitriles are still hampered by a restricted 
availability of enzymes, but they hold great synthetic potential.  
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1.2.1 Lipases 
A large number of fat-cleaving enzymes - lipases - are produced on an industrial 
scale for applications in the food, detergent and fine chemical industry18. Due to their 
ready availability, they have enjoyed enormous use in the development of 
enantioselective hydrolysis and carboxyl esters formation19. Considering that the natural 
substrates for lipases - glycerides - possess a chiral alcohol moiety, it is reasonable to 
understand why lipases are synthetically useful for the resolution or asymmetrization of 
esters bearing a chiral alcohol moiety (Fig. 1-3).16c, 20 From the literature data available, 
the following broad-spectrum blueprint of lipase-substrates interface can be agreed upon: 
(i) optimal chiral recognition can be guaranteed if the stereogenic center is located as 
close as possible to the reaction site (i.e. the ester carbonyl group); (ii) The nature of both 
substituents R1 and R2 should differ in size and/or polarity2; (iii) The alkyl chain of the 
acid moiety (R3) should preferably possess a straight-chain nature at at least three to four 
carbon atoms3; (iv) The hydrogen atom must not be replaced by a substituent, since esters 
of tertiary alcohols and α,α,α-trisubstituted carboxylates are typically not accepted by 
lipases. (v) The stereochemical preference of the most commonly used lipases (e.g. from 
Pseudomonas and Candida spp.) for esters of secondary alcohols follows an empirical 
model generally referred to as 'Kazlauskas-rule' 21,22.  
                                                 
2 Heavily hydrated polar groups, such as carboxylate, amide or amine are not tolerated and they should be 
protected with a lipophilic unit. 
3 'Aactivated' esters bearing haloalkyl groups, e.g. Cl-CH2- and Cl-(CH2)2- for Type I and II may be used to 
improve reaction rates 
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 Enzyme 
Type 
Preferred 
Substrate Type 
R1, R2 R3 
Lipases Type I > Type II wide tolerance of 
(functionalized) alkyl 
and aryl; 
long-chain (> n-C3H7) 
Esterases 
and 
Proteases 
Type II > Type I different in size, not too 
polar. 
short-chain (CH3 > C2H5) 
 
Fig. 1-3 Substrate types for lipases, esterases or proteases 
 
The general guidelines described above can be successfully employed in resolving 
almost every secondary alcohol by lipase biocatalysis. Tthe stereochemical outcome (a 
'digital' decision) can be predicted with fair precision, whereas the stereoselectivity4 (i.e. 
an 'analog' value) is largely empirical. Despite an impressive effort in molecular 
                                                 
4 Usually expressed as the ratio of the relative rate constants of the enantiomers, the 'Enantiomeric Ratio' 
(E) (ref. 27). 
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modelling,23 attempts to develop reliable methods for the prediction of lipase-
stereoselectivity have failed so far.  
The high stability of lipases towards organic solvents makes them extremely 
useful for the reverse reaction, i.e. ester formation by condensation or (more 
advantageous) transesterification reactions24,25. Moreover, the use of non-natural 
nucleophiles in acyl-transfer reactions such as amines26, ammonia, hydrazine, oximes, 
and hydrogen peroxide allows the lipase-catalyzed aminolysis, ammonolysis27, 
hydrazinolysis28, oximolysis and perhydrolysis29 of esters giving rise to carboxamides, 
hydrazides, hydroxamic acids and peracids, respectively.  
Stereoselective variation on enzyme selectivity can be controlled by varying the 
solvent´s properties30. Given the fragility of enzymes, it may be anticipated that any 
solvent exerts a significant influence on the catalytic properties of an enzyme, such as 
reaction rate. For reactions performed in water, however, this is hardly possible, because 
its physicochemical properties are determined by Nature and can be altered only within a 
very narrow margin. An organic solvent may be chosen within certain limits5 from a wide 
arsenal having different properties such as dipole moment, water-solubility, straight-
chain or cyclic structure, flexibility and the ability to form hydrogen bonds31. Therefore, 
the stereoselectivity of an enzyme-catalyzed reaction in organic solvent is still a largely 
empirical task.  
Presently, lipases are continuously used for the generation of enantiomerically 
enriched primary and secondary alcohols. However, limitations with respect to the 
predictability of stereoselectivity will persist for some time.  
                                                 
5  From a number of methods to estimate the compatibility of an organic solvent ensuring sufficient enzyme 
activity, the log P-value has been shown to be most reliable. As a rule of thumb, an organic solvent 
having a log P of 1 should not deactivate a reasonably stable enzyme. 
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1.2.2 Esterases  
The large majority of esterase-catalyzed reactions have been performed by using 
porcine liver esterase (PLE)32. This enzyme has been widely used for the hydrolysis of 
Type II esters Fig. 1-3 with R3 being preferably methyl or ethyl, whilst Type I substrates 
(employed as the acetate esters) have been used to a lesser extent. In comparison to 
lipases, the applicability of PLE is significantly restricted to reactions performed in an 
aqueous medium, as PLE has been shown to exhibit low activity and erratic results with 
respect to stereoselectivity when placed in (nearly) anhydrous organic solvents6.  
Because of both the smaller availability and narrow operational range of esterases 
as compared to lipases, whole microbial cells have been used instead of isolated enzyme 
preparations33. Although some surprising highly selective transformations have been 
reported, this technique is of limited use because the nature of the active enzyme system 
is unknown and, as a consequence, optimization is a complicated task.  
The general rules for the substrate-construction for esterases are closely related to 
those for lipases (Fig. 1-3). However, R3 should preferably be a short-chain unit, leading 
to acetates (Type I). The number of commercially available esterases is small and their 
applicability in organic solvents is limited. Thus, the development of novel esterases from 
microbial sources is a worthwhile endeavour. 
 
1.2.3 Proteases  
Peptides have gained increasing attention due to their diverse biological activity. 
They may be used as sweeteners, antibiotics and chemotactic agents, as well as growth 
                                                 
6 This problem has been circumvented recently by using chemically modified PLE (ref. 35). 
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factors and they play an important role in hormone release by acting either as stimulators 
or inhibitors. The enzymatic hydrolysis of the carboxamide bond34 is naturally linked to 
amino acid and peptide chemistry and an increasing number of optically pure L-amino 
acids are produced on an industrial scale by an enzymatic method. The exquisite 
specificity of proteases for L-configured substrates turns into a drawback when the 
incorporation of D-amino acids is required.35 Attempts have been reported to 'weaken' the 
L-specificity of proteases by ‘solvent engineering’ or by enzyme-modification on the 
genetic level. The general rules for the substrate-construction for esterases and proteases 
are closely related to those for lipases (Fig. 1-3). However, R3 should preferably be a 
short-chain unit, leading to acetates (Type I) and methyl carboxylates (Type II), 
respectively. 
1.2.4 Epoxide Hydrolases  
Epoxides are versatile building blocks in synthetic organic chemistry. As a result 
of the ring strain, their susceptibility towards nucleophiles, oxidizing and reducing agents 
makes them versatile intermediates for the preparation of various complex molecules. 
Optically active epoxides have been synthesized by a variety of biotransformation 
reactions (Figure 1-4).
36,37a 
They can be prepared by direct epoxidation of alkenes using 
monooxygenases or peroxidases, by enantioselective hydrolysis using epoxide 
hydrolases37b, or by enantioselective nucleophilic ring opening using a haloalcohol 
dehalogenase or lipase.
38-42 
Optically active halohydrins, which are direct precursors of 
epoxides, have been prepared using haloalcohol dehalogenases, haloperoxidases, lipases 
or by microbial reduction of haloacetophenones.
43-45
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Figure 1-4. Biocatalytic preparation methods of optically active epoxides and 
chloroalcohols. 
 
The asymmetric hydrolysis of an epoxide provides access to chiral 1,2-diols and 
(in kinetic resolutions) also to enantiomerically enriched epoxides. Both of these 
materials are widely used as highly valuable intermediates7 for asymmetric synthesis46. In 
principle, the asymmetric biocatalytic hydrolysis of an epoxide may be conducted in 
various ways (Fig. 1-4): (i) Kinetic resolution provides the corresponding 1,2-diol and the 
residual substrate in 50% theoretical yield. (ii) Alternatively, enantioconvergent 
hydrolysis leads to the vicinal diol as the sole product in 100% theoretical yield. The 
latter transformation may be achieved by using (iia) two different biocatalysts possessing 
opposite enantio- and regio-selectivity47 or (iib) by using a bio- and chemo-catalytic step 
in a sequence48.  
 
7 Vicinal diols are employed as the corresponding cyclic sulfite or sulfate esters. 
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1.2.5 Phosphatases and Kinases  
Phosphate ester formation is of considerable importance because numerous 
bioactive agents display their highest activity only when they are transformed into 
phosphorylated analogues. Thus the phosphorylation of OH-groups at the expense of 
adenosine triphosphate (ATP) by using kinases has been developed to a great extent49.  
1.2.6 Dehalogenases and Halohydrin Epoxidases  
The replacement of halogen with hydroxyl in a formal hydrolysis reaction is catalyzed by 
dehalogenases8, 50 (Fig 1-4). Depending on the enzyme used, the reaction usually proceeds 
with inversion of configuration, e.g. L-α-chloropropionic acid yields D-lactate, and vice 
versa51. On the other hand, the formal elimination of hydrogen halide from a halohydrin 
under catalysis of a halohydrin epoxidase yields an epoxide. The bulk of research 
published so far has shown that these enzymes exhibit low enantio-selectivity in 
general52.  
1.3 Novel Techniques 
At present, the research goals within the area of biotransformations are 
undergoing a rapid change. The majority of biotransformations involving chiral 
molecules are performed with racemic substrates rather than prochiral or meso-forms9 - 
i.e. they constitute kinetic resolutions as opposed to asymmetrizations. The former, 
however, are impeded by several drawbacks such as (i) limited yield (50% of each 
enantiomer), (ii) reduced enantiomeric purity of substrate and product for kinetic reasons, 
                                                 
8 Dehalogenases are classified depending on their substrate type; for biotransformations, haloalkane 
dehalogenase and α-haloacid dehalogenase are most important. 
9 The ratio of kinetic resolution versus asymmetrization is about 4:1. 
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(iii) close reaction monitoring required, because the process has to be stopped at a certain 
point of conversion at (or near) 50% and (iv) separation of the product formed from 
unreacted substrate. All of these impediments are largely circumvented by using 
processes which lead to the formation of a single enantiomeric product. As a 
consequence, the theoretical yield is now 100% with optical purities being higher, the 
separation step is obsolete and monitoring can be simplified because the reaction can be 
run to completion. Such processes are, for instance, (i) dynamic resolutions and (ii) 
stereo-inversions (Fig. 1-5)53. Any kinetic resolution of a racemic starting material (R, S) 
following a classic profile can be converted into a dynamic process by adding one 
additional reaction - an in-situ-racemization of the substrate. While in classic resolutions 
the fast reacting enantiomer (e.g. R) is transformed into P leaving its enantiomer S 
behind, in a dynamic process S is converted to P via racemization. As a consequence, all 
of the starting material (R, S) is eventually transformed into P as the sole product. The 
dynamic resolution processes developed so far made use of racemization through 
chemical catalysis, but it can be expected that two-enzyme processes involving racemases 
are possible. The latter shows great potential, considering the greater compatibility of 
biocatalysts as opposed to the combination of chemo- and biocatalysis.   
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Fig. 1-5 Dynamic resolution and stereo-inversion processes. 
A particular reaction sequence leading to the formation of a single enantiomeric 
product makes use of an enantioselective stereoinversion53. Suppose that one enantiomer 
out of a racemic mixture is selectively inverted into its mirror-image counterpart, the final 
product is 100% of one enantiomer. This type of process has been exemplified with the 
stereoinversion of racemic secondary alcohols through a two-step oxidation-reduction 
sequence using microbial whole cells54. Although the actual nature of the enzymes and 
cofactors involved is not known at present, the chemical and optical yields achieved are 
impressive. It can be anticipated, that once the catalytic and thermodynamic details about 
this sequence are known, more synthetic applications will appear. The methodology 
concerning the application of enzymes in non-aqueous solvents with respect to enzyme 
activity is sufficiently understood as to be highly useful for organic chemists. Thus, the 
synthesis of esters, lactones, amides, peptides and peracids by using enzymes is standard 
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methodology. On the other hand, an understanding of the influence of the nature of the 
solvent on an enzyme´s selectivity is still in its infancy and we are far away from being 
able to provide rules of general applicability30. The same is true with regard to the 
understanding of the factors involved in substrate-binding where assistance will be given 
by means of molecular modelling55.  
1.4 Common Prejudices Against Enzymes 
In the bio-transformations of non-natural organic compounds the following 
prejudices are often encountered: 
– ‘Enzymes are sensitive’. This is certainly true for most enzymes but if certain 
precautions are met, enzymes are remarkably stable. Some are known to tolerate hostile 
environments such as temperature greater then 100oC and pressures beyond several 
hundred bar56-58.  
– ‘Enzymes are expensive’. Some enzymes are indeed expensive, but many are produced 
cheaply on a large scale. Considering their high catalytic power and the fact that they are 
recyclable10 most reasonably price crude enzyme preparations are adequate when 
compared to chemical catalysts.   
– ‘Enzymes are only active on their natural substrates’. Although this statement is 
certainly true for some enzymes, for the majority of them it’s false. Biocatalysts are 
capable of accepting non-natural substrates of an unrelated structural type by often 
exhibiting the same high specificities as for the natural counterparts.  
– ‘Enzymes work only in their natural environment’. Although it is generally true that 
enzymes display their highest catalytic activity in aqueous media, this is often not the 
                                                 
10 The overall efficiency of a process may be better even if a rather expensive enzyme is required. 
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solvent of choice for organic chemists. Providing certain guidelines are followed, 
enzymes can function in organic solvents. Although lower activity may be expected, 
other advantages can be accrued59-62.  
 
1.5 Advantages and Disadvantages of Biocatalysts 
1.5.1 Advantages of Biocatalysts 
– ‘Enzymes are very efficient catalysts’. Compared to their non-enzymatic reactions, 
enzyme-assisted processes are accelerated by a factor of 108-1010, far out seeding those of 
chemical catalysts. Consequently, whereas chemical catalysts are generally employed in 
concentrations of mole percentage 0.1-1%, enzymatic reactions can be performed at 
reasonable rates with mole percentage of 0.001-0.0001%. 
– ‘Enzymes are environmentally acceptable.’ Biocatalysts are environmentally benign 
reagents since they are completely degradable, unlike heavy metals.  
– ‘Enzymes act under mild conditions.’ Enzymes act in a pH range of about 5-8, typically 
around 7, and in a temperature range of 20-40oC, preferably around 30oC. This 
minimizes undesired side-reactions11 which often plague traditional methodology. 
– ‘Enzymes are compatible with each other63.’ Since enzymes normally function under 
similar conditions, biocatalytic reaction can be carried out in tandem making sequential 
reactions feasible in multienzyme synthetic methodology, particularly if isolation of 
unstable intermediates is not always possible. 
– ‘Enzymes are not bound to their natural role.’ Enzymes can tolerate a large variety of 
man-made unnatural substrates. Often, aqueous medium can sometimes be replaced by an 
organic solvent. 
                                                 
11 Side-reactions may include decomposition, isomerization, racemization and rearrangement. 
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– ‘Enzymes can catalyze a broad spectrum of reactions.’12 There’s an enzyme-catalyzed 
process equivalent to almost every type of organic reaction. For example, as have been 
previously described common examples range from: 
(i) Hydrolysis-synthesis of esters, amides, lactones, lactams, ethers, acid anhydrides, 
epoxides and nitriles. 
(ii) Oxidation-reduction of alkanes, alkenes, aromatics, alcohols, aldehydes and ketones, 
sulfides and sulfoxides. 
(iii) Addition-elimination of water, ammonia, hydrogen cyanide. 
(iv) Halogenation and dehalogenation, alkylation and dealkylation, carboxylation and 
decarboxylation, isomerization, acyloin and aldol reactions. Even Michael-additions, 
Diels-Alder and Claisen-rearrangement reactions have been reported.  
 Enzymes display three major types of selectivities: 
– Chemoselectivity. Since enzymes tend to act on a single type of functional group, other 
sensitive functionalities that are sensitive to chemical catalysis do survive. Thus, 
reactions tend to be cleaner and laborious purification can be largely omitted. 
– Regioselectivity and Diastereoselectivity. The complexity of an enzyme’s three 
dimensional structure affords an enzyme to distinguish between functional groups which 
are chemically situated in different regions of the same substrate molecule.64,65
– Enantioselectivity. Since almost all enzymes are made from L-amino acids, they are 
thus chiral catalysts. Consequently, chirality present within a substrate molecule is 
‘recognized’ upon enzyme-substrate complex formation. A prochiral substrate, as a 
consequence, may be transformed into an optically active product through 
                                                 
12 Enzymes can only accelerate a reaction, but they have no impact on the position of the thermodynamic 
equilibrium of the reaction. Thus, in principle, some enzyme-catalyzed reactions can be run in both 
directions. 
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asymmetrization and both enantiomers of a racemic substrate may react at different rates, 
affording a kinetic resolution. Collectively, these properties constitute the ‘specificity’ of 
an enzyme and represents its most important feature for selective and asymmetric 
exploitation. 13, 66 
 
1.5.2 Disadvantages of Biocatalysis 
There are certainly drawbacks to the use of biocatalysis: 
– ‘Enzymes are provided by Nature in only one enantiomeric form.’ Since there’s no 
general way of creating mirror-image enzymes, it is impossible to invert the chiral 
induction of a given enzymatic reaction by choosing the ‘other enantiomer’ of the 
biocatalyst, a strategy possible if chiral chemical catalysts are involved.  
– ‘Enzymes require narrow operation parameters.’ Working under mild reaction 
conditions can certainly have its drawback. For example, if a reaction has a narrow 
window of operation at a given pH and temperature, elevated temperature, extreme pH or 
even high salt concentration may deactivate the enzyme. Some enzymes, however, 
remain catalytically active even in ice.67
– ‘Enzymes display their highest catalytic activity in water.’ Enzymes display their 
highest catalytic activity in water, but the majority of organic compounds are only poorly 
soluble. Hence, shifting to an organic medium would be highly desirable, but some loss 
in activity is the opportunity cost in shifting the enzymatic reactions. 
– ‘Enzymes are bound to their natural cofactors.’ Although enzymes are extremely 
flexible in accepting non-natural substrates, they are almost exclusively bound to their 
natural cofactors. The majority of these ‘biological reagents’ are relatively unstable 
                                                 
13 It’s remarkable that this key feature was recognized by E. Fischer as long ago as 1898! 
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molecules and are prohibitively expensive when used in stoichiometric amounts. 
Unfortunately, they cannot be replaced by more economical man-made substitute.14
– ‘Enzymes are prone to inhibition phenomena.’ The efficiency of a reaction may be 
limited if the enzymatic reactions are prone to substrate or product inhibition. Whereas 
substrate inhibition can be circumvented easily by keeping substrate concentration low, 
product inhibition is a little more complicated. 
– ‘Enzymes may cause allergic reactions.’ Enzymes may cause allergic reactions but 
careful handling may minimize reaction. 
 
1.6 Summary and Outlook 
As the field of biocatalysis undergoes still fast development, it can be expected, 
that some of the limitations will be overcome in the near future by using novel 
(genetically engineered) enzymes and through the development of novel techniques.  
Despite tremendous efforts in the field of genetic engineering (such as site-directed 
mutagenesis) aimed at the development of enzymes possessing altered specificities it is 
clear that at this stage, screening for novel microorganisms and enzymes is much more 
likely to lead to a solution of a particular problem than painstaking modification of the 
enzyme.  
In summary, biocatalysts represent a new class of chiral catalysts useful for a 
broad range of selective organic transformations. Synthetic chemists capable of using this 
potential will have a clear advantage over those limited to non-biological methods in their 
ability to tackle the new generation of synthetic problems appearing at the interface 
between chemistry and biology. 
                                                 
14 Despite an impressive amount of progress, the recycling of cofactors is still not a trivial task. 
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CHAPTER TWO 
 
Lipase-Catalyzed Resolution of 4-Aryl-Substituted β-Lactams: Effect of Substitution on 
the 4-Aryl Ring 
 
2.1 General Introduction 
 
 The use of lipolytic enzymes, such as lipases, provides one of the most 
useful and versatile biocatalytic methods in asymmetric synthesis and resolution of 
organic substrates with high efficiency and selectivity.1-4 Lipases, in this regard, are 
excellent biocatalysts since they have the remarkable ability of assuming a variety of 
conformations to accommodate substrates of varying sizes and complexities.5-9  Above all 
lipases do not require the use of co-factors, can be recycled, and are effective under mild, 
environmentally benign conditions.  As a result of this broad substrate specificity and 
their distinctive stereopreferences, lipases have been used in numerous applications 
ranging from enantioselective syntheses to the resolution of racemic mixtures.5-9  
Stereoselective synthesis of enantiomerically pure compounds is required not only 
for clinical compounds but also for fine chemical industries and agrochemicals.  It is 
possible that an enantiomer in a racemic mixture may have detrimental side effects.  
Syntheses of such homochiral compounds, however, are often too difficult to obtain via 
conventional chemical synthetic methods. Recently we have reported the preparation of 
optically active substituted ε-caprolactones,10 versatile building blocks in organic 
synthesis, through lipase-catalyzed kinetic resolution in absence of added solvent.  In 
another report,11 we have described solventless stereoselective polymerizations of 
racemic substituted caprolactones catalyzed by Candida antarctica lipase.   
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The β-lactam (azetidin-2-one) is an interesting ring system found in penicillins, 
one of the most utilized antibacterials in clinical medicine.12,13  Moreover, β-lactams can 
be readily synthesized via the Staudinger reaction starting from an imine and an aldehyde 
(Scheme 2) and serve as chiral synthons in organic synthesis.13  For example, β-lactams 
have been used for assembly of the C-13 side chain in the anti-tumor drug paclitaxel,14 in 
the asymmetric synthesis of human leukocyte elastase inhibitors,15 and as key 
intermediates for penems and carbepenems.16  Recently, the stereocontrolled synthesis of 
monocyclic β-lactams has been an active area of chemical research owing to their utility 
as synthons for a variety of natural products14 and activity against MRSA bacterial 
strains.13  Since these compounds are interesting from chemical and pharmacological 
aspects, our goal was to study lipase catalyzed resolution of monocyclic β-lactams in 
order to obtain them in optically pure form.  The previous results on enzymatic resolution 
of racemic β-lactams have largely concentrated on resolution of N-hydroxymethylated 
derivatives17-22 via lipase catalyzed asymmetric acylation of the primary hydroxyl on the 
N-hydroxymethyl group or by the hydrolysis of their corresponding ester derivatives.17-22  
In a different approach, the β-lactam ring has been enantiospecifically hydrolyzed via 
enzymatic catalysis to the corresponding β-amino acid.23,24  This approach, however, 
results in loss of the β-lactam ring in the hydrolyzed enantiomer and would not be 
synthetically appealing especially if the hydrolyzed enantiomer is needed for subsequent 
synthetic transformations. In their quest to prepare the C-13 side chain of paclitaxel, 
Brieva et al.14 obtained enantiomerically enriched 3-hydroxy-4-phenyl-β-lactams 
derivatives via lipase-catalyzed hydrolysis and transesterification of racemic ester and 
alcohols, respectively.  These authors14 subjected three β-lactams with different 
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substituents (H-, PhCO-, and 4-CH3OPh-) on the ring nitrogen and observed that lipase-
catalyzed resolutions were influenced by the nature of the substituents on the lactam 
nitrogen.14 For example, introduction of the N-benzoyl substituent, an electron 
withdrawing group, caused the cleavage of the β-lactam ring in tert-butyl methyl ether in 
the presence of CH3OH as a nucleophile.14  
The goal in this study was to develop an enzyme system that invokes a resolution 
of the monocyclic β-lactams upon hydrolysis of its 3-acetoxy derivatives and to probe the 
effects of the nature of the lactam ring C-4 substituents on enzyme selectivity.  In this 
report kinetic enzymatic resolution of the 3-acetoxy derivatives was investigated as an 
attractive alternative to the classical salt resolution or the resolution of the N-
hydroxymethyl derivatives.25 The kinetic resolution led to quantitative yields and 
enantiomerically pure (>98% ee) β-lactams were thus prepared.  Importantly, the nature 
of the substituent on the C-4 position affected the enzymatic resolution to a great extent.  
Efforts to understand the effect of the C-4 substituent on the selectivity of the lipase 
catalyst are reported herein.  
 
 
2.2 Introduction to Azetidin-2-ones (β-lactams) 
 
 
Azetidin-2-ones and their derivatives, because of their diverse and interesting 
antibiotic activities,26-30 have occupied a central place among medicinally important 
compounds. With the discovery of Penicillin in 1928, new and novel synthetic methods 
have been developed toward the effort of synthesizing azetidin-2-one derivatives with 
novel biological properties. In fact, β-lactam antibiotics constitute over 60% of the 
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clinically valuable antibiotics today.31 For the synthetic organic chemist, the β-lactam 
ring holds a particular attraction. These four-membered, chiral heterocycles are present in 
many natural products and many homochiral, synthetic approaches have been developed. 
A testament to the biological and synthetic importance of β-lactams in organic chemistry 
was illustrated when an entire issue of Tetrahedron (2000, Issue 31, Vol. 56) was devoted 
to β-lactam chemistry. Reports attributing the therapeutic utility of azetidinones as agents 
to cholesterol absorption inhibitors32-35 and enzyme inhibitors36-37 are sure to give 
momentum to their therapeutic use other than antibiotics. 
 
2.3 General Synthesis of Azetidin-2-ones 
 The Staudinger’s ketene-imine reaction (Scheme 2-1) is the most common 
method for the synthesis of β-lactams38 and has been the subject of a recent review by 
Palomo et al.39 The reaction utilizes the use of an acid chloride and an imine (Schiff base) 
in the presence of a tertiary amine (typically triethylamine). A ketene is generated in situ 
from the β-elimination of the base and the acid chloride followed by a [2 + 2] 
cycloaddition reaction between the generated ketene and the imine. This results in the 
formation of up to four possible racemic diastereomers. 
 In cases where the acid halide was too unstable or difficult to prepare, carboxylic 
acid activating agents were employed like trifluoroacetic anhydride40, ethyl 
chloroformate41, p-toluenesulfonyl chloride42, phosphorous derived reagents43, 
Mukaiyama reagent44, cyanuric chloride45, and triphosgene46. 
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Scheme 2-1. The Staudinger Ketene-imine Reaction. 
 
  
2.3.1 Synthesis of 4-Aryl-Substituted β-Lactams (±1 - ±23) 
 Herein, the racemic 3-acetoxy-1,4-diaryl-azetidin-2-ones (±1 - ±23) were 
synthesized in a three-step reaction scheme as described previously13 starting with the 
acid-catalyzed Schiff base formation from the corresponding substituted benzaldehyde 
and para-methoxyaniline. The Schiff base was then reacted with acetoxyacetyl chloride 
and triethylamine in dichloromethane to yield the β-lactam (Scheme 2-2).  In all 
reactions, only one diastereoisomer possessing the C-3 acetoxy and C-4 aryl groups in the 
cis configuration was produced resulting in formation of (±) racemates. 
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Scheme 2-2.  General Synthesis of 4-Aryl-substituted β-lactams.  1 R = H; 2 C4 = (-CH=CH-
Ph); 3 C4 = (-C≡C-Ph); 4 C4 = (-C4H3S); 5 R = 4-OCH3; 6 R = 4-C (O) OCH3 7  R = 4-NO2; 
8 R = 3-NO2;  9 R = 4-CN; 10 R = 4-(CH3)2N; 11 R = 3-F; 12 R = 4-F;  13 R = 4-Cl; 14 R= 3-
Cl; 15 R = 2-Cl; 16 R = 2,4-di-Cl; 17 R = 2-Br; 18 R = 3-Br; 19 R= 2-I; 20 R = 4-Br; 21 R = 
4-CF3; 22 R = 4-C(CH3)3; 23 R = 4-CH(CH3)2. 
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2.4 Chemical Synthesis of Optically Enriched 3-Hydroxy-4-Aryl-cis-β-lactams 
 
 As stated, 3-hydroxy-4-aryl-cis-β-lactams have become important substrates as 
precursors for analogues of the taxol side chain and also as a source of enantiomerically 
pure α-hydroxy-β-amino acids which are present in numerous biologically important 
compounds. 47-49 To date, a number of enantioselective and diastereoselective syntheses 
have been developed in order to make available optically pure large scale quantities. 
 Shinkre et al50 has reported the use of a chiral auxiliary derived from (-)-
ephedrine (Scheme 2-3) toward the synthesis of enantiopure 3-hydroxy-4-aryl-cis-β-
lactams. (-)-Ephedrine was reacted with α-ketopropionoyl chloride or oxalyl chloride 
followed by Grignard addition to prepare a hemiketal of known stereochemistry. 
Subsequent alkylation with ethyl bromoacetate followed by base hydrolysis afforded the 
chiral acid which was reacted with triphosgene, an acid activator, and various imines in 
the presence of triethylamine. Refluxing the resulting compounds in THF with PTSA 
afforded the 3-hydroxy-4-aryl-cis-β-lactams. 
 In an effort to synthesize enantiomerically pure taxol C-13 side chain (N-benzoyl-
(2R,3S)-3-phenylisoserine), Ojima et al. successfully applied a lithium chiral ester 
enolate-imine cyclocondensation resulting in the synthesis of 3-hydroxy-4-aryl-β-lactams 
in good yield and with enantiomeric excesses of >96%.51 The reactions were carried out 
using a chiral lithium ester enolates, generated in situ from (silyloxy)acetates and N-
(trimethylsilyl)imines to give the corresponding chiral β-lactams (Scheme 2-3). 
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Scheme 2-3. β-lactam Formation from Lithium Chiral Ester Enolate-imine 
Cyclocondensation. 
 
 Fernandez et al. focused on the [2+2] cycloaddition of chiral aldehyde hydrazone 
to α-benzyloxyketene (Scheme 2-4) as an approach to the synthesis of enantioenrich 4-
alkyl(aryl)-3-hydroxy-β-lactams.52 Studies started with the reaction of proline-derived 
hydrazones 1a ± 5a with benzyloxyacetylchloride 6 which leads to the desired 
cycloadducts 7a ± 11a, respectively, in excellent yields (84 – 98%), even for compounds 
derived from easily enolizable substrates (Table 2-1, entries 1 – 4). Under optimized 
conditions (toluene, Et3N, 80oC for primary substrates, 100oC for secondary or aromatic 
substrates), moderate to good 3R, 4S/3S, 4R selectivities were found, and only traces of 
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trans isomers were detected in some cases. Nevertheless, the collected results were 
satisfactorily evaluated because the diastereomers could be separated easily in all cases, 
thus allowing the isolation of the optically pure major cis isomers (3R, 4S)-7a – (3R, 4S)-
11a in yields of 70 – 82%. 
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Scheme 2-4. [2+2] Cycloadditions of N,N-dialkylhydrazones to benzyloxyketene. 1: R= 
n-pentyl, 2: R= iBu, 3: R= PhCH2CH2 , 4: R= iPr, 5: R= Ph. Bn= benzyl. 
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Table 2-1. Synthesis of 1-N,N-dialkylamino-3-benzyloxyazetidin-2-ones 7a ± 11a, 
11b, and 8c. 
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The N-N bond cleavage, which is required to remove the auxiliaries, was successfully 
removed with magnesium monoperoxyphthalate (MMPP) to afford the deaminated 
lactams in high yields. 
In yet another synthesis, Georg et al reported the first synthesis of taxol 
derivatives with substituted phenyl rings at the C-13 N-benzoyl-( 2′R,3′S)-3′- 
phenylisoserine side chain of taxol.53 The synthesis of the novel phenylisoserine side 
chains was achieved through the asymmetric synthesis of 3-hydroxy-4-aryl-2-azetidinone 
 
derivatives via the ester enolate-imine cyclocondensation reaction (Scheme 2-5).  
cheme 2-5. Ester Enolate-imine Condensation of Optically Active Glycolates and N-
(trimethylsily1)imines. 
The N-trimethylsilyl aldimines are readily available from aldehydes and lithium 
bis(trim
not an exhaustive review of the synthesis 
of 3-hy
hydroxy-4-aryl-2-azetidinones as discussed below. 
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ethylsilyl)amide. The ester enolate cyclocondensation allows for the facile 
introduction of different substituents at the C-4 position of the β-lactam ring system. 
Thus, the methodology is very well suited for the synthesis of 3-phenylisoserine 
analogues with modified C-3 phenyl groups.53  
By all means, the above procedures are 
droxy-4-aryl-2-azetidinones. They do, however, form the basis of many common 
synthetic methodologies. Our method utilizes enzymes in the resolution of racemic 3-
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2.5 Lipase-Catalyzed Asymmetric Deacetylation of ±1 - ±23 
Our experiences with lipase catalyzed resolution of esters and lactones6 in 
etylation of the β-lactams 
in anhy
1 – (±)23, which were exposed to a 
series 
anhydrous organic solvents prompted investigation of the deac
drous solvents.  Pseudomonas fluorescens (AK), Porcine pancreatic lipase (PPL) 
and Candida antarctica (Novozym-435) lipases did not catalyze the transesterification 
reaction between the n-butanol and β-lactam acetoxy group in anhydrous tetrahydrofuran 
(THF), which we have previously found to be a solvent of choice for lipase catalyzed 
transesterifications.54 Pseudomonas cepacia (PS-30) lipase did catalyze the 
transesterification in anhydrous THF, however, deacetylation proceeded at an 
exceedingly slow rate and prolonged reaction times (> 6 days) were required for any 
reasonable substrate conversion. For example, hydrolysis of compound 7 in buffer (pH 
7.2) led to 50% conversion within 48 hours, while deacetylation in dry THF/ n-butanol 
gave only 35% substrate conversion after 6 days. 
The synthesis of the stereochemically pure β-lactam, therefore, was conceived via 
hydrolysis (Scheme 2-6) of the racemic acetates (±)
of lipases from different sources (PS-30, Novozym-435, AK, PPL) in aqueous 
buffer.  
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Scheme 2-6. Lipase-Catalyzed Asymmetric Deacetylation of 4-Aryl-substituted β-
lactams.   1 R = H; 2 C4 = (-CH=CH-Ph); 3 C4 = (-C≡C-Ph); 4 C4 = (-C4H3S); 5 R = 4-
OCH3; 6 R = 4-C (O) OCH3 7  R = 4-NO2; 8 R = 3-NO2;  9 R = 4-CN; 10 R = 4-(CH3)2N; 11 
R = 3-F; 12 R = 4-F;  13 R = 4-Cl; 14 R= 3-Cl; 15 R = 2-Cl; 16 R = 2,4-di-Cl; 17 R = 2-Br; 
18 R = 3-Br; 19 R= 2-I; 20 R = 4-Br; 21 R = 4-CF3; 22 R = 4-C(CH3)3; 23 R = 4-CH(CH3)2. 
 
Generally, microbial lipases exhibit pH optima ranging from 5.6-8.5 and at 
temperatures between 30-40 oC; we found that highest conversions were obtained in pH 
7.2 phosphate buffer at 25 oC. Of the enzymes screened, lipases Novozym-435, AK and 
PPL did catalyze the hydrolysis of the β-lactam acetates in buffer solution however long 
reaction times (>10 days) were required.  With Pseudomonas cepacia lipase (PS-30) 
reactions proceeded with moderate to excellent substrates conversion and hence it was 
identified as the most suitable biocatalyst for hydrolysis. Brieva14 et al also had 
previously described the lipase PS-30 as a suitable catalyst for enantioselective 
hydrolysis of the racemic 3-acetoxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one (1) in 
sodium phosphate buffer (pH 7.5).  For optimal production of the alcohols (-) 1a – (-) 23a 
(Scheme 2), water insoluble racemic acetates (±) 1 - (±) 23 were dissolved in a minimal 
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amount of acetone and dispersed in an aqueous phosphate medium (pH 7.2) at 25 oC.  
The reaction was initiated by addition of predetermined amounts of lipase PS-30.  The 
product alcohol and the unreacted acetate were extracted with ethyl acetate and separated 
readily by silica gel column chromatography (Table 2-2). Using a stepwise elution of 
ethyl acetate/petroleum ether (15:85) followed by ethyl acetate/petroleum ether (30:70), 
unreacted acetate and the alcohol were isolated in successive order. 
The enantiopurity of the unreacted acetates were calculated from their 1H-NMR 
spectra acquired in presence of (+)-Eu(hfc)3, a chiral shift reagent (Figure 2-1). The 
resonance signal of the acetoxy protons in the racemic mixture, a singlet in absence of the 
chiral shift reagent, was split into two signals of equal intensity for the two enantiomers 
in the presence of (+)-Eu(hfc)3.  The product alcohol was acetylated and enantiomeric 
purity was determined using (+)-Eu(hfc)3 in 1H-NMR experiments.  
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Table 2-2. Lipase PS-30 Catalyzed Hydrolysis of Substituted β-lactams (±)1 – (±)23. 
(3R, 4S)-acetoxy- (3S, 4R)-hydroxy-  
Substratea 
Convb 
(%) eesc %yieldd [α]D25e
 
E eepc % yieldd [α]D25e
-4-phenyl (1)   50 >99 71 +11.6 991057 98  -184.6
-4-(2-phenylethyenyl) (2)     
      
     
     
         
    
     
    
         
   
     
     
     
    
        
    
    
     
    
       
     
      
48 91 99 +59.6 1057 99 96 -348.0
-4-phenylethynyl (3) 48 >99 99 +149 1057 99 96 -353.0
-4-thiophen-2-yl (4)g 49 >99 88 +19.2 1057 99 98 -115.0
-4-(4-methoxyphenyl) (5) 50 >99 87 +16.7 1057 >99 95 -216.3
-4-(4-methoxycarbonylphenyl) (6)
 
50 >99 98 +43.3 1057 >99 95 -404.4
-4-(4-nitrophenyl) (7) 50 99 98 +56 1057 - 99 0
-4-(3-nitrophenyl) (8) 48 >99 84 +37.7 1057 99 96 -194.2
-4-(4-cyanophenyl) (9) 29 40 66f +15.1 295 99 60 -203.6
-4-(4-dimethylaminophenyl) (10)
 
39 71 80 +29.5 424 99 69 -175.4
-4-(3-fluorophenyl) (11) 50 >99 97 +13.3 1057 98 98 -328.0h 
-4-(4-fluorophenyl) (12) 50 >99 93 +2.2 1057 98 99 -203.9
-4-(4-chlorophenyl) (13) 50 >99 88 +21.5 1057 99 66 -208.2
-4-(3-chlorophenyl) (14) 49 >99 92 +12.5 1057 99 96 -338.0
-4-(2-chlorophenyl) (15) 35 56 90 +62.4 350 99 72 -284.7
-4-(2,4-dichlorophenyl) (16) 28 29 57f +20.1 264 99 48 -238.4
-4-(2-bromophenyl) (17) 36 64 85 +229.0 386 99 56 -187.0
-4-(3-bromophenyl) (18) 19 34 68f +4.7 277 99 46 -138.6
-4-(2-iodophenyl) (19) 21 15 68f +6.5 230 99 10 -153.1
-4-(4-bromophenyl) (20) 50 >99 98 +265 1057 >99 99 -174.4
-4-(4-trifluoromethylphenyl) (21)
 
50 >99 99 +196.5 1057 >99 98 -150.0h
-4-(4-tertbutylphenyl) (22) 17 10 80 +90.5 219 99 15 -183.5
-4-(4-isopropylphenyl) (23) 27 68 75 +194.5 407 99 25 -187.2
 
aRepresents the aryl substituents on the β-lactam ring.  bDetermined from 1H-NMR of crude product mixture after 48 h. 
cDetermined from 1H-NMR spectra in the presence of Eu(hfc)3, by integration of CH3C=O.  dYield 100% at 50% conversion. 
ec=0.01 (g/ml), CHCl3  f Yield 100% at 0% conversion. gconfiguration of unreacted substrate (3R,4R) and that of reacted 
substrate (3S, 4S). h c = 0.01 (g/ml), CH3OH. 
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Figure 2-1. a) 1H-NMR of Racemic 3-acetoxy-1-(4-methoxyphenyl)-4-phenyl-β-lactam 
with Eu(hfc)3.  b) 1H-NMR of unreacted (+) (3R, 4S)-3-acetoxy-1-(4-
methoxyphenyl)-4-phenyl-β-lactam with Eu(hfc)3. c) 1H-NMR of acetylated (-) 
(3R, 4S)-3-hydroxy-1-(4-methoxyphenyl)-4-phenyl-β-lactam with Eu(hfc)3 . 
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The activity of different lipases was greatly dependent upon its source, i.e., while 
lipases CALB (Novozym-435, immobilized form from Candida antarctica), AK (from 
Pseudomonas fluoresescens) and Porcine pancreatic lipase (PPL) showed little activity, 
the lipase PS-30 (from Pseudomonas cepacia) was highly efficient in buffer solution.  
The effect of the enzyme concentration on the substrate conversion was studied using a 
1:1 (w/w) and 2:1 (w/w) lactam 1 to lipase PS-30 ratio (Figure 2-2). The rate of acetate 
hydrolysis, as expected, was higher using more lipase in the reaction, for example 50 % 
conversion was achieved after 11 hours using 1:1 while more than 18 hours were required 
using 2:1 substrate to lipase ratios. For subsequent studies, a 1: 1 (w/w) substrate to lipase 
ratio was used (Table 2-2). 
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Figure 2-2. Variation in Substrate Conversion with Time using Lactam 1 to PS-30 ratio 
(w/w) of 1:1 (▲) and 2:1 (■). 
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To understand the effect of β-lactam ring substitution on hydrolytic activity of lipase PS-
30, twenty three β-lactam substrates with different substituents on C-4 were synthesized 
and subjected to lipase-catalyzed hydrolysis in phosphate buffer (pH 7.2).  The results of 
the Pseudomonas cepacia lipase-catalyzed hydrolysis after 48 hours are shown in Table 
2-2.  Even though lipase PS-30 accepted substituted β-lactam rings with phenyl (1), 
thiophen-2-yl (4), phenylethenyl (2), and phenylethynyl (3) at the C-4 position as 
substrates, the C-4 substituent on the β-lactam ring influenced the hydrolysis to a great 
extent and substrate conversions were greatly affected (Table 2-2). For all substrates, the 
lipase-catalyzed hydrolysis proceeded with high enantioselectivity towards the 3S 
enantiomer.  For example, in compound 1, prolonged reaction time (>72 h, not shown) 
beyond 50 % conversion did not result in hydrolysis of the 3R enantiomer (Figure 2) 
indicating that the enzymatic reaction proceeded with great efficiency as measured by 
enantioselectivity (E = 1057) and substrate conversion (~50%). The lipase 
enantioselectivity (E) values were determined from the following equation: E = ln[(1-
c)(1-ees)] / ln[(1-c)(1+ees)] where the ee = [(S)-(R)] / [(S)+(R)] * 100%.  The 
enantiomeric excesses were determined from 1H-NMR spectra recorded in presence of 
the (+)-[Eu(hfc)3] (Figure 2-1).  
To understand how the C-4 substituent affected lipase PS-30’s ability to hydrolyze 
the acetoxy group, a number of substrates that differ in the position, size, and electronic 
nature of substituent(s) on the C-4 phenyl ring were subjected to hydrolysis and substrate 
conversions were carefully monitored as a function of reaction time by 1H-NMR (Figure 
2-3). From figure 2-3, it is important to note that:    
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• The hydrolytic ability of the lipase PS-30, as illustrated by substrate conversion, 
was greatly affected by the substituent(s) on the C-4 aryl ring.  
• Substrates 6, 14, 13, 20 and 21 with electron withdrawing groups (EWG) on the 
aryl ring typically had quantitative conversions (~50 %) within 48 h, while 
compounds 5, 10, 22 and 23 with electron donating groups (EDG) had lower 
substrate conversions and more than 48 h were needed to achieve reasonable 
conversion (Figure 2-3 and Table 2-2).  
• Among the electron withdrawing groups screened, the position of the 
substituent(s) on the phenyl ring was of importance in realizing high conversion.  
In general, a group at the C-4′ position, i.e., further away form the lactam ring, on 
the phenyl moiety gave higher conversion.  For example, with C-4′ chloro (in 13) 
or bromo (in 20) substituents quantitative conversions were achieved but the C-2′ 
chloro (in 15) and bromo (in 17) analogs gave only 32 and 27 % substrate 
conversions, respectively, in 13 hours (Figure 3). In the case of compound 16 
having two chloro groups at C-4′ and C-2′, the substrate conversion were about 
32%, i.e., much lower than that in compound 13 with a C-4′ chloro substituent. 
• The size of a substituent on the C-4 phenyl ring was another important factor that 
affected substrate conversion. For an electron withdrawing group at C-4′ the 
conversion increased with increasing size (12<7<21<13<20), while for group at 
C2′ or C-3′ the conversion decreased with increasing size of the substituent 
(15<17<19).  For example, only 21 % substrate conversion in 48h was achieved 
for compound 19, with a large iodo group at C-2′, while 35 % substrate 
conversion was observed for compound 15 with chloro, a relatively smaller 
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group, at C-2′.  Compounds 15, 17, and 19 with chloro, bromo and iodo groups 
have decreased substrate conversion, which follow the order of their size 
(Cl<Br<I, Figure 2-3) or electronegativity (Cl>Br>I). For compounds with 
electron donating groups on the C-4 phenyl ring the substrate conversion 
decreased as the size of the substituent increased, ie., 4-tert-butyl < 4-isopropyl < 
4-N,N-dimethylamino < 4-methoxy < phenyl.  The lower substrate conversion in 
these substrates may be attributed to their steric bulkiness, which could result in 
van der Waals repulsive interactions in the enzyme active site. 
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Figure 2-3. Effect of C-4 Substitution on Substrate Conversion in PS-30 Catalyzed Hydrolysis. 
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• The dependence of the substrate conversion on the size and electronic nature of 
the C-4 substituent suggested that steric as well as electronic characteristic of the 
substrates drive the lipase PS-30 catalyzed hydrolysis.  
In compound 7, analysis of the 1H-NMR spectra (Figure 2-4) of the reaction mixture 
at 50 % conversion revealed that the product alcohol was a 1:1 racemic mixture of the cis 
and trans alcohols.  The reaction mixture was subjected to flash column chromatography 
to obtain the recovered (3R, 4S)-acetate (50 %, [α]D25 = +56o, %ee = 99), racemic-cis- 
alcohol (25 %, [α]D25 = 0o, % ee= 0), and racemic-trans-alcohol (25 %, [α]D25 = 0o, %ee= 
0) (Figure 2).  The formation of the cis- and trans- alcohols from a cis- actetate can only 
be explained via an unusual ring opening across the lactam C3-C4 bond to a benzylic 
carbanion (stabilized by the 4'-nitro group) that regenerates the lactam ring by attack on 
the planar carbonyl group resulting in formation of the racemic cis- and trans-3-hydroxy-
β-lactam derivatives upon double epimerization (Scheme 2-7).55 The observation that the 
recovered β-lactam derivative, i.e., (3R)-acetoxy-(4S)-(4-nitrophenyl) was optically 
active ([α]D25 = +112o) but the hydroxy compounds were not only racemic but a mixture 
of cis- and trans- stereoisomers suggested that the ring opening across the C3-C4 bond in 
the hydroxyl compound might involve a non enzymatic process. However, it was not 
obvious if the double epimerization involved an enzymatic process or was just a reaction 
artifact.  
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Figure 2-4. 1H-NMR Spectrum of the Crude Product Mixture form Lipase-Catalyzed      
Hydrolysis of 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-nitrophenyl)azetidin-2-
one (±)-7. 
 To uncover the role of enzyme in the epimerization process, 3-hydroxy-4-(4-
nitrophenyl)-1-(4-methoxyphenyl)azetidin-2-one was sought.  The compound 7, 
however, was stable to hydrolysis in phosphate buffer (pH 7.2) in the absence of the 
lipase, indicating that the hydrolysis observed in the presence of lipase indeed was an 
enzymatic process.  Several attempts to obtain the cis-hydroxy compound upon chemical 
hydrolysis of racemic cis-7 (Scheme 2-7) using K2CO3/acetone and K2CO3/ CH3OH at 
room temperature or 0oC led to the formation of the diastereomeric racemic cis- and 
trans- alcohols, suggesting that the epimerization of the hydroxy lactam (under basic 
conditions) was a chemical process.  Further, when the cis-3-hydroxy-4-(4-nitrophenyl)-
1-(4-methoxyphenyl)azetidin-2-one, isolated upon column chromatography from the cis-
/trans- mixture, was stirred in phosphate buffer (pH 7.2, without lipase) it rapidly led to 
an equilibrium mixture of the cis-/trans- hydroxy products.  To elucidate the role of 
buffer in this racemization reaction, we removed the buffer from the enzymatic reaction 
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and instead the lipase catalyzed deacetylation of 7 was carried out in dry THF/n-butanol.  
Though deacetylation in THF/n-butanol was slow, optically pure cis-hydroxy compound 
([α]D25 = -71.2o) and unreacted optically enriched (+)-cis-acetate were isolated after 6 
days.  The positive and negative sign of the optical rotation for the recovered acetate and 
the hydroxy product, respectively, established that the enantiopreference of the lipase PS 
remained unchanged between the buffer and the THF reaction media.  The optically pure 
(-)-cis-hydroxy compound was subsequently stirred in phosphate buffer, pH 7.4, in 
absence of lipase. The isolated compound was found to be racemic mixture of the cis- 
and trans- hydroxyl compounds.  The formation of the trans- isomer from the cis - 
isomer in absence of the lipase confirmed that the double epimerization was a result of a 
non-enzymatic reaction and that a free hydroxyl group was required for the double 
epimerization.  In light of these observations, it was concluded that (1) racemization of 
the product alcohol was an artifact and not a result of the enzymatic catalysis and (2) a 
non-enzymatic cleavage of the C3-C4 bond followed by ring closure involving double 
epimerization, it is believed, resulted in formation of a racemic, diastereomeric mixture 
of the hydroxyl products (Scheme 2-7).  
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Scheme 2-7. Schematic Representation of Different Chemical and Enzymatic Processes leading 
to the Double Epimerization of 3-Hydroxy-4-(4-nitrophenyl)azetidin-2-one.  
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2.6 Determination of Absolute Configuration 
 
The absolute configuration of the two enantiomers was determined by X-ray 
crystallography.  Single crystals suitable for x-ray crystallographic analysis were selected 
following examination under a microscope. Single-crystal x-ray diffraction data for the 
compound were collected on a Bruker-AXS SMART APEX/CCD diffractometer. 
Diffracted data were corrected for absorption using the SADABS program. Direct 
methods and the structure solution solved the structures and refinement was based on F2. 
All non-hydrogen atoms were refined with anisotropic displacement parameters whereas 
hydrogen atoms were placed in calculated positions and given isotropic U values based 
on the atom to which they are bonded. All crystallographic calculations were conducted 
with the SHELXTL 6.1 program package. 
For the crystal of (+)-(3R, 4S)-3-acetoxy-1-(4-methoxyphenyl)-4-phenylazetidin-
2-one, two molecules were found in each unit cell. The compound crystallizes in a 
monoclinic space group P2 (1), with cell dimensions a = 5.7617 (8) Å, b = 8.1159 (11) Å, 
c = 16.889 (2) Å. A total of 4910 unique reflection data were obtained to give a final R 
index [I > 2σ(I)] of 0.0466 and a flack parameter of 0.0 (9).  The results of the structure 
determination study confirmed the cis- (3R, 4S) configuration of the unreacted substrate, 
(+)-(3R, 4S)-3-acetoxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one (Figure 2-5). In the 
crystal of (+)-(3R, 4R)-3-acetoxy-1-(4-methoxyphenyl)-4-thiophen-2-ylazetidin-2-one, 
two molecules were found in each unit cell. The compound crystallized in a monoclinic 
space group P2 (1), with cell dimensions a = 5.3082 (10) Å, b = 8.4869 (16) Å, c = 
17.005 (3) Å. A total of 4638 unique reflection data were obtained to give a final R index 
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[I > 2σ(I)] of 0.0618 and flack parameter of 0.19(16).  The results of the structure 
determination study confirmed the cis- (3R, 4R) configuration (Figure 2-5). 
a)  b  
 
Figure 2-5. Ortep Plot for the X-ray structures (a) of (+)-(3R, 4S)-3-acetoxy-1-(4-
methoxyphenyl)- 4-phenylazetidin-2-one (1) and (b) (+)-(3R,4R)-3-acetoxy-1-
(4-methoxyphenyl)-4-thiophen-2-ylazetidin-2-one (4). 
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2.7  Stereopreference of the Lipase PS-30  
X-ray crystallographic data (Figure 2-5) collected using a single crystal of the 
unreacted enantiomer of the 4-phenyl (1) and 4-thiophen-2-yl (4) β-lactam supported the 
(S)- enantiopreference of the Pseudomonas cepacia lipase.  The data confirmed (3R, 4S) 
and (3R, 4R) as the absolute configurations for the unreacted enantiomer of 1 and 4, 
respectively.  Hence the reacted enantiomers must possess the (3S) absolute 
configurations.   
Modeling experiments56-58 have indicated that Pseudomonas cepacia has a 
stereochemical preference for the (R)-substrate over the (S)-substrate but its 
stereoselectivity seems to be dependent on the chemical nature and/or physical state of 
the substrate, as has been observed for other lipases.59 The stereopreference of the lipase 
PS-30 for the (3S, 4R) enantiomer was rationalized using a known active site model 
(Figure 2-6) for the lipase as described by Zuegg et al.56 While the hydrogen at the 
asymmetric center of both enantiomers is directed towards the same site (referred to as 
H-alignment), the medium sized group (the carbonyl function) and the large group (the 
phenyl attached to the C-4 stereogenic center) trade places. This allows the medium-sized 
group to fit into the smaller hydrophobic pocket in the favored enantiomer whereas the 
larger-sized group is made to accommodate the smaller hydrophobic pocket in the 
disfavored enantiomer.   
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Figure 2-6. Schematic representations of the orientation of favored (3S, 4R) and 
disfavored (3R, 4S) enantiomer in active site of the lipase PS-30. M = medium, L = large. 
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2.8 Experimental Methods and Materials 
Lipases PS-30 and AYS were generous gifts from Amano Enzymes, Novozym-
435 was donated by Novo Nordisk. 1H-NMR spectra were recorded on a Bruker 250 
MHz spectrometer and a Bruker 360 MHz spectrometer (Appendix A) in CDCl3 or 
CD3OD with TMS as the internal standard. Optical rotations were measured with an 
AutoPol-IV (Rudolph research analytical) automatic polarimeter. Elemental analysis was 
performed using a NC-2100 Soil Analyzer. Thin-layer chromatography (TLC) was 
performed on glass plates coated with 0.25mm thickness of silica-gel. All solvents were 
distilled prior to use and organic solvent extracts dried over Na2SO4. 
Single-crystal x-ray diffraction data for the compounds 1 and 4 were collected on 
a Bruker-AXS SMART APEX/CCD diffractometer using a Mo radiation source. 
Diffracted data were corrected for absorption using the SADABS program. 
Crystallographic data (excluding structure factors) for the structures in this paper have 
been deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication numbers CCDC 191837 & 191838. Copies of the data can be obtained, free 
of charge, on application to CCDC, 12 Union road, Cambridge CB2 1Ez, UK [Fax: 
+44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk]. 
 
2.8.1 General Procedure for Synthesis of Racemic 3-Acetoxy-4-arylazetidin-2-ones 
1-23 60
A solution of acetoxyacetyl chloride (7.30 mmol) in dry dichloromethane (12 ml) was 
added drop wise over 1 hr at room temperature to a mixture of the appropriately 
substituted Schiff base (8.76 mmol) and triethylamine (17.52 mmol) in dry 
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dichloromethane (18 ml). The reaction mixture was stirred for an additional hour at room 
temperature and was then washed with water (2 x 50 ml). The organic layer was 
separated and dried over sodium sulfate. Evaporation of the solvent followed by 
purification by column chromatography (dichloromethane/ ether, 9:1) afforded the 
desired product.  
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one (±) –114,60
With the procedure described above 1 was prepared as a white solid, mp 163 – 165oC 
(lit.60 158-160oC). 1H-NMR (250 MHz, CDCl3) δ (ppm): 1.67 (3H, s, CH3C=O), 3.75 
(3H, s, CH3O), 5.34 (1H, d, J = 4.84 Hz, 4H), 5.94 (1H, d, J = 4.85 Hz, 3H), 6.78-7.34 
(9H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 19.8, 55.5, 61.4, 77.3, 114.1, 114.4, 118.8, 
127.9, 128.5, 128.8, 130.3, 132.2, 156.6, 161.3, 169.3.  
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(2-phenylethyenyl)azetidin-2-one (±) –261
With the procedure described above 2 was prepared as a yellow solid, mp 138 – 140oC. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 2.07 (3H, s, CH3C=O), 3.77 (3H, s, CH3O), 4.94 
(1H, dd, J = 4.71, 2.98 Hz, 3H), 5.90 (1H, d, J = 4.92 Hz,  4H), 6.16 (1H, dd, J = 8.0, 
8.04 Hz, 5H), 6.80 (1H, d, J = 17.0 Hz,  6H), 6.83-7.43 (9H, m, Ph). 13C-NMR (62.5 
MHz, CDCl3): 20.3, 55.4, 60.1, 76.3, 114.1, 114.4, 118.7, 121.4, 126.7, 128.7, 130.6, 
135.5, 137.1, 156.6, 161.1, 169.5.  
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Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(phenylethynyl)azetidin-2-one (±) -3 
With the procedure described above 3 was prepared as a white solid, mp 94-96oC. 1H-
NMR (250 MHz, CDCl3) δ (ppm): 2.21 (3H, s, CH3C=O), 3.80 (3H, s, CH3O), 5.12 (1H, 
d, J = 4.67 Hz, 4H), 5.88 (1H, d, J = 4.66 Hz, 3H), 6.90-7.54 (9H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3): 20.3, 51.7, 55.3, 76.7, 81.0, 114.2, 118.7, 121.5, 128.3, 129.1, 130.0, 
132.0, 156.6, 161.1, 169.5. Anal calcd. for C20H17NO4.0.22H20: C, 70.78; H, 5.05; N, 
4.13. Found: C, 70.92; H, 5.06; N, 3.95. 
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(thiophen-2-yl)azetidin-2-one (±) –462
With the procedure described above 4 was prepared as a white solid, mp 148-149oC.  1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.87 (3H, s, CH3C=O), 3.76 (3H, s, CH3O), 5.62 (1H, 
d, J = 4.72 Hz, 4H), 5.96 (1H, d, J = 4.73 Hz, 3H), 6.80-7.38 (7H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3): 20.0, 55.4, 57.6, 114.4, 118.8, 126.8, 127.4, 128.4, 130.0, 135.6, 
156.7, 161.0, 169.3.  
 
Racemic 3-Acetoxy-1, 4-bis-(4-methoxyphenyl)azetidin-2-one (±) –561
With the procedure described above 5 was prepared as a white solid, mp 144-145oC.  1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.66 (3H, s, CH3C=O), 3.68 (3H, s, CH3O), 3.73 (3H, 
s, CH3O), 5.22 (1H, d, J = 4.78 Hz, 4H), 5.82 (1H, d, J = 4.78 Hz, 3H), 6.71-7.22 (8H, m, 
Ph). 13C-NMR (62.5 MHz, CDCl3): 19.9, 55.4, 61.1, 113.6, 113.9, 114.3, 118.8, 124.0, 
129.2, 130.3, 156.5, 159.9, 161.4, 169.3.  
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Racemic 3-Acetoxy-4-(4-methoxycarbonylphenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) 
- 6 
With the procedure described above 6 was prepared as a white solid, mp 151-152oC.  1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.62 (3H, s, CH3C=O), 3.68 (3H, s, CH3O), 3.85 (3H, 
s, CH3O), 5.32 (1H, d, J = 4.85 Hz, 4H), 5.89 (1H, d, J = 4.9 Hz, 3H), 6.72-7.97 (8H, m, 
Ph). 13C-NMR (62.5 MHz, CDCl3): 19.8, 52.3, 55.5, 61.1, 76.3, 114.5, 118.7, 127.9, 
129.7, 130.0, 130.6, 137.6, 156.7, 160.9, 166.5, 169.2. Anal calcd. for 
C20H19NO6.0.82H2O: C, 62.52; H, 4.98; N, 3.64. Found: C, 62.64; H, 4.99; N, 3.48. 
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-nitrophenyl)azetidin-2-one (±) –755
With the procedure described above 7 was prepared as a yellow solid, mp 162-164oC 
(lit.55 165oC).  1H-NMR (250 MHz, CDCl3) δ (ppm): 1.74 (3H, s, CH3C=O), 3.76 (3H, s, 
CH3O), 5.45 (1H, d, J = 4.93 Hz, 4H), 5.99 (1H, d, J = 4.93 Hz, 3H), 6.80-8.24 (8H, m, 
Ph). 13C-NMR (62.5 MHz, CDCl3): 19.9, 55.5, 60.6, 114.6, 118.6, 123.7, 128.9, 129.6, 
140.0, 148.2, 156.9, 160.6, 169.1.  
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(3-nitrophenyl)azetidin-2-one (±) -8 
With the procedure described above 8 was prepared as a brown solid, mp 89-91oC.  1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.73 (3H, s, CH3C=O), 3.76 (3H, s, CH3O), 5.45 (1H, 
d, J = 4.85 Hz, 4H), 5.99 (1H, d, J = 4.90 Hz, 3H), 6.80-8.24 (8H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3): 19.8, 55.3, 60.2, 76.3, 113.2, 114.3, 118.6, 122.9, 123.5, 129.6, 
133.8, 135.00, 148.3, 156.8, 160.6, 169.0. Anal calcd. for C18H16N2O6.0.75H2O: C, 
58.46; H, 4.36; N, 7.57. Found: C, 58.79; H, 4.39; N, 7.00. 
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Racemic 3-Acetoxy-4-(4-cyanophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -9 
With the procedure described above 9 was prepared as a yellow solid, mp 178-180oC. 1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.66 (3H, s, CH3C=O), 3.69 (3H, s, CH3O), 5.32 (1H, 
d, J = 4.88 Hz, 4H), 5.90 (1H, d, J = 4.9 Hz, 3H), 6.73-7.61 (8H, m, Ph). 13C-NMR (62.5 
MHz, CDCl3): 19.8, 55.5, 60.8, 76.4, 112.8, 114.6, 118.2, 118.6, 128.6, 129.7, 132.3, 
138.0, 156.9, 160.6, 169.1. Anal calcd. for C19H16N2O4.1.6H2O: C, 62.26; H, 4.39; N, 
7.64. Found: C, 62.83; H, 4.44; N, 6.87. 
 
Racemic 3-Acetoxy-4-(4-dimethylaminophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -
10. 
With the procedure described above 10 was prepared as a white solid, mp 198-199oC.  
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.67 (3H, s, CH3C=O), 2.88 (6H, s, N(CH3)2), 
3.67(3H, s, CH3O), 5.18 (1H, d, J = 5.11 Hz, 4H), 5.81 (1H, d, J = 5.11 Hz, 3H), 6.61-
7.24 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3) δ (ppm): 20.0, 40.6, 55.4, 61.4, 112.9, 
114.3, 118.9, 129.0, 130.5, 156.4, 161.6, 169.4. Anal calcd. for C20H22N2O4.2.75H20: C, 
59.45; H, 5.49; N, 6.93. Found: C, 60.35; H, 5.57; N, 5.71. 
 
Racemic 3-Acetoxy-4-(3-fluorophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -11 
With the procedure described above 11 was prepared as a white solid, mp 166-167oC.  
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.67 (3H, s, CH3C=O), 3.69 (3H, s, CH3O), 5.26 
(1H, d, J = 4.85 Hz, 4H), 5.88 (1H, d, J = 4.88 Hz, 3H), 6.73-7.22 (8H, m, Ph). 13C-
NMR (62.5 MHz, CDCl3): 19.8, 55.4, 60.8, 76.2, 114.5, 114.7, 115.6, 116.0, 118.7, 
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123.6, 130.0, 135.0, 135.2, 156.7, 160.7, 161.0, 164.7, 169.2. Anal calcd. for 
C18H16FNO4.0.7H2O: C, 63.12; H, 4.71; N, 4.09. Found: C, 63.29; H, 4.39; N, 3.98. 
 
Racemic 3-Acetoxy-4-(4-fluorophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) –1260
With the procedure described above 12 was prepared as a yellow solid, mp 136 oC (lit.60 
136-137oC).  1H-NMR (250 MHz, CD3OD) δ (ppm): 1.60 (3H, s, CH3C=O), 3.62 (3H, s, 
CH3O), 5.39 (1H, d, J = 4.79 Hz, 4H), 5.84 (1H, d, J = 4.82 Hz, 3H), 6.73-7.24 (8H, m, 
Ph). 13C-NMR (62.5 MHz, CD3OD): 19.7, 55.9, 62.0, 77.7, 115.2, 115.5, 116.2, 116.5, 
120.1, 130.2, 131.4, 158.3, 163.3, 170.5.  
 
Racemic 3-Acetoxy-4-(4-chlorophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -13.  
With the procedure described above 13 was prepared as a white solid, mp 172-173oC.  
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.67 (3H, s, CH3C=O), 3.68(3H, s, CH3O), 5.25 
(1H, d, J = 4.81 Hz, 4H), 5.85 (1H, d, J = 4.82 Hz, 3H), 6.72-7.28 (8H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3) δ (ppm): 55.4, 58.8, 84.9, 114.4, 118.6, 127.0, 128.9, 129.5, 130.3, 
131.1, 133.2, 156.4, 163.6. Anal calcd. for C18H16ClNO4.1.25H20: C, 58.71; H, 4.38; N, 
3.80. Found: C, 57.50; H, 4.29; N, 3.35. 
 
Racemic 3-Acetoxy-4-(3-chlorophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -14 
With the procedure described above 14 was prepared as a yellow solid, mp 132-134oC. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.68 (3H, s, CH3C=O), 3.69 (3H, s, CH3O), 5.23 
(1H, d, J = 4.88 Hz, 4H), 5.87 (1H, d, J = 4.90 Hz, 3H), 6.73-7.25 (8H, m, Ph). 13C-
NMR (62.5 MHz, CDCl3): 19.8, 55.4, 60.8, 76.2, 114.2, 114.5, 118.7, 126.1, 127.9, 
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129.1, 130.0, 134.6, 156.7, 161.0, 169.2. Anal calcd. for C18H16ClNO4: C, 62.52; H, 4.66; 
N, 4.05. Found: C, 61.23; H, 4.56; N, 3.91. 
 
Racemic 3-Acetoxy-4-(2-chlorophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -15.  
With the procedure described above 15 was prepared as a yellow solid, mp 95-97oC.  1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.69 (3H, s, CH3C=O), 3.69(3H, s, CH3O), 5.71 (1H, 
d, J = 4.98 Hz, 4H), 6.09 (1H, d, J = 4.98 Hz, 3H), 6.74-7.38 (8H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3) δ (ppm): 19.9, 55.4, 58.2, 75.4, 114.5, 118.6, 126.8, 128.7, 129.8, 
130.0, 130.2, 133.8, 156.7, 161.4, 168.7. Anal calcd. for C18H16ClNO4.2.45H2O: C, 
55.45; H, 4.13; N, 3.59. Found: C, 51.82; H, 4.56; N, 3.56. 
 
Racemic 3-Acetoxy-4-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) –16 
With the procedure described above 16 was prepared as a white solid, mp 116-118oC.  
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.86 (3H, s, CH3C=O), 3.75 (3H, s, CH3O), 6.07 
(1H, d, J = 5.0 Hz, 4H), 6.21 (1H, d, J = 5.0 Hz, 3H), 6.80-7.43 (7H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3) δ (ppm): 20.0, 55.4, 57.8, 75.4, 114.5, 118.6, 127.2, 128.9, 129.7, 
134.6, 135.2, 156.8, 161.2, 168.7. Anal calcd. for C18H15Cl2NO4: C, 56.86; H, 3.98; N, 
3.68. Found: C, 56.51; H, 3.96; N, 3.57. 
 
Racemic 3-Acetoxy-4-(2-bromophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) –1763
With the procedure described above 17 was prepared as a white solid, mp 79-80oC.  1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.77 (3H, s, CH3C=O), 3.77 (3H, s, CH3O), 5.76 (1H, 
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d, J = 5.0 Hz, 4H), 6.19 (1H, d, J = 5.0 Hz, 3H), 6.81-7.64 (8H, m, Ph). 13C-NMR: 
114.2, 114.8, 118.7, 123.7, 127.3, 128.9, 130.0, 131.7, 133.1, 156.7, 161.4, 168.7. 
 
Racemic 3-Acetoxy-4-(3-bromophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) –1864
With the procedure described above 18 was prepared as a yellow solid, mp 150-152oC.  
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.75 (3H, s, CH3C=O), 3.76 (3H, s, CH3O), 5.29 
(1H, d, J = 4.86 Hz, 4H), 5.94 (1H, d, J = 4.86 Hz, 3H), 6.80-7.46 (8H, m, Ph). 13C-
NMR (62.5 MHz, CDCl3): 19.8, 55.4, 60.8, 76.2, 114.5, 118.7, 122.6, 126.6, 130.0, 
130.8, 132.1, 134.8, 156.7, 161.0, 169.1.  
 
Racemic 3-Acetoxy-4-(2-iodophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) -19 
With the procedure described above 19 was prepared as a white solid, mp 139-142oC.  
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.76 (3H, s, CH3C=O), 3.77 (3H, s, CH3O), 5.63 
(1H, d, J = 4.96 Hz, 4H), 6.18 (1H, d, J = 4.99 Hz 3H), 6.82-7.91 (8H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3): 20.0, 55.5, 65.4, 75.4, 98.8, 114.5, 118.7, 128.2, 128.6, 130.0, 130.3, 
134.5, 139.8, 156.7, 161.3, 168.7. Anal calcd. for C18H16INO4: C, 49.45; H, 3.69; N, 3.20. 
Found: C, 49.37; H, 3.68; N, 3.04. 
 
Racemic 3-Acetoxy-4-(4-bromophenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) –20 
With the procedure described above 20 was prepared as a white solid, mp 178-180oC. 1H-
NMR (360 MHz, CDCl3) δ (ppm): 1.76 (3H, s, CH3C=O), 3.78 (3H, s, CH3O), 5.30 (1H, 
d, J = 4.95 Hz, 4H), 5.92 (1H, d, J = 5.0 Hz, 3H), 6.80-7.51 (8H, m, Ph). 13C-NMR (62.5 
MHz, CDCl3): 19.9, 55.4, 60.9, 76.2, 114.5, 118.7, 122.9, 129.6, 130.0, 131.5, 131.7, 
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156.7, 161.0, 169.2. Anal calcd. for C18H16BrNO4: C, 55.40; H, 4.13; N, 3.59. Found: C, 
55.35; H, 4.07; N, 3.55. 
 
Racemic 3-Acetoxy-4-(4-trifluoromethylphenyl)-1-(4-methoxyphenyl)azetidin-2-one (±) –
21 
With the procedure described above 21 was prepared as a white solid, mp 154-156oC. 1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.70 (3H, s, CH3C=O), 3.76 (3H, s, CH3O), 5.40 (1H, 
d, J = 5.0 Hz, 4H), 5.97 (1H, d, J = 5.0 Hz, 3H), 6.80-7.66 (8H, m, Ph). 13C-NMR (62.5 
MHz, CDCl3): 19.7, 55.4, 60.8, 76.3, 114.5, 118.6, 125.4, 128.3, 129.8, 130.7, 136.6, 
156.7, 160.8, 169.1. Anal calcd. for C19H16F3NO4: C, 60.16; H, 4.25; N, 3.69. Found: C, 
60.14; H, 4.25; N, 3.74. 
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-tert-butyl phenyl)azetidin-2-one (±) –22 
With the procedure described above 22 was prepared as a white solid, mp 175 – 177oC. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.22 (9H, s, C(CH3)3), 1.56 (3H, s, CH3C=O), 3.68 
(3H, s, CH3O), 5.24 (1H, d, J = 4.8 Hz, 4H), 5.84 (1H, d, J = 4.8 Hz, 3H), 6.72-7.29 (8H, 
m, Ph). 13C-NMR (62.5 MHz, CDCl3): 19.7, 31.2, 34.6, 55.4, 61.2, 114.3, 118.8, 125.3, 
127.6, 129.1, 130.3, 151.9, 156.5, 161.3, 169.3. Anal calcd. for C22H25NO4: C, 71.91; H, 
6.86; N, 3.81. Found: C, 71.85; H, 6.72; N, 3.74. 
 
Racemic 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-isopropylphenyl)azetidin-2-one (±) –23 
With the procedure described above 23 was prepared as a white solid, mp 131 – 133oC. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.15 (6H, d, J = 7 Hz, CH(CH3)2), 1.58 (3H, s, 
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CH3C=O), 2.82 (1H, sep., J = 6.9 Hz, CH(CH3)3), 3.68 (3H, s, CH3O), 5.24 (1H, d, J = 
4.83 Hz, 4H), 5.84 (1H, d, J = 4.83 Hz,3H), 6.72-7.24 (8H, m, Ph). 13C-NMR (62.5 MHz, 
CDCl3): 19.7, 23.9, 33.8, 55.4, 61.3, 114.3, 118.8, 126.5, 127.9, 129.4, 130.3, 149.6, 
156.5, 161.4, 169.2. Anal calcd. for C21H23NO4: C, 71.37; H, 6.56; N, 3.96. Found: C, 
71.30; H, 6.44; N, 3.85. 
 
2.8.2 General Procedure for Lipase-Catalyzed Hydrolysis of the Acetoxy β-Lactam 
The racemic 3-acetoxy β-lactam (1-23, 200 mg) was dissolved in acetone (5 ml) 
and then added to phosphate buffer (25 ml, pH 7.2) in a 50 ml round bottom flask. To this 
reaction mixture was added the enzyme catalyst (lipase PS-30, 100mg) and reaction flask 
was capped to prevent loss of co-solvent due to evaporation.  The reaction mixture was 
stirred at 25 oC and progress of the reaction was monitored via TLC until no further 
change was detected.  The products were isolated by extraction of the reaction mixture 
with ethyl acetate.  The crude product mixture was analyzed by 1H-NMR to determine 
the percent conversion.  The hydrolyzed product (the secondary alcohol) and the 
unreacted O-acetate were separated by column chromatography using a stepwise elution 
of ethyl acetate: petroleum ether (15:85) followed by ethyl acetate: petroleum ether 
(30:70).   
For monitoring substrate conversion with time, reactions were done in 20 mL 
scintillation vials using 1:1 ratio (w/w) of substrate to the lipase PS-30. After 
predetermined times, aliquot were withdrawn from the reaction, extracted with ethyl 
acetate, and the crude reaction product after evaporation of the solvent was analyzed by 
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1H-NMR spectroscopy to determine the substrate conversion. (See Appendix A for NMR 
spectra.)  
 
3-Hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one (-)-1a14
With the enzymatic hydrolysis procedure described above, the reaction of racemic 1 
afforded 1a as a white solid, mp 190-192oC (lit.60 210-212oC). 1H-NMR (250 MHz, 
CDCl3) δ (ppm): 3.76 (3H, s, CH3O), 5.16 (1H, d, J = 5.0 Hz, 4H), 5.27 (1H, d, J = 4.98 
Hz, 3H), 6.79-7.45 (9H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 55.4, 62.2, 77.2, 114.1, 
114.4, 118.8, 127.4, 129.0, 129.2, 130.4, 133.1, 156.4, 165.3. 
 
3-Hydroxy-1-(4-methoxyphenyl)-4-(2-phenylethyenyl)azetidin-2-one (-)-2a65
With the enzymatic hydrolysis procedure described above, the reaction of racemic 2 
afforded 2a as a white solid, mp 166-167oC (lit.65 157-160oC). 1H-NMR (250 MHz, 
CDCl3) δ (ppm): 3.74 (3H, s, CH3O), 4.38 (1H, bs, OH), 4.80 (1H, dd, J = 5.13, 2.73 Hz, 
3H), 5.13 (1H, d, J = 4.98 Hz, 4H), 6.41 (1H, dd, J = 8.0, 8.0 Hz, 5H), 6.81-6.84 (1H, d, J 
= 18.6 Hz, 6H), 6.76-7.44 (9H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 55.4, 61.6, 77.2, 
113.6, 114.0, 114.3, 114.6, 118.8, 123.0, 126.8, 128.6, 130.8, 135.8, 136.5, 156.4, 166.3. 
 
3-Hydroxy-1-(4-methoxyphenyl)-4-(phenylethynyl)azetidin-2-one (-)-3a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 3 
afforded 3a as a yellow solid, mp 170-171oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.66 
(3H, s, CH3O), 4.20 (1H, d, J = 4.95 Hz, 4H), 4.93 (1H, d, J = 4.70 Hz, 3H), 5.04 (1H, 
bs, OH), 6.66-7.42 (9H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 51.7, 55.3, 76.7, 81.0, 
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114.2, 118.7, 121.5, 128.3, 129.1, 130.0, 132.0, 156.6, 165.1. Anal calcd. for 
C18H15NO3.0.47H2O: C, 71.64; H, 5.01; N, 4.65. Found: C, 71.39; H, 4.99; N, 4.46. 
 
3-Hydroxy-1-(4-methoxyphenyl)-4-(thiophen-2-yl)azetidin-2-one (-)-4a34
With the enzymatic hydrolysis procedure described above, the reaction of racemic 4 
afforded 4a as a white solid, mp 189-191oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.76 
(3H, s, CH3O), 5.18 (1H, dd, J = 5.05 Hz, 4H), 5.51 (1H, d, J = 5.05 Hz, 3H), 6.80-7.38 
(7H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 55.4, 58.7, 114.4, 118.9, 126.6, 127.3, 127.6, 
130.2, 136.5, 156.5, 165.5.  
 
3-Hydroxy-1,4-bis-(4-methoxyphenyl)-azetidin-2-one  (-) 5a66
With the enzymatic hydrolysis procedure described above, the reaction of racemic 5 
afforded 5a as a white solid, mp 158-159oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.67 
(3H, s, CH3O), 3.72 (3H, s, CH3O), 5.07 (1H, d, J = 5.17 Hz, 4H), 5.13 (1H, d, J = 5.13 
Hz, 3H), 6.69-7.22 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 55.3, 61.9, 114.3, 114.4, 
114.6, 118.9, 124.8, 128.8, 130.5, 156.3, 159.9, 166.0.  
 
3-Hydroxy-4-(4-methoxycarbonylphenyl)-1-(4-methoxyphenyl)azetidin-2-one (-)-6a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 6 
afforded 6a as a white solid, mp 180-182 oC. 1H-NMR (250 MHz, CDCl3) δ (ppm): 3.67 
(3H, s, CH3O), 3.82 (3H, s, CH3O), 5.12 (1H, d, J = 4.53 Hz, 4H), 5.18 (1H, d, J = 4.9 
Hz, 3H), 6.71-7.97 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 52.1, 55.3, 62.3, 114.3, 
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118.7, 127.6, 129.7, 129.9, 130.2, 139.1, 156.4, 166.3, 166.9. Anal calcd. for 
C18H17NO5.0.96H2O: C, 62.75; H, 4.97; N, 4.07. Found: C, 62.03; H, 4.91; N, 3.62. 
 
Cis-3-Hydroxy-1-(4-methoxyphenyl)-4-(4-nitrophenyl)azetidin-2-one (±)-7a55
With the enzymatic hydrolysis procedure described above, the reaction of racemic 7 
afforded 7a as a yellow solid, mp 182-183 oC, ([α]D25 = 0o).  1H-NMR (250 MHz, 
CDCl3) δ (ppm): 3.65 (3H, s, CH3O), 5.22 (1H, d, J = 5.18 Hz, 4H), 5.26 (1H, d, J = 5.28 
Hz, 3H), 6.64-8.16 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 55.9, 63.4, 78.6, 115.2, 
115.8, 119.9, 124.5, 130.0, 131.7, 143.7, 149.2, 158.1, 167.7.  
 
Trans-3-Hydroxy-1-(4-methoxyphenyl)-4-(4-nitrophenyl)azetidin-2-one (±)-7b55
With the enzymatic hydrolysis procedure described above, the reaction of racemic 7 
afforded 7b as a yellow solid, mp 98-99oC, ([α]D25 = 0o).  1H-NMR (250 MHz, CD3OD) 
δ (ppm): 3.60 (3H, s, CH3O), 4.52 (1H, d, J = 1.52 Hz, 4H), 4.91 (1H, d, J = 1.40 Hz, 
3H), 6.69-8.13 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 55.9, 66.4, 85.2, 115.2, 
115.5, 120.3, 125.2, 128.4, 131.3, 145.6, 149.3, 158.2, 167.5.  
 
3-Hydroxy-1-(4-methoxyphenyl)-4-(3-nitrophenyl)azetidin-2-one (-)-8a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 8 
afforded 8a as a brown solid, mp 151-152oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.65 
(3H, s, CH3O), 4.70 (1H, bs, OH), 5.22 (2H, d, J = 5.13 Hz, 3H, 4H), 6.69-8.15 (8H, m, 
Ph). 13C-NMR (62.5 MHz, CDCl3): 55.4, 61.9, 144.5, 118.8, 122.9, 123.5, 129.7, 133.9, 
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136.0, 148.3, 156.7, 166.2. Anal calcd. for C16H14N2O5.0.37H2O: C, 59.88; H, 4.40; N, 
8.73. Found: C, 59.99; H, 4.41; N, 8.09. 
 
4-(4-Cyanophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one (-)-9a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 9 
afforded 9a as a white solid, mp 85-88 oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.69 
(3H, s, CH3O), 4.17 (1H, bs, OH), 5.20 (2H, s, 3H, 4H), 6.72-7.61 (8H, m, Ph). 13C-NMR 
(62.5 MHz, CDCl3): 55.5, 60.8, 77.2, 112.4, 114.5, 118.4, 118.7, 128.4, 129.8, 132.5, 
139.2, 156.8, 165.8. Anal calcd. for C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 
69.25; H, 4.55; N, 9.32. 
 
3-Hydroxy-4-(4-dimethylaminophenyl)-1-(4-methoxyphenyl)azetidin-2-one (-)-10a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 10 
afforded 10a as a brown solid, mp 187-190oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 
2.88 (6H, s, N(CH3)2), 3.67 (3H, s, CH3O), 5.02 (1H, d, J = 5.0 Hz, 4H), 5.11 (1H, d, J = 
5.0 Hz, 3H), 6.67-7.25 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3) δ (ppm): 40.5, 55.4, 
62.0, 112.9, 114.3, 118.9, 128.4, 130.7, 150.4, 156.2, 165.9. Anal calcd. for C18H20N2O3: 
C, 69.21; H, 6.45; N, 8.97. Found: C, 68.98; H, 6.43; N, 8.80. 
 
4-(3-Fluorophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one (-)-11a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 11 
afforded 11a as a white solid, mp 217-218oC. 1H-NMR (250 MHz, CDCl3/CD3OD) δ 
(ppm): 3.67 (3H, s, CH3O), 5.08 (1H, d, J = 4.88 Hz, 4H), 5.12 (1H, d, J = 5.05 Hz, 3H), 
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6.71-7.21 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3/CD3OD): 55.3, 61.1, 76.8, 114.3, 
114.7, 115.1, 115.4, 118.7, 123.2, 130.2, 136.3, 136.4, 156.3, 166.4. Anal calcd. for 
C19H16FNO3: C, 66.89; H, 4.91; N, 4.88. Found: C, 66.43; H, 4.88; N, 4.58. 
 
4-(4-Fluorophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one   (-)-12a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 12 
afforded 12a as a yellow solid, mp 163-166oC.  1H-NMR (250 MHz, CDCl3/CD3OD) δ 
(ppm): 3.69 (3H, s, CH3O), 6.16 (1H, d, J = 5.09 Hz, 4H), 6.23 (1H, d, J = 5.07 Hz, 3H), 
7.82-8.36 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3/CD3OD): 55.3, 62.0, 76.6, 114.6, 
115.3, 118.7, 129.3, 130.2, 156.3, 160.7, 164.6, 166.5. Anal calcd. for 
C19H16FNO3.5.84H2O: C, 48.96; H, 3.59; N, 3.57. Found: C, 43.65; H, 3.20; N, 3.02. 
 
4-(4-Chlorophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one   (-)-13a67.  
With the enzymatic hydrolysis procedure described above, the reaction of racemic 13 
afforded 13a as a white solid, mp 180-181oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.68 
(3H, s, CH3O), 5.13 (1H, d, J = 5.13 Hz, 4H), 5.16 (1H, d, J = 5.13 Hz, 3H), 6.71-7.31 
(8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3) δ (ppm): 55.4, 61.9, 114.4, 118.8, 129.0, 
129.1, 130.1, 131.8, 134.7, 156.6.  
 
4-(3-Chlorophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one   (-)-14a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 14 
afforded 14a as a white solid, mp 197-198oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.68 
(3H, s, CH3O), 5.12 (2H, s, 3H, 4H), 6.71-7.28 (8H, m, Ph). 13C-NMR (62.5 MHz, 
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CDCl3): 55.4, 62.0, 77.2, 114.2, 114.4, 118.8, 125.8, 127.7, 129.0, 130.1, 134.9, 135.6, 
156.6, 165.8. Anal calcd. for C16H14ClNO3.0.75H2O: C, 60.56; H, 4.45; N, 4.41. Found: 
C, 60.96; H, 4.48; N, 4.09. 
 
4-(2-Chlorophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one   (-)-15a.  
With the enzymatic hydrolysis procedure described above, the reaction of racemic 15 
afforded 15a as a brown solid, mp 214-217oC.  1H-NMR (250 MHz, CDCl3/CD3OD) δ 
(ppm): 3.69 (3H, s, CH3O), 5.19 (1H, d, J = 4.98 Hz, 4H), 5.53 (1H, d, J = 4.95 Hz, 3H), 
6.75-7.38 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3/CD3OD) δ (ppm): 55.1, 60.2, 114.2, 
118.5, 126.6, 128.2, 129.0, 129.3, 130.2, 131.3, 133.1, 156.2, 166.3. Anal calcd. for 
C16H14ClNO3.1.13H2O: C, 59.30; H, 4.36; N, 3.35. Found: C, 58.30; H, 4.28; N, 3.69. 
 
4-(2,4-Dichlorophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one   (-)-16a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 16 
afforded 16a as a brown solid, mp 181-183oC.  1H-NMR (250 MHz, CDCl3/CD3OD) δ 
(ppm): 3.70 (3H, s, CH3O), 5.19 (1H, d, J = 4.55 Hz, 4H), 5.49 (1H, d, J = 4.18 Hz, 3H), 
6.75-7.41 (7H, m, Ph). 13C-NMR (62.5 MHz, CDCl3/CD3OD) δ (ppm): 55.3, 59.8, 114.4, 
118.5, 127.1, 129.4, 130.1, 130.2, 134.0, 156.5. Anal calcd. for C16H13Cl2NO3: C, 56.82; 
H, 3.87; N, 4.14. Found: C, 56.75; H, 3.90; N, 4.05. 
 
4-(2-Bromophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one    (-)-17a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 17 
afforded 17a as a white solid, mp 205-206oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.69 
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(3H, s, CH3O), 5.32 (1H, d, J = 5.09 Hz, 4H), 5.56 (1H, d, J = 5.06 Hz, 3H), 6.74-7.53 
(8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 29.3, 55.1, 62.4, 114.1, 118.5, 127.1, 128.4, 
129.3, 130.2, 132.5, 132.8, 156.2, 166.3. Anal calcd. for C16H14BrNO3.0.23H2O: C, 
54.54; H, 4.00; N, 3.97. Found: C, 54.71; H, 4.01; N, 3.37. 
 
4-(3-Bromophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one    (-)-18a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 18 
afforded 18a as a yellow solid, mp 182-183oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 
3.68 (3H, s, CH3O), 5.11 (2H, s, 3H, 4H), 6.71-7.44 (8H, m, Ph). 13C-NMR (62.5 MHz, 
CDCl3): 55.4, 62.0, 77.2, 114.2, 114.5, 118.7, 118.9, 123.0, 126.2, 127.7, 130.1, 130.6, 
130.7, 131.9, 135.9, 156.6, 165.9. Anal calcd. for C16H14BrNO3: C, 55.15; H, 4.05; N, 
4.02. Found: C, 55.10; H, 4.00; N, 4.05. 
 
3-Hydroxy-4-(2-iodophenyl)-1-(4-methoxyphenyl)azetidin-2-one   (-)-19a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 19 
afforded 19a as a yellow solid, mp 78-80oC.  1H-NMR (250 MHz, CDCl3) δ (ppm): 3.69 
(3H, s, CH3O), 5.27 (1H, bs, 4H), 5.36 (1H, d, J = 5.01 Hz, 3H), 6.73-7.86 (8H, m, Ph). 
13C-NMR (62.5 MHz, CDCl3): 55.4, 66.5, 76.9, 98.2, 114.2, 114.5, 118.8, 128.4, 130.1, 
130.3, 135.5, 139.7, 156.5, 165.4. Anal calcd. for C16H14INO3: C, 48.63; H, 3.57; N, 3.54. 
Found: C, 43.65; H, 3.45; N, 3.50. 
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4-(4-Bromophenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one (-)-20a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 20 
afforded 20a as a pale yellow solid, mp 193-194oC. 1H-NMR (360 MHz, CDCl3) δ 
(ppm): 3.68 (3H, s, CH3O), 5.05 (2H, s, 3-H,4H), 6.62-7.46 (8H, dd, J = 7.1, 5.98 Hz 
Ph). 13C-NMR (62.5 MHz, CDCl3): 55.4, 61.9, 114.5, 118.8, 122.9, 129.3, 130.2, 132.1, 
132.4, 156.6, 165.6. Anal calcd. for C16H14BrNO3: C, 55.19; H, 4.05; N, 4.02. Found: C, 
55.02; H, 3.97; N, 3.99. 
 
4-(4-Trifluoromethylphenyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one (-)-21a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 21 
afforded 21a as a white solid, mp 220-223oC. 1H-NMR (250 MHz, CDCl3/CH3OH) δ 
(ppm): 3.66 (3H, s, CH3O), 5.10 (1H, d, 3-H), 5.17 (1H, d, 3H), 6.70-7.55 (8H, 2dd, Ph). 
13C-NMR (62.5 MHz, CDCl3): 55.2, 62.1, 76.8, 114.3, 118.6, 125.3, 128.0, 130.1, 138.0, 
156.4, 166.3. Anal calcd. for C17H14F3NO3: C, 60.54; H, 4.18; N, 4.15. Found: C, 60.32; 
H, 4.25; N, 4.10. 
 
3-Hydroxy-4-(4-tert-butylphenyl)-1-(4-methoxyphenyl)azetidin-2-one (-)-22a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 22 
afforded 22a as a white solid, mp 180-182oC. 1H-NMR (250 MHz, CDCl3) δ (ppm): 1.30 
(9H, s, C(CH3)3), 3.76 (3H, s, CH3O), 5.14 (1H, d, J = 5.03 Hz, 4H), 5.21 (1H, d, J = 5.05 
Hz, 3H), 6.79-7.41 (8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3): 30.8, 34.2, 55.0, 62.4, 
114.0, 118.6, 125.2, 127.1, 130.1, 130.3, 151.0, 156.1. Anal calcd. for C20H23NO3: C, 
73.82; H, 7.12; N, 4.30. Found: C, 73.74; H, 7.05; N, 4.19. 
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3-Hydroxy-4-(4-isopropylphenyl)-1-(4-methoxyphenyl)azetidin-2-one (-)-23a 
With the enzymatic hydrolysis procedure described above, the reaction of racemic 23 
afforded 23a as a white solid, mp 238-240oC. 1H-NMR (250 MHz, CDCl3) δ (ppm): 1.17 
(6H, d, J = 6.83 Hz, CH(CH3)2), 2.50 (1H, bs, OH), 2.83 (1H, sep., J = 6.85 Hz, 
CH(CH3)3), 3.68 (3H, s, CH3O), 5.07 (1H, bs, 4H), 5.17 (1H, d, J = 5 Hz, 3H), 6.71-7.24 
(8H, m, Ph). 13C-NMR (62.5 MHz, CDCl3/ CH3OH): 23.3, 33.5, 54.9, 62.5, 114.0, 118.6, 
126.3, 127.3, 130.3, 130.5, 148.7, 156.0, 166.5. Anal calcd. for C19H21NO3: C, 73.29; H, 
6.80; N, 4.50. Found: C, 73.15; H, 6.55; N, 4.40. 
 
 
2.8.3 Non-enzymatic Hydrolysis of Racemic cis-7.  
In a 50 mL round bottom flask, 200 mg of the racemic cis-7 was added to a 
suspension of potassium carbonate (100 mg) in 25 mL of methanol.  The reaction mixture 
was stirred for 15 minutes at 0oC.  The potassium carbonate was filtered off and the crude 
reaction mixture was isolated upon removal of methanol under reduced pressure. The 
crude mixture was analyzed from its 1H-NMR spectrum, which confirmed the formation 
of the diastereomeric racemic cis- and trans- alcohols 7a and 7b. 
 
2.8.4 Enzymatic Transesterification of Racemic cis-7. 
In a 50 mL round bottom flask, 100 mg of the racemic cis-7 was dissolved in dry 
THF (10 mL) to which 40 µL of n-butanol was added. To this reaction mixture, 100 mg 
PS-30 was added and the reaction was stirred at 40oC for 6 days. The reaction mixture 
was filtered through a bed of celite and the crude reaction mixture was analyzed by 1H-
NMR to determine its percent conversion. The hydrolyzed product (the secondary 
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alcohol, ee > 98 %, [α]D25 = -71.2o) and the enantioenriched O-acetate were separated by 
column chromatography using a stepwise elution of ethyl acetate: petroleum ether 
(20:80) followed by ethyl acetate: petroleum ether (50:50).   
 
2.8.5 Determination of the Enantiomeric Excess.   
The enantio-purity (the e.e. values) was determined from the 1H-NMR spectrum 
acquired on a Bruker 250-MHz NMR spectrometer in presence of (+)-[Eu(hfc)3, a chiral 
shift reagent.  The resonance signal of the acetoxy protons, a singlet in absence of the 
chiral shift reagent, was split into two signals of equal intensity for the two enantiomers 
in the racemic mixture.  The ratio of the intensity of the CH3C=O signal in the 1H-NMR 
spectra for the respective enantiomer was used to calculate the % enantiomeric excess.  
The % ee values for the hydrolyzed alcohols were also obtained using (+)-[Eu(hfc)3 as a 
chiral shift reagent after their acetylation with Ac2O/DMAP in dry THF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71
2.9 References 
 
1. Klibanov, A. M. Nature, 2001, 409, 241-246. 
2. Vulfson, E. N.; Halling, P. J.; Holland, H. L., Eds. Enzymes in nonaqueous solvents, 
in Methods in Biotechnology, vol. 15, Humana Press: New Jersey, 2001. 
3. Wolfenden, R.; Snider, M.J. Acc. Chem. Res. 2001, 34, 938-945. 
4. Drauz, K.; Waldmann, H., Eds. Enzyme catalysis in organic synthesis: A 
comprehensive handbook. VCH Verlag: Weinheim, 1995. 
5. Gandhi, N. N.; Patil, N. S.; Sawant, S.B.; Joshi, J.B.; Wangikar, P. P.; Mukesh, D. 
Cat. Rev.-Sci. Eng. 2000, 42, 439-480.   
6. Parmar, V.S.; Bisht, K. S.; Singh, A.; Jha, A. Proc. Indian Aca. Sci., Chem. Sci., 
1996, 108, 576-583.   
7. Bisht, K. S.; Parmar, V.S.; Crout, D.H.G. Tetrahedron Asymm. 1993, 4, 957-958. 
8. Bisht, K. S.; Tyagi, O. D.; Prasad, A. K.; Sharma, N. K.; Gupta, S.; Parmar, V. S. 
Bioorg. Med. Chem. 1994, 2(10), 1015-1020. 
9. Theil, F. Chem. Rev. 1995, 95, 2203. 
10. Kondaveti, L; Al-Azemi T.F.; Bisht, K.S. Tetrahedron Asymm. 2002, 13, 129-135. 
11. Al-Azemi, T.F.; Kondaveti, L.; Bisht, K.S. Macromolecules 2002, 35, 3380-3386. 
12. Hardman, J. G.; Limbird, L. E., eds. Goodman and Gillman’s the Pharmacological 
Basis of Therapeutics, 10th edition, McGraw-Hill: New York, 2001. 
13. Turos, E.; Konaklieva, M. I.; Ren, R. X.-F., Shi, H.; Gonzalez, J.; Dickey, S.; Lim, D. 
Tetrahedron, 2000, 56, 5571-5578.  Turos, E.; Long. T. E.; Konaklieva, M. I.; 
Coates, C.; Shim, J.-Y.; Dickey, S.; Lim, D. V.; Cannons, A. Bioorg. Med. Chem. 
Lett. 2002, 12, 2229-2231.  Coates, C.; Long, T. E.; Turos, E.; Dickey, S.; Lim, D. 
 72
V. Bioorg. Med. Chem. 2003, 11, 193-196.  Turos, E.; Konaklieva, M. I.; Ren, R. 
X.-F.; Shi, H.; Gonzalez, J.; Dickey, S.; Lim, D. V. Tetrahedron, 2000, 56, 5571-
5578.  Ren, X.-F.; Konaklieva, M. I.; Shi, H.; Dickey, S.; Lim, D. V.; Gonzalez, J.; 
Turos, E.J. Org. Chem., 1998, 63, 8898-8917.  Long, T. E.; Turos, E.; Konaklieva, 
M.I.; Blum, A. L.; Amry, A.; Baker, E. A.;  Suwandi, L. S.; McCain, M. D.; 
Rahman, M. F.; Dickey, S.; Lim, D. V. Bioorg. Med. Chem., 2003, 11, in press.  
Long T. E.; Turos, E. Curr. Med. Chem. - Anti-Infect. Agents 2002, 1, 251-268.  
Smith, D. M.; Kazi, A.; Smith, L.; Long, T. E.; Heldreth, B.; Turos, E.; Dou, Q. P. 
Mol. Pharmacol., 2002, 61, 1348-1358. 
14. Brieva, R; Crich, J. Z.; Sih, C. J. J. Org. Chem. 1993, 58, 1068-1075. 
15. Cvetovich, R.J.; Chartrain, M.; Hartner Jr., F.W.H.; Roberge, C.; Amato, J.S.; 
Grabowski, E.J.J. J. Org. Chem. 1996, 61, 6575. 
16. Seki, M.; Furutani, T.; Miyake, T.; Yamanaka, T.; Ohmizu, H.; Tetrahedron Asymm. 
1996, 7, 1241. 
17.  Nagai, H.; Shiozawa, T.; Achiwa, K.; Terao, Y. Chem. Pharm. Bull. Jpn. 1992, 40, 
2227.  
18. Jouglet, B.; Rousseau, G. Tetrahedron Lett. 1993, 34, 2307.  
19. Nagai, H.; Shiozawa, T.; Achiwa, K.; Terao, Y. Chem. Pharm. Bull. Jpn. 1992, 41, 
1933.  
20. Oumoch, S.; Rousseau, G. Bioorg. Med. Chem. Lett. 1994, 4, 2841.  
21. Jones, J. B. Tetrahedron 1986, 42, 3351. 
22. Forro, E.; Fulop, F. Tetrahedron Asymm. 2001, 12, 2351. 
 73
23. Adam, W.; Groer, P.; Humpf, H.U.; Saha-Moller, C. R. J. Org. Chem. 2000, 65, 
4919.   
24. Evans, C.; McCaugue, R.; Roberts, S. M.; Sutherland, A. G.; Wisdom, R. J. Chem. 
Soc., Perkin Trans. 1 1991, 2276. 
25. Brown, S.; Jordon, A.M.; Lawrence, N.J.; Pritchard, R. C.; McGown, A. T. 
Tetrahedron Lett. 1998, 39, 3559. 
26. Manhas, M.S.; Bose, A.K. Synthesis of Penicillin and Cephalosporin C and Analogs; 
Marcel Dekker: New York, 1969; pp 13. 
27. Mukerjee, A.K.; Singh, A.K. Tetrahedron 1978, 34, 1731. 
28. Greenberg, A.; Breneman, C.M.; Liebman, J.F. β-Lactams: Cyclic Amides of 
Distinction, Eds.; Wiley: New York, 2000; pp 157.  
29. George, G.L.; Ravikumar, V.T. The Organic Chemistry of β-Lactams, Eds.; VCH: 
New York, 1993; pp 295. 
30. Morin, R.B.; Gorman, M. Chemistry and Biology of β-Lactam Antibiotics, Eds.; 
Academics: New York, 1982; Vol. 1-3. 
31. McDonough, M.A.; Lee, W.; Silvaggi1, N.R.; Kotra, L.P.; Li, Z-H.; Takeda, Y.; 
Mobashery, S.O.; Kelly, J.A. NSLS Activity Report 2001, 2, 38. 
32. Burnett, D.A. Tetrahedron Lett. 1994, 35, 7339. 
33. Zarks, A.; Chackalamamil, S.; Dugar, S. J. Org. Chem. 1996, 61, 8341. 
34. Annunziata, R.; Bengalia, M.; Cinquini, M.; Cozzi, F. Tetrahedron Asymm. 1999, 10, 
4841. 
35. Vacarro, W.D.; Davis, H.R. Bioorg. Med. Chem. Lett. 1998, 8, 313. 
36. Vacarro, W.D.; Sher, R.; Davis, H.R. Bioorg. Med. Chem. Lett. 1998, 8, 35. 
 74
37. Brothwick, A.D.; Weingarte, G.; Haley, T.M.; Tomaszewski, M.; Wang, W.; Hu, Z.; 
Bedard, J.; Jin, H.; Yuen, L.; Mansour, T.S. Bioorg. Med. Chem. Lett. 1998, 8, 365. 
38. Staudinger, H. Liebigs Ann. Chem. 1907, 356, 51. 
39. Palomo, C.; Aizpurua, J.M.; Ganboa, I.; Oirabide, M. Euro. J. Org. Chem. 1999, 8, 
3223. 
40. Bose, A.K.; Kapur, J.C.; Sharma, S.D.; Manhas, M.S. Tetrahedron Lett. 1973, 2319. 
41. Bose, A.K.; Manhas, M.S.; Amin, S.G.; Kapur, J.C.; Kreder, J.; Mukkavilli, L.; Ram, 
B.; Vencent, J.E. Tetrahedron Lett. 1979, 2771. 
42. Miyake, M.; Tokutake, N.; Kirisawa, M. Synthesis 1983, 833. 
43. (a) Cossio, F.P.; Lecea, B.; Palomo, C. J. Chem. Soc., Chem. Commun. 1987, 1743; 
(b) Arrieta, A.; Lecea, B.; Cossio, F.P.; Palomo, C. J. Org. Chem. 1988, 53, 3784; (c) 
Manhas, M.S.; Lal, B.; Amin, S.G.; Bose, A.K. Synth. Commun. 1976, 6, 435; (d) 
Shridhar, D.R.; Ram, B.; Narayana, V.L. Synthesis 1982, 63; (e) Cossio, F.P.; 
Ganboa, I.; Garcia, J.M.; Lecea, B.; Palomo, C. Tetrahedron Lett. 1987, 28, 1945. 
44. Georg, G.I.; Mashava, P.M.; Guan, X. Tetrahedron Lett. 1991, 32, 581. 
45. Manhas, M.S.; Bose, A.K.; Khajavi, M.S. Synthesis 1981, 209. 
46. Krishnaswamy, D.; Govande, V.V.; Gumaste, V.K.; Bhawal, B.M.; Deshmukh, 
A.R.A.S. Tetrahedron 2002, 58, 2215. 
47. (a) Rowinsky, E.K.; Casenave, L.A.; Donehower, R.C. J. Natl. Cancer Inst. 1990, 82, 
1247; (b) Nicolaou, K.C.; Guy, R.K.; Pitsinos, E.N.; Wrasildo, W. Angew. Chem., Int. 
Ed. Engl. 1994, 33, 15; (c) Boa, A.N.; Jenkins, P.R.; Lawrence, N.J. Contemporary 
Org. Synth. 1994, 1, 47. 
 75
48. (a) Umezawa, H.; Aoyagi, T.; Suda, H.; Hamada, M.; Takeuchi, T. . J. Antibiot. 1976, 
29, 97; (b) Umezawa, H. Drug Exptl. Clin. Res. 1984, 10, 519; (c) Miura, K.; Sawa, 
T.; Takeuchi, T.; Umezawa, H. J. Antibiot. 1986, 39, 734. 
49. Blomgren, H.; Wasserman, J. Canc. Lett. 1981, 11, 303. 
50. Shinkre, B.A.; Puranik, V.G.; Bhawal, B.M.; Deshmukh, A.R.A.S. Tetrahedron 
Asymm. 2003, 14, 453. 
51. Ojima, I; Habus, I; Zhao, M. J. Org. Chem. 1991, 56, 1681. 
52. Fernandez, R.; Ferrete, A.; Lassaletta, J.M. ; Llera, J.M. ; Martin-Zamora, E. Angew. 
Chem. Int. Ed. 2002, 41, 5. 
53. Georg, G.I.; Cheruvallath, Z.S. J. Med. Chem. 1992, 35, 4230. 
54. Bisht, K.S.; Gross, R.A.; Kaplan, D.L. J. Org. Chem. 1999, 64, 780-789. 
55. Buttero, P.D.; Baldoli, C.; Molteni, G.; Pilati, T. Tetrahedron Asymm. 2000, 11, 
1927-41. 
56. Zuegg, J; Honig, H.; Schrag, J.D.; Cygler, M. J. Mol. Cat. B 1997, 3, 83. 
57. Lang, D.A.; Mannesse, Maurice M.L.M.; De Hass, G.H.; Verheij, H.M.; Dijkstra, 
B.W. Eur. J. Biochem. 1998, 254, 333. 
58. Itoh, T.; Takagi, Y.; Nishiyama, S. J. Org. Chem. 1991, 56, 1521. 
59. Stadler, P.; Kovac, A.; Haalck, L.; Spener, F; Paltauf, F. Eur. J. Biochem. 1995, 227, 
335. 
60. Walsh, O.M.; Meegan M.J.; Prendergast, R.M.; Al-Nakib, T. Eur. J. Med. Chem. 
1996, 31, 989-1000. 
61. Guo, M.; Min, J.; Li, R.; Zhang, L. Gaodeng Xuexiao Huaxue Xuebao 1992, 7, 919-
922. 
 76
62. Mihovilovic, M.D.; Feicht, A.; Kayser, M.M. J. Prak. Chemie 2000, 342(6), 585-590. 
63. Alcaide, B.; Rodriguez-Vicente, A. Tetrahedron Lett. 1998, 39, 6589-6592. 
64. Taylor, G.F.; Thornton, S.S.; Tallent, C.R.; Kepler, J.A. J. Labelled Compd. 
Radiopharm. 1993, 33, 501-515. 
65. Borer, B.C.; Balogh, D.W. Tetrahedron Lett. 1991, 32, 1039-1040. 
66. Joshi, S.N.; Deshmukh, A.R.A.S.; Bhawal, B.M. Tetrahedron Asymm. 2000, 11, 
1477-1485. 
67. Matsui, S.; Hashimoto, Y.; Saigo, K. Synthesis 1998, 8, 1161-1166. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77
Chapter Three 
 
Enzyme-catalyzed Regioselective Transesterification of Peracylated Sophorolipids 
 
 
3.1 General Introduction 
 
Sophorolipids, dimeric sophorose sugars (2'-O-β-D-glucopyranosyl-β-D-
glucopyranose) linked β-glycosidically to a hydroxy-fatty acid, are amphipathic 
biomolecules produced by the yeast Candida bombicola (formerly Torulopsis 
bombicola)1 or Candida apicola2 from simple sugars and lipid substrates. Native 
sophorolipid is a complex mixture of up to 14 different compounds with the 
macrolactone and the sophorose glycoside being the major constituents of such 
mixtures3a-c. The fatty acid portion (17-hydroxyoctadecenoic acid) forms a 1′,4″ 
macrocyclic lactone ring (lactonic SLs) or has a free carboxylic end (acidic SLs) (Figure 
3-1). These molecules, because of their structure, naturally act as biosurfactants (any type 
of compound produced by microorganisms with surface active or emulsifying properties) 
finding applications in the petroleum, pharmaceuticals and food processing industries 
where they can be used to reduce surface tension, stabilize emulsions, and promote 
foaming.4 Compared to their synthetic counterparts, biosurfactants offer some distinct 
advantages: they can be produced from renewable resources or even industrial waste, 
they are biodegradable and nontoxic, they are environmentally friendly and are effective 
under extreme conditions in small quantities and are structurally diverse5a-c. In addition, 
biosurfactants can enhance the emulsification of hydrocarbons and therefore have the 
potential to solubilize hydrocarbon contaminants and increase their availability for 
microbial degradation6a-c.   
 78
There has been considerable interest in the physiological properties of 
sophorolipids, which have shown exciting potential in the treatment of a host of 
disorders. SLs have been reported to have caused differentiation and protein kinase C 
inhibition in the HL60 leukemia cell line.7  Additionally they are useful as 
immunomodulators for Parkinson’s disease, Alzheimer’s disease, psoriasis, AIDS 
treatment, as well as for antiviral immunostimulation.8 Consequently, there has been a 
great deal of interest in the synthesis of novel SL derivatives. To date, however, the 
primary strategy identified for the ‘tailoring’ of SL structure has been during in vivo 
formation by the selective-feeding of lipophilic substrates.  For example, changing the 
co-substrate from sunflower to canola oil resulted in a large increase (50 to 73%) of the 
lactonic portion of SLs.9  Interestingly, using oleic acid (alone or with glucose) increased 
the fraction of non-acetylated 1′,4″ sophorolipid lactone.10 Unsaturated C-18 fatty acids 
such as oleic acid may be incorporated unchanged into sophorose lipids.11   
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Figure 3-1. Classes of Sophorolipid: the 1′, 4″ lactonic sophorolipid (lactonic SLs, 1) and 
the acidic sophorolipid (acidic SLs, 2) where R1 is the acetyl group. 
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A limited number of studies on selective in-vitro enzymatic modifications of the 
natural SLs have been reported. 10,12a-d  Deacetylation of the 6′, 6″-diacetylated lactonic 
SLs has been reported to result in formation of the 6′-hydroxy compound upon incubation 
with the enzymes acetylesterase,10 cutinase,12b or lipases12a (from Candida antarctica-B, 
Candida rugosa, Humicola sp., porcine pancreas, Pseudomonas sp., and Mucor miehei), 
while keeping the lactone ring intact.12c,d Enzymatic conversion of SLs to glucose lipids 
has also been reported using glycosidases, which released one glucose molecule from the 
disaccharide lipid.13 Highly regioselective lipase Novozym-435 (Candida antartica- 
Lipase B)-catalyzed acylations of the C-6′ and C-6″ hydroxyl groups, in the non-lactonic 
SL methyl ester, have also been described for synthesis of well-defined sophorolipid 
analogs.14a,b Such derivatives are essential for evaluation of their bioactivities and for 
preparation of glycolipid-based polymers.14a,b  
Lipase-catalyzed transformations provide a useful mean for the selective 
modification of sophorolipids and its derivatives since the glycosidic bonds between the 
glucose moieties and many acetyl groups may also be targets for hydrolysis under acidic 
or basic hydrolytic conditions. The utility of lipases in catalyzing selective 
transformations in lactonic sophorolipids has been previously demonstrated.12c Lipases, 
in addition to having a large fatty acid binding site are activated at the hydrophobic 
hydrophilic interfaces, which are likely to be present in the sophorolipids solutions.  Our 
interest in lipases arises from their ability to catalyze reactions in non-aqueous solvents 
under relatively mild conditions with high chemo-, regio- and enantio-selectivities, to 
accept a broad spectrum of substrates, and their biocompatibility15a-c. 
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In this thesis, we describe and discuss regioselective transesterifications and 
hydrolysis of peracylated sophorolipid derivatives catalyzed by lipases.  This study is the 
first evaluation of the lipase-catalyzed reactions on the peracylated non-lactonic SL 
derivatives.  Four lipases, namely from Porcine pancreas (PPL, Type II), Candida rugosa 
(AYS, TypeVII), Pseudomonas cepacia (PS-30), and Candida antarctica (Novozym 435, 
carrier fixed lipase fraction B) were used in anhydrous THF or in phosphate buffer (pH = 
7.4, 0.2M).  Literature reports attest to the binding of the lactonic SLs in the lipase 
binding pocket such that the sophorose moiety is accessible to the active site.12b The data 
presented in this thesis suggests that in peracylated sophorolipids the absence of the 1′,4″-
macrolactone ring results in its binding in the lipase active site such that the carboxyl end 
of the octadecenoic acid chain rather than that on the sophorose head group is 
preferentially accessible. 
 
 
3.2 Sophorolipid Biosynthesis 
 Sophorolipids belong to a special class of biosurfactants known as glycolipids, 
low molecular weight compounds containing a mono- or disaccharide unit linked to a 
fatty acid moiety.  Sophorolipids and biosurfactants in general, may either be synthesized 
de novo or may be assembled from substrates and commonly available central 
intermediates. For instance, Daniel et al.16 developed a two-step batch cultivation process 
where they used the yeast C. curvatus in the first and the yeast C. bombicola in the 
second step (Fig. 3-2).  In the first step was a crossflow filtration for removing major 
solid paticles. The second step was a sterile filtration into an autoclave bioreactor. When 
deproteinized whey was used as a substrate C. bombicola was not able to consume 
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lactose directly therefore the first cultivation step of C. curvatus (formerly known as 
Candida Curvata and Apiotrichum Curvatum) was necessary. A low yield (12g/L) of 
sophorolipids production was achieved using the above cultivation process. The same 
authors later described an improved method than that previously described. Another two-
step bioprocess was used but rapeseed oil was continually fed in the second step 
increasing the yield of sophorolipids to an excellent final concentration of 422g/L.12a  
 
Figure 3-2. Flow Chart of the Coupled Process including Filtration. 
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3.3 Chemical Synthesis of Sophorolipid 
 Recently, the first total synthesis of sophorolipid was reported by Fürstner et al. In 
this approach, the 26-membered macrolide that contains the Z-alkene in the lipidic 
moiety spanning the sophorose backbone was created by a intramolecular ring-closure 
metathesis reaction of a diyne catalyzed by Mo[N(t-Bu)(Ar)]3 (where Ar = 3,5-
dimethylphenyl) activated in situ by CH2Cl2, followed by catalytic reduction of the 
resulting cycloalkyne (Scheme 3-1).17 The β-glycosidic linkages were installed by means 
of glucal epoxide method followed by a modified Koenigs-Knorr reaction promoted by 
AgOTf/lutidine. It is of importance to note that the ring-closing alkyne metathesis 
constituted the first application to the carbohydrate series. Compared to the two-step, 
high-yielding biosynthetic method, many steps in this synthetic strategy suffer from low 
to moderate yields resulting in an overall low yield. However, it provides a concise 
preparative method to the parent sophorolactone (Fig. 3-1) in analytically pure samples. 
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Scheme 3-1. Synthesis of Sophorolipid Macrolactone. Legend: (a) Mo[N(t-Bu)(Ar)]3 (Ar 
) 3,5-dimethylphenyl), 5 (10 mol %), CH2Cl2/toluene, 80 °C, 78%; (b) H2 (1 atm), 
Lindlar catalyst (Pd, 5% w/w, on CaCO3 poisoned with Pb), quinoline, CH2Cl2, room 
temperature, quantitative; [c] DDQ, CH2Cl2/MeOH (18/1), room temperature, 8 h, 93% 
(containing only trace impurities; analytically pure sample after preparative HPLC: 64%). 
 
3.4 Lipase-catalyzed Modification of Sophorolipids 
Scheme 3-2 shows how the peracylated sophorolipids were synthesized from the 
corresponding naturally occurring lactonic sophorolipids (1). Methanolysis of the 
sophorolipid macrolactone with freshly prepared 0.022 N sodium methoxide resulted in 
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formation of the sophorolipid methyl ester (SL-Me) (3). Structural assignment of the 
methyl ester (3) was previously described using 1H-NMR, 13C-NMR, 1H-1H COSY and 
1H-13C HETCOR spectral data.14a Since the naturally occurring SLs are a mixture of as 
many as 14 different compounds,10 the use of the methyl ester intermediate provides a 
useful alternative to the otherwise cumbersome purification procedures while preserving 
the structural motif of the natural acidic SLs. The resulting SL-Me ester was acylated 
using acetic and propionic anhydride in dry THF in the presence of dimethylamino 
pyridine (DMAP) as the catalyst to give the peracetylated and perpropionated 
sophorolipid methyl esters 4 and 5, respectively.  The structures of the peracetate and 
perpropionate 4 and 5, respectively, were confirmed from their respective 1H-NMR and 
13C-NMR spectral data.  For example, the proton NMR spectra of 4 showed multiple new 
singlets at ~2.0 ppm which integrated for additional 21 hydrogens compared to 2 
hydrogens of C-2 H signal at 2.3 ppm (Table 2).  The 13C NMR spectrum also showed 
additional resonance signals for the acetoxy carbonyls (-C(O)CH3) between 169.2-170.6 
ppm and the methyl ester carbonyl carbon (C-1) appeared at 174.2 ppm (Table 3-2).  The 
structure of the perpropionate 5 was also established from its NMR spectral data and the 
assignments in the proton NMR were made using 1H-1H COSY correlations (Table 3-3 
and Appendix B).  For example, in the 1H-1H COSY NMR spectrum, the propionyl 
methyl (C(O) CH2CH3) proton resonance signals in 5 at 1.01-1.17 ppm showed cross 
peaks to the methylene protons (C(O) CH2CH3) signals at 2.21-2.39 ppm.  The integral 
ratio of the methyl protons (1.01-1.17 ppm, 21H), in the propionyl group, to the 
resonance signal of the C-9H and 10 H signal (5.35 ppm, 2H) in 5 was used to confirm 
complete acylation of the SL-Me ester.  
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3.4.1  Screening of Lipases   
The screening for lipases that would accept the peracylated SL-Me esters as 
substrates were carried out in a 50 mL round bottom flasks using 1: 1 substrate to lipase 
ratio (w/w). The transesterification reactions were carried out in dry THF in presence of 
1-butanol and 2-methylpropanol for 72 h.  The hydrolysis reactions were evaluated by 
incubating the lipases with the substrates in phosphate buffer (pH = 7.4, 0.2M) for 72 h.  
Since the size of the scissile fatty acid binding pocket in lipases is known to vary 
considerably,18 four lipases were screened, namely, Novozym-435 (immobilized 
preparation from Candida antarctica), PS-30 (from Pseudomonas cepacia), PPL (from 
porcine pancreas) and AYS (from Candida rugosa) exhibited different specificity for the 
SL substrates (Table 3-1).  While no activity was seen for PPL and PS-30 lipases in any 
of the tested reaction media, formation of a single product was observed (different Rf 
values compared to the substrate) within 72 h upon incubation of the peracylated SL-Me 
ester substrates (4 and 5) with the lipase from Candida antarctica (Novozym-435).  The 
lipase AYS did not catalyze transesterifications in THF although was able to catalyze the 
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hydrolysis of 4 and 5 in aqueous phosphate buffer (pH = 7.4, 0.2M).  Interestingly, the 
specificity of the lipases Novozym-435 and lipase AYS was same for the peracetylated 
(4) and perpropionated (5) substrate, i.e., the corresponding products formed had the 
same Rf and same structures, confirmed from their NMR data as discussed in following 
sections.  
 
Table 3-1. Screening of Commercially Available Lipases for Peracylated SL-Me Esters 
Transesterification after 72h Incubation. 
 
Substrate 4 (5)a conversion (%) Media  
         Lipases ? AYS Novozym 
THF/ n-butanol n.r 83 (77)a
THF/ iso-butanol n.r 58 (55) 
Buffer (pH = 7.4, 0.2M) 91 (54) 85 (90) 
 
a The value in parenthesis are conversions for perpropionate 5.  No 
reactions were observed in absence of lipase. 
n.r - no conversion observed.   
 
 
3.4.2  Lipase-catalyzed Regioselective Transesterifications.  
Enzyme catalyzed deacetylation in aqueous buffer of 6′,6″-diacetylated lactonic 
SLs has been reported to give the corresponding 6′-hydroxy lactonic SL.12a  It has been 
proposed, based upon 3D models, that the lactonic SL fit well in the binding pocket of 
several lipases and that while the 6″-OAc is buried inside the macrolactone structure the 
6′-OAc is well accessible to the active site of the lipase.19 The lipase catalyzed 
deacylation reactions, however, have only been reported with lactonic sophorolipids and 
no investigation of the acidic SLs has been reported to date.   
No report on the investigation of the lipase catalyzed transesterification/ 
hydrolysis of peracylated acidic SLs were reported.  Since the only lipase that accepted 
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peracylated SL-Me esters as substrates in transesterification reactions was Novozym-435, 
it was the only lipase used in further studies (Table 3-1).  The transesterifications of the 
peracylated compounds 4 and 5 were conducted using excess 1-butanol and 2-
methylpropanol in dry THF (Scheme 3-3).  The product of the reaction was isolated by 
column chromatography.  Upon comparison of the Rf values of the starting materials with 
the product, which had a higher value, the deacylation of one or more ester groups on the 
sophorose seemed unreasonable.  The deacetylated product should have had Rf value 
lower than the starting material because of the resulting free hydroxyl group(s).  It was 
confirmed from the detailed spectral analysis of the products that alcoholysis failed to 
furnish any free hydroxyls on the sophorose ring. Instead, transesterification took place 
on the methyl ester located at the carboxylic end of the 17-hydroxyoctadecenoic acid 
chain attached to the C-1′ position of the sophorose ring.   
Scheme 3-3. Lipase-catalyzed Hydrolysis and Transesterification Reactions of Peracylated Sophorolipid Methyl Esters.
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3.4.3  NMR spectroscopy.  
Detailed structural analysis of the products isolated from the transesterification reactions 
was undertaken using 1H-, 13C- and 2D- NMR spectral data (Figure 3-3, Tables 3-2 and 
3-3).  The 1H-NMR spectra of the products 6-11 when compared to the respective starting 
compounds 4 and 5, varied little and because of a relatively short width of the spectra (0-
10 ppm) unambiguous assignments were not possible (Tables 2 and 3). For example in 
proton NMR spectrum of product 6, the integral value of the resonance attributed to the 
acetoxy methyl protons (1.98-2.08 ppm, 21H) was unchanged relative to the integral of 
the H-9 and H-10 vinylic protons (5.35 ppm, 2H). Although the sharp singlet for protons 
of the methyl ester between 3-5 ppm was absent in its proton NMR spectrum, structure of 
the product 6 could not be ascertained unambiguously from its 1H-NMR spectrum.   
Bisht et al14a had previously carried out detailed NMR analysis of the SL-methyl 
ester and noted limited utility of the 1H NMR spectra in establishing the structure and 
assignment of various resonances.  It was suggested that the 13C NMR spectrum because 
of its wider spread (0-200 ppm) was better suited for the assignment of individual carbon 
in SLs.14a The 13C-NMR assignments were used to assign resonances in the proton 
spectra, utilizing correlations obtained from a 1H-13C HETCOR spectrum.  In this paper 
we will restrict ourselves to spectral information concerning the identification of the 
position of the various acyl groups.  In particular, we will focus on the position of the 
transesterification reaction in the peracetate 4 upon its incubation with lipase Novozym in 
dry THF containing 1-butanol and extend the argument, in light of data observed, to 
products 7-9.   
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In the 13C-NMR spectrum of the peracetylated sophorolipid methyl ester 4 
(Figure 3-3), the methyl carbon (C(O)OCH3) resonates at 51.4 ppm.  Upon comparing 
the 13C-NMR spectra of 4 and 6, the disappearance of the methyl ester carbon 
(C(O)OCH3) in product 6 and concomitant new resonance signals appearing at 63.8 
(C(O)OCH2-), 30.5 (C(O)OCH2-CH2-), 18.8 (C(O)OCH2-CH2-CH2-) and 13.4 
(C(O)OCH2-CH2-CH2-CH3) ppm suggested formation of the butyl ester upon Novozym-
435 catalyzed transesterification in the presence of 1-butanol.  Importantly, a downfield 
shift was observed for the three methylene group protons in the butyl chain as compared 
to that of 1-butanol further suggesting formation of the butyl ester. The assignments were 
supported by a DEPT-135 and a 1H-13C HETCOR spectra (see supporting information). 
For example in the DEPT-135 spectrum of 6, negative resonance signals at 63.8, 30.5 and 
18.8 ppm and a positive resonance signal at 13.4 ppm were assigned to the methylene and 
the methyl carbons, respectively, of the butyl group.  In the 1H-13C HETCOR spectrum a 
direct correlation was observed between the butyl carbons and corresponding protons 
allowing us to unambiguously assign the resonance signals of the hydrogens for this 
independent spin system (Tables 3-2 and 3-3). The methylene carbon at 63.8 along the f2 
axis of 1H-13C HETCOR spectrum showed correlation with the resonance signals on the 
f1 axis at 4.03-4.10 ppm, which integrated to four hydrogens. The –OCH2- hydrogens in 
the butyl ester were thus assigned to the resonance multiplet at 4.03-4.10 ppm.  
Furthermore, the two different methylene carbons at 30.5 and 18.8 ppm showed 
correlations to the broad singlet (4H) at 1.32 ppm and the methyl carbon at 13.4 ppm to 
the triplet (3H) at 0.92 ppm.  
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Importantly, carbon resonances of the sophorose, the acetates groups, and the fatty acid 
chain were relatively unchanged (Figure 3-3).  It was therefore concluded that 
regioselective transesterification of methyl ester took place and the acetate groups on 
sophorose sugar did not participate in this reaction.  In a separate experiment, when the 
peracetate 4 was incubated with Novozym-435 in dry THF in presence of 2-
methylpropanol under similar transesterification reaction conditions, disappearance of the 
methyl ester at 52.0 ppm was also observed with concomitant resonance signals 
appearing at 70.2 (C(O)OCH2-), 27.5 (C(O)OCH2 CH(CH3)2), and 18.9 
(C(O)OCH2CH(CH3)2) ppm suggesting the formation of the isobutyl ester at the carboxyl 
end of the octadecenoic acid. Again, the carbon resonances of the sophorose moiety and 
the acetate groups were relatively unaffected (Figure 3-3).  It is important to mention that 
all reactions were carried out using 2:1 and 5:1 molar excess of the alcohol to the 
substrate and that the resulting product was the same regardless of the quantity of alcohol 
used. After column chromatographic purification yields were typically above 75%.  
The 13C-NMR spectrum of the perpropionate 5 was more complex because of 
additional resonances arising from the propionate groups.  Assignments shown in Table 3 
were established using DEPT-135, 1H-13C-HETCOR, and 1H-1H-COSY spectra.  The 
transesterification reaction catalyzed by Novozym in the presence of 1-butanol and 2-
methylpropanol resulted in formation of the corresponding butyl (8) and isobutyl (9) 
esters, respectively at the carboxyl end of the octadecenoic acid. To reiterate, carbon 
resonances of the sophorose moiety and propionate groups were unchanged in products 8 
and 9, compared to the starting perpropionate methyl ester, 5.  It was thus established that  
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Figure 3-3.  13C-NMR Spectra of Peracetyl Sophorolipid Methyl Ester and its 
Derivatives. 
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Novozym catalyzed regioselctive transesterification of the methyl ester in the peracetate 
5 and perpropionate 6. 
Hu et al12e have recently reported lipase catalyzed deacetylation of 6′,6″-diacetoxy 
lactonic SL in anhydrous organic solvents suggesting that the lactonic SL fit well in the 
binding pocket of several lipases such that 6′-OAc is well accessible to the active site.  
Therefore, it was somewhat intriguing that the non-lactonic (or acidic) peracylated SLs 
were not deacylated under the reaction condition described in this report.  Bisht et al 14a 
have previously investigated lipase catalyzed acylation of non-lactonic SL-methyl ester 
(3) in anhydrous organic solvents.  In absence of an acylating agent, the authors reported 
formation of a (17-hydroxyoctadec-9-enoic acid)-1′,6″-lactonized sophorolipid. The 
observation made by Bisht et al.14a and those made in this report suggest that presence of 
the macrolactone is necessary for proper placement of the peracylated sophorose moiety 
in the binding pocket of a lipase such that it is accessible to the active site of the lipase 
for deacylation of the sophorose esters in SLs.  Herein, we suggest that the macrolactone 
provides a structural motif to the SLs that allow it to fit in the binding cavity of the lipase 
such that an acylated sophorose moiety is accessible to the active site. In absence of the 
lactonic structural motif, the binding of the SLs in the lipase binding pocket takes place 
such that the carboxyl group of the octadecenoic acid, not the acyl groups on sophorose 
sugar, is preferentially accessible to the active site.   
The formation of 6′-acyloxy-(17-hydroxyoctadec-9-enoic acid)-1′,6″-lactonized 
sophorolipid in two steps, reported by Bisht et al.,14a thus can be rationalized as a two 
step mechanistic process. In the first step, the SL methyl ester binds such that an enzyme 
activated complex (EAC) is formed upon attack of the Ser-105 (in the active triad of the 
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lipase-B from Candida antarctica) on the carbonyl of the methyl ester group in the 17-
hydroxyoctadec-9-enoic acid chain. In absence of another nucleophile (the reaction was 
done under anhydrous solvents) the 6″-hydroxyl of the sophorose attacks the EAC to 
yield a macrolactone. In the second step, the macrolactone reenters the binding pocket 
such that the sophorose unit is now accessible to the active site and the acylation 
proceeds to give the 6′-acyloxy- (17-hydroxyoctadec-9-enoic acid)-1′,6″-lactonized 
sophorolipids in presence of an acylating agent.  If this sequence of events were actually 
what was happening in the lipase active site then the presence of another nucleophile, 
during the first step, would not result in formation of a macrolactone. If the nucleophile 
were an alcohol, a transesterification of the methyl ester and the alcohol would result.   
To explore this hypothesis, we preformed an experiment to investigate formation 
of the (17-hydroxyoctadec-9-enoic acid)-1′,6″-lactonized sophorolipids as described 
previously by Bisht el al.14a but in presence of a nucleophile, i.e., 1-butanol.  The SL-Me 
ester was incubated with Novozym in THF at 40 oC in presence of 3 mole equivalent of 
1-butanol for 72 h (Scheme 3). Progress of the reaction was monitored by thin layer 
chromatography.  The product 12 was characterized from its detailed NMR spectral 
analysis.  The 1H-NMR spectrum of 12, had the methyl ester singlet missing, observed at 
3.64 ppm (3H) in the proton NMR spectrum of 3, with concomitant appearance of a 
triplet at 3.96 ppm (2H), a broad singlet at 1.21 ppm (4H) and another triplet at 0.84 ppm 
(3H) suggesting the formation of the butyl ester. The triplets at 3.96 ppm and 0.84 ppm 
were assigned to the methyleneoxy (–C(O)OCH2) and the methyl (-CH3) groups, 
respectively, and the broad singlet at 1.21 ppm was assigned to the two methylene groups 
(-CH2CH2-) of the butyl ester.  These assignments were supported by the 13C-NMR 
 95
spectrum in which the –OCH3 signal at 52.0 ppm, observed in 3, disappeared with new 
resonance signals appearing at 65.2, 31.8, 20.2 and 14.1 ppm for the butyl carbons.  The 
carbon resonances of the sophorose moiety were unperturbed, i.e., formation of the 
macrolactone was not observed.  The structure of the resulting product (Scheme 3-4) was 
thus determined to be butyl-17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-
cis-9-octadecenoate (12), i.e., butyl ester of sophorolipids. 
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Table 3-2. Assignment of 1H and 13C Signals of Sophorolipid-Me ester (3) and Peracetylated Sophorolipid Derivatives (4, 6, 7, 
and 10). 
 
3 4    6 7 10Position 1H 13C 1H 13C 1H 13C 1H 13C 1H 13C 
1 -      175.9 - 174.2 - 173.7 - 173.8 - 178.8
2 2.31, 2H, t, J = 7.4 
Hz 35.3 
2.30, 2H, t, J = 7.3 
Hz 34.0 2.31, 2H, t, J = 7.4 Hz 34.0 
2.31, 2H, t, J = 7.4 
Hz 34.2 
2.34, 2H, t, J = 7.3 
Hz 33.8 
3, 15 1.60, 4H, bs 25.9, 26.2 1.60, 4H, bs 24.8, 24.9 1.60, 4H, bs 24.7 1.60, 4H, bs 24.9 1.60, 4H, bs 24.6, 24.9 
4-7, 12-14, 
16 1.32, 16H, bs 
30.6-31.7, 
38.2 1.31, 16H, bs 
29.0-29.7, 
36.4 1.32, 16H, bs 
28.9-29.5, 
36.2 1.31, 16H, bs 29.0-29.7, 36.3 1.31, 16H, bs 
28.9-29.7, 
36.3 
8, 11 2.04, 4H, bs 28.6 1.98-2.08, 4H, m 27.1 1.98-2.08, 4H, m 26.9 1.98-2.08, 4H, m 27.0, 27.1 1.98-2.08, 4H, m 27.1 
9, 10 5.35, 2H, bs 130.7, 130.8 5.35, 2H, bs 129.7, 129.8 5.35, 2H, bs 129.5, 129.6 5.35, 2H, bs 129.6, 129.8 5.35, 2H, bs 129.7, 129.9 
17 3.82-3.87, 1H, m 79.4 3.66-3.73, 1H, m 77.5 3.66-3.73, 1H, bs 77.3 3.66-3.73, 4H, m 77.5 3.66-3.73, 4H, m 77.5 
18 1.25, 3H, d, J = 6.1 
Hz 22.4 
1.22, 3H, d, J = 6.1 
Hz 21.1 
1.22, 3H, d, J = 6.1 
Hz 21.0 
1.22, 3H, d, J = 6.2 
Hz 21.1 
1.22, 3H, d, J = 6.1 
Hz 21.1 
1′ 4.45, 1H, d, J = 7.5 
Hz 105.1 
4.49, 1H, d, J = 7.6 
Hz 101.0 
4.49, 1H, d, J = 7.5 
Hz 100.9 
4.49, 1H, d, J = 7.6 
Hz 101.0 
4.49, 1H, d, J = 7.6 
Hz 101.1 
2′ 3.35-3.59, 1H, m 82.3 3.66-3.73, 1H, m 77.8 3.66-3.73, 1H, bs 77.6 3.66-3.73, 4H, m 77.8 3.66-3.73, 4H, m 77.8 
3′ 3.35-3.59, 1H, m 78.7 5.06-5.17, 1H, m 74.5 5.03-5.21, 1H, m 74.4 5.06-5.17, 3H, m 74.5 5.06-5.17, 3H, m 74.5 
4′ 3.20-3.31, 1H, m 71.9 5.06-5.17, 1H, m 67.8 5.03-5.21, 1H, m 67.9 5.06-5.17, 3H, m 68.0 5.06-5.17, 3H, m 68.1 
5′ 3.20-3.31, 1H, m 78.2 3.66-3.73, 1H, m 71.2 3.66-3.73, 1H, bs 71.0 3.66-3.73, 4H, m 71.1 3.66-3.73, 4H, m 71.1 
6′ 3.64, 2H, s 63.5 4.27, 2H, m 62.1 4.22-4.34, 2H, m 61.9 4.27, 2H, m 62.1 4.27, 2H, m 62.1 
1″ 4.64, 1H, d, J = 7.7 
Hz 103.2 
4.75, 1H, d, J = 7.6 
Hz 100.3 
4.74, 1H, d, J = 7.7 
Hz 100.1 
4.75, 1H, d, J = 7.6 
Hz 100.2 4.75, 1H, d 100.3 
2″ 3.20-3.31, 1H, m 76.3 4.91-4.93, 1H, m 71.6 4.87-4.97, 2H, m 71.4 4.91-4.93, 2H, m 71.5 4.91-4.93, 2H, m 71.5 
3″ 3.35-3.59, 1H, m 78.2 5.06-5.17, 1H, m 72.9 5.03-5.21, 1H, m 72.8 5.06-5.17, 3H, m 72.9 5.06-5.17, 3H, m 72.9 
4″ 3.20-3.31, 1H, m 72.2 4.91-4.93, 1H, m 68.7 4.87-4.97, 2H, m 69.2 4.91-4.93, 2H, m 68.7 4.91-4.93, 2H, m 68.7 
5″ 3.64, 1H, s 78.7 3.66-3.73, 1H, m 71.7 3.66-3.73, 1H, bs 71.5 3.66-3.73, 4H, m 71.7 3.66-3.73, 4H, m 71.7 
6″ 3.82-3.87, 2H, m 63.1 4.08, 2H, d, J = 10 Hz 61.8 4.03-4.10, 4H, bm 61.6 
4.08, 2H, d, J = 7.5 
Hz 61.8 4.08, 2H, d 61.8 
-OCH3 3.64, 3H, s 52.00 3.66-3.73, 3H, m 
 
51.4 - - - - - 
-C(O)CH3 -       
         
         
- - 169.2-170.6 - 169.0-170.3 - 169.1-170.5 - 169.3-170.6
-C(O)CH3 - - 1.98-2.08, 21H, m 20.4-20.7 1.98-2.08, 21H, m 20.2-21.0 1.98-2.08, 21H, m 20.3-21.1 1.98-2.08, 21H, m 20.4-20.7 
-OCH2CH2CH2CH3 - - - - 4.03-4.10, 4H, bm 63.8 - - - - 
-OCH2CH2CH2CH3 - - - - 1.32, 2H, bs 30.5 - - - - 
-OCH2CH2CH2CH3 - - - - 1.32, 2H, bs 18.8 - - - - 
-OCH2CH2CH2CH3 - - - - 0.92, 3H, t, J = 6.9 Hz 13.4 - - - -
-OCH2CH(CH3)2 - - - - - - 3.85, 2H, d, J = 6.7 Hz 70.2 - -
-OCH2CH(CH3)2 - - - - - - 1.90-1.95, 1H, m 27.5 - - 
-OCH2CH(CH3)2 - - - - - - 0.93, 6H, d, J = 6.7 Hz 18.9 - - 
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Table 3-3. Assignment of 1H and 13C Signals of Perpropionyl Sophorolipid Derivatives (5, 8, 9, and 11). 
 
5 8   9 11Position 1H 13C 1H 13C 1H 13C 1H 13C 
1 -      174.3 - 173.8 - 173.9 - 179.0
2 2.21-2.39, 2H, bm 34.0 2.21-2.35, 2H, bm 34.2 2.14-2.31, 2H, bm 34.2 2.18-2.36, 2H, bm 33.9 
3, 15 1.60-1.63, 4H, bs 24.9, 25.0 1.58-1.64, 4H, bs 24.8 1.53-1.55, 4H, bs 24.9 1.60-1.63, 4H, bs 24.6, 24.9 
4-7, 12-14, 16 1.30, 16H, bs 29.0-29.7, 36.4 1.31, 16H, bs 29.3-29.6, 36.3 1.24, 16H, bs 29.0-29.7, 36.3 1.31, 16H, bs 
28.9-29.7, 
36.4 
8, 11 2.03, 4H, bs 27.1, 27.2 2.03, 4H, bs 27.1 1.96, 4H, bs 26.9, 27.1 2.03, 4H, bs 27.0, 27.2 
9, 10 5.35, 2H, bs 129.6, 129.9 5.35, 2H, bs 129.5, 129.8 5.28, 2H, bs 127.5-127.8 5.35, 2H, bs 129.6, 129.9 
17 3.65-3.71, 1H, m 77.3 3.67-3.74, 1H, m 77.2 3.60-3.67, 1H, m 77.2 3.67-3.74, 1H, m 77.3 
18 1.16, 3H, d, J = 5.1 
Hz 21.1 
1.21, 3H, d, J = 6.0 
Hz 21.1 
1.14, 3H, d, J = 5.8 
Hz 21.1 1.14, 3H, d, J = 5.1 Hz 21.1 
1′ 4.47, 1H, d, J = 7.5 
Hz 100.3 
4.49, 1H, d, J = 7.4 
Hz 101.0 
4.42, 1H, d, J = 7.0 
Hz 100.2 4.49, 1H, d, J = 7.5 Hz 100.3 
2′ 3.65-3.71, 1H, m 77.8 3.67-3.74, 1H, m 77.7 3.60-3.67, 1H, m 77.8 3.67-3.74, 1H, m 77.8 
3′ 5.11-5.18, 1H, m 74.5 5.08-5.22, 1H, m 74.4 5.02-5.11, 1H, m 74.4 5.08-5.19, 1H, m 74.5 
4′ 4.93-4.95, 1H, m 68.6 4.90-4.94, 2H, m 68.6 4.83-4.91, 1H, m 69.0 4.91-4.98, 1H, m 68.6 
5′ 3.65-3.71, 1H, m 71.9 3.67-3.74, 1H, m 71.8 3.60-3.67, 1H, m 71.8 3.67-3.74, 1H, m 71.9 
6′ 4.27, 2H, m 62.1 4.21-4.33, 2H, m 62.0 4.14-4.21, 2H, m 62.0 4.27, 2H, m 62.1 
1″ 4.74, 1H, d, J = 7.9 
Hz 101.0 
4.72, 1H, d, J = 7.9 
Hz 100.2 
4.66, 1H, d, J = 7.9 
Hz 101.0 4.73, 1H, d, J = 7.9 Hz 101.0 
2″ 4.93-4.95, 1H, m 71.3 4.90-4.94, 1H, m 71.3 4.83-4.91, 1H, m 71.2 4.91-4.98, 1H, m 71.3 
3″ 5.11-5.18, 1H, m 72.8 5.08-5.22, 1H, m 72.7 5.02-5.11, 1H, m 72.7 5.08-5.19, 1H, m 72.8 
4″ 5.11-5.18, 1H, m 68.0 5.08-5.22, 1H, m 67.9 5.02-5.11, 1H, m 67.8 5.08-5.19, 1H, m 67.9 
5″ 3.65-3.71, 1H, m 71.4 3.67-3.74, 1H, m 71.4 3.60-3.67, 1H, m 71.3 3.67-3.74, 1H, m 71.4 
6″ 4.11, 2H, d 61.8 4.08, 4H, d 61.7 4.02, 2H, d 61.7 4.09, 2H, d, J = 12 Hz 61.8 
-OCH3 3.65-3.71, 3H, m 
 
51.4 - - - - - - 
-OC(O)CH2CH3 - 172.7-174.0       
       
       
       
- 172.5-173.4 - 172.5-173.6 - 172.7-174.0
-OC(O)CH2CH3 2.21-2.39, 14H, bm 27.1 2.21-2.35, 14H, bm 27.1 2.14-2.31, 14H, bm 27.1 2.18-2.36, 14H, bm 27.2 
-OC(O)CH2CH3 1.01-1.17, 21H, brm 8.9 1.02-1.17, 21H, bm 8.74 0.97-1.07, 21H, bm 8.8 0.91-1.17, 21H, bm 8.8 
-
OCH2CH2CH2CH3
- - 4.08, 4H, d 63.8 - - - - 
-
OCH2CH2CH2CH3
- - 1.31, 2H, bs 30.5 - - - - 
-
OCH2CH2CH2CH3
- - 1.31, 2H, bs 18.9 - - - - 
-
OCH2CH2CH2CH3
- - 0.94, 3H, t, J = 7.2 Hz 13.5 - - - -
-OCH2CH(CH3)2 - - - - 3.78, 2H, d, J = 6.3 Hz 70.2 - -
-OCH2CH(CH3)2 - - - - 1.86-1.89, 1H, m 27.1 - - 
-OCH2CH(CH3)2 - - - - 0.86,  6H, d, J = 6.4 Hz 18.9 - -
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3.4.4  Lipase-Catalyzed Hydrolysis. 
  Otto et al.12a have described the selective deacetylation of lactonic sophorolipid 
6′, 6″-diacetate using lipase AYS (from Candida rugosa) in a phosphate buffer medium 
(pH = 7.4, 0.2M). The author reported that the 6′,6″-diacetate was converted to the 6′-
hydroxy lactonic sophorolipid.  Choice of a reaction medium in an enzymatic reaction is 
very important because organic solvents may alter enzyme conformation or at worst 
denature the enzyme.16  Hydrolysis of the peracetate 4 and perpropionate 5 was therefore 
investigated upon incubation with the lipases Novozym-435 and AYS in phosphate 
buffer (pH = 7.4, 0.2M) at 25 oC.  
For the current study, the reaction procedure needed to be modified due to poor 
solubilities of the compounds 4 and 5 in buffer.  A common approach for improving the 
biocatalytic reaction rates of water insoluble substrates is the use of cosolvents.15c 
Compounds 4 or 5 was therefore dissolved in minimum amount of acetone prior to their 
addition to the buffer solution followed by addition of the lipase.  The reaction product 
was isolated upon its extraction in ethyl acetate followed by rotoevaporation of the 
solvent.  In separate reactions with compound 4 and 5 only one hydrolysis product in 
each was isolated.  In the 1H-NMR spectra of the compound 10 and 11, isolated from 
reaction of 4 and 5, respectively, the methyl ester resonance between 3.65-3.73 ppm 
disappeared.  The 13C-NMR spectra of 10 and 11 corroborated the hydrolysis of the 
methyl ester. For example, in the 13C-NMR spectrum of the product 10, the resonance for 
O-methyl ester carbon (C(O)OCH3) at 51.4 ppm had disappeared along with an observed 
downfield shift in the carboxylic acid carbonyl carbon to 178.8 ppm (in 4). More 
significantly, the resonances for sophorose carbons and acetate groups remained 
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unchanged confirming that sophorose acetate esters were not hydrolyzed by the lipase 
under reaction conditions described.  Similarly, the 13C- NMR spectrum of the product 11 
(of the perpropionate 5) also had the O-methyl ester carbon (C(O)OCH3) resonance 
missing at 51.4 ppm along with a carboxyl carbonyl carbon signal shifted downfield to 
179 ppm.  The resonances for the sophorose carbons and the perpropionates groups were 
unchanged in the 13C-NMR spectrum of 11 (Scheme 3-3) reaffirming that deacylation of 
the propionate esters was not catalyzed by the lipase.  The NMR results thus established 
that enzymatic hydrolysis of the peracylated SL-Me esters 4 and 5 by Novozym-435 and 
AYS occurred with high chemo and regioselectivity, i.e., only hydrolysis of the methyl 
ester took place while the peracyl esters were left untouched. These observations lend 
additional support to the proposition that the macrolactone ring is necessary for proper 
binding of the SLs in the lipase binding pocket such that the acyl ester on the sophorose 
moiety are accessible to the lipase active site.  
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Scheme 3-4. Formation of the Butyl Ester from Sophorolipid Methyl Ester. 
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3.5 Experimental Section 
Chemicals and enzymes. All reagents were purchased from commercial sources and 
used as received. All solvents were purified and dried prior to use by known literature 
procedures. Prior to their use, the sophorolipids were dried over P2O5 in a vacuum 
desiccator (0.1 mmHg, 12 h, 56oC). Porcine pancreatic lipase (PPL) Type II Crude 
(activity = 61 units/mg protein) and Candida rugosa lipase (AYS) TypeVII (activity = 
4570 u/mg protein) were purchased from the Sigma Chemical Co. The lipase PS-30 from 
Pseudomonas cepacia (20,000 units/g) was obtained from Amano Enzymes Co., Ltd. The 
carrier fixed lipase Novozym 435 (10,000 units/g from Candida antarctica, fraction B) 
was a gift from Novo Nordisk Inc.  
 
Column chromatography. Column chromatographic separations were performed over 
silica gel 60 (Silicycle Inc.). In a typical separation, silica gel was used to pack a glass 
column (5cm x 50cm) in the eluent (ethyl acetate/ hexane mixture). The compounds were 
dissolved in a minimal volume of eluent and loaded onto the top of the silica bed in the 
column. Different fractions were subsequently eluted and monitored by thin-layer 
chromatography (TLC). Fractions containing the purified compounds were pooled 
together, and the solvent was evaporated to give the pure compound.  
 
Nuclear magnetic resonance. 1H-NMR and 13C-NMR spectra were recorded using 
Bruker ARX-250 spectrometer (Appendix B). Chemical shifts in parts per millions are 
reported downfield from 0.00 ppm using deuterated chloroform (unless stated otherwise) 
with trimethylsilane (TMS) as the internal reference. Unambiguous assignments were 
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derived from COSY and HETCOR spectra. The following abbreviations are used to 
present the spectral data: s = singlet, bs = broad singlet, bm = broad multiplet, d = 
doublet, t = triplet. 
Optical rotations were measured with an AutoPol-IV (Rudolph research 
analytical) automatic polarimeter. IR spectra were recorded on a Nicolet Avatar Smart 
Miracle 320 FT-IR spectrometer. High resolution mass analyses (HRESIMS) were 
obtained using a JEOL JMS-600H with Agilent 6890 Series GC System at Florida State 
University (Tallahassee) Mass Spectral Analysis Facilities.  
 
Synthesis of methyl 17-L-([2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-
octadecenoate (SL-Me, 3).14a
In a 100 mL round-bottomed flask equipped with a reflux condenser 10 g of dry crude 
sophorolipid and 10 mL 0.022 N freshly prepared sodium methoxide in methanol were 
added. The reaction assembly was protected from atmospheric moisture by a CaCl2 guard 
tube. The reaction mixture was refluxed for 3 h, cooled to room temperature (25 °C), and 
neutralized using glacial acetic acid. The reaction mixture was concentrated by 
rotoevaporation and poured with stirring onto 100 g of crushed ice that resulted in the 
precipitation of the sophorolipid methyl ester as a white solid. The white precipitate was 
filtered, washed with ice-water, and dried overnight under pressure in a vacuum oven 
(8.77 g, yield = 95.0%).  
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Synthesis of methyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (4). 
In a 50ml round-bottomed flask was added 2g (3.06 mmol) of methyl 17-L-([2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (3) and dissolved in dry 
THF (30ml).  Acetic anhydride 8 mL (0.847 mmol) and 0.15g of dimethylamino pyridine 
(DMAP) was added to the solution and the reaction was allowed to stir at room 
temperature for 6 h while protected from atmospheric moisture by a CaCl2 guard tube. 
The reaction mixture was concentrated by rotoevaporation followed by extraction with 
ethyl acetate and washing with sodium bicarbonate solution. The organic layer was dried 
over anhydrous sodium sulfate and concentrated by rotoevaporation. The viscous liquid 
was then dried overnight in a vacuum desiccator at 40oC to yield the peracetylated 
sophorolipid methyl ester (4) (2.79g, yield = 98%) as a clear viscous liquid, [α]25D =  -
7.3o (CHCl3, c = 0.01); IR υ 2923, 1748, 1430, 1376, 1240, 1037, 888 cm-1. HRESIMS 
m/z: 930.4466 [M + Na]+ (calcd for C45H70O20, 930.4461). 
 
Synthesis of methyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptapropionyloxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (5). 
A procedure similar to the one above for the peracetylated sophorolipid methyl ester (4) 
was used to prepare the perpropionated sophorolipid methyl ester. Sophorolipid methyl 
ester 3 (2.0 g, 3.06 mmol), propionic anhydride (10.0g, 0.0768 mmol) and DMAP (0.15g) 
were dissolved in dry THF (30ml). The reaction mixture was allowed to stir for 6 h at 
room temperature. After usual workup the perpropionated sophorolipid methyl ester (5) 
was isolated as a light amber colored viscous liquid (3.0 g, yield = 97%), [α]25D =  -4.5o 
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(CHCl3, c = 0.01); IR υ 2936, 1740, 1450, 1351, 1165, 1053, 1012, 813 cm-1.  HRESIMS 
m/z: 1028.5571 [M + Na]+ (calcd for C52H84O20, 1028.5556). 
 
Screening of lipases and general procedure of lipase catalyzed transesterification 
reactions.  In a 50ml round-bottomed flask was added the appropriately substituted 
analogue (4 or 5) dissolved in dry THF (30 ml).  To this solution, the appropriate enzyme 
(AYS, Novozym-435, PPL, PS-30) was added followed by addition of n-butanol (or iso-
butanol) and the reaction mixture was stirred at 40oC for 72 h. Novozym-435 was found 
to be the only enzyme that catalyzed the transesterification reaction and was used in 
subsequent reactions. The reaction mixture was then filtered through a bed of celite and 
concentrated by rotoevaporation. The resulting crude product was purified by wet column 
chromatography using an ethyl acetate: hexane mixture as eluent. 
 
Synthesis of n-butyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (6). 
A procedure similar to the one above was used to prepare (6). 0.8g (8.6 mmol) of 4, 0.4g 
of Novozym-435 and 456 µl (4.98 M mol) of 1-butanol was stirred at 40oC for 72 h. The 
reaction was worked up as specified and the resulting crude product was purified by wet 
column chromatography using a 35:65 ethyl acetate: hexane mixture as eluent to afford 6 
(0.159g, yield = 83%) as a light amber viscous liquid, [α]25D =  -5.9o (CHCl3, c = 0.01); 
IR υ 2921, 1749, 1376, 1229, 1045, 903 cm-1. HRESIMS m/z: 972.4937 [M + Na]+ (calcd 
for C48H76O20, 972.4930).  
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Synthesis of n-butyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptapropionyloxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (8). 
A procedure similar to the one above was used to prepare (8). 0.8g (0.79 mmol) of 5, 0.4g 
of Novozym-435 and 456 µl (4.98 M mol) of 1-butanol was stirred at 40oC for 72 h. The 
reaction mixture was worked up as specified and the resulting crude product was purified 
by silica gel column chromatography using a 35:65 ethyl acetate: hexane mixture as 
eluent to afford 8 (0.645g, yield = 77%) as an amber colored viscous liquid, [α]25D =  -
5.2o (CHCl3, c = 0.01); IR υ 2942, 2871, 1739, 1450, 1352, 1169, 1057, 1031, 804 cm-1. 
HRESIMS m/z: 1070.6022 [M + Na]+ (calcd for C55H90O20, 1070.6026). 
 
Synthesis of isobutyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (7). 
A procedure similar to the one above was used to prepare (7). 0.4g (4.3 mmol) of 4, 0.4g 
of Novozym-435, and 456 µl (4.98 M mol) of 2 methylpropanol was stirred at 40oC for 
72 h. The reaction mixture was worked up as specified and the resulting crude product 
was purified by silica gel column chromatography using a 35:65 ethyl acetate: hexane 
mixture as eluent to afford 7 (0.245g, yield = 58%) as a light amber colored viscous 
liquid, [α]25D =  -6.7o (CHCl3, c = 0.01); IR υ 2929, 2840, 1757, 1374, 1227, 1036, 906 
cm-1. HRESIMS m/z: 972.4931 [M + Na]+ (calcd for C48H76O20, 972.4930). 
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Synthesis of isobutyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptapropionyloxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate (9). 
A procedure similar to the one above was used to prepare (9). 0.4g (3.95 mmol) of 5, 0.4g 
of Novozym-435 and 456 µl (4.98 Mmol) of 2-methylpropanol and the reaction was 
stirred at 40oC for 72 h. The reaction mixture was worked up as specified and the 
resulting crude product was purified by silica gel column chromatography using a 35:65 
ethyl acetate: hexane mixture as eluent to afford 9 (0.231g, yield = 55%) as a light amber 
colored viscous liquid, [α]25D =  -4.2o (CHCl3, c = 0.01); IR υ 2929, 1735, 1454, 1347, 
1174, 1049, 1022, 804 cm-1. HRESIMS m/z: 1070.6038 [M + Na]+ (calcd for C55H90O20, 
1070.6026). 
 
General procedure of lipase screening for hydrolysis reactions.  To a 50 mL 
Erlenmeyer flask containing 20 ml phosphate buffer solution (pH = 7.4, 0.2M), the 
appropriately substituted sophorolipid analogue dissolved in 5mL acetone was added.  To 
this solution, lipase (AYS or Novozym-435) was added and the flask was closed with a 
rubber stopper (to prevent evaporation of the co-solvent).  The reaction mixture was 
stirred at room temperature for 72 h.  The reaction mixture was extracted with ethyl 
acetate (3 x 30 mL), and the organic layer was dried over anhydrous sodium sulfate and 
concentrated by rotoevaporation. Purification was achieved using ethyl acetate : hexane 
as the eluent in a silica gel chromatographic column. 
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Synthesis of 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-2′-O-β-D-glucopyranosyl-β-D-
glucopyranosyl]-oxy)-cis-9-octadecenoic acid (10). 
A procedure similar to the one above was utilized in the synthesis of 10. 0.3g (0.32 
mmol) of 4, 0.15g of lipase (AYS or Novozym-435) was added to a phosphate buffer 
solution and stirred at room temperature for 72 h.  Workup was accomplished as directed 
to yield 10 (Novozym-435- 150 mg, yield 85%, [α]25D =  -11.1o (CHCl3, c = 0.01); AYS- 
150 mg, yield 91%) as a clear viscous liquid which was purified using ethyl acetate : 
hexane (50:50) as the chromatographic eluent; IR υ 2925, 2854, 1746, 1366, 1218, 1019 
cm-1. HRESIMS m/z: 916.4308 [M + Na]+ (calcd for C55H90O20, 916.4304). 
 
Synthesis of 2″,3′,3″,4′,4″,6′,6″-heptapropionyloxy-17-L-([2′-O-β-D-glucopyranosyl-
β-D-glucopyranosyl]-oxy)-cis-9-octadecenoic acid (11). 
A procedure similar to that above was used in the synthesis of 11. 0.3g (0.30 mmol) of 5, 
0.15g of lipase (AYS or Novozym-435) was added to phosphate buffer solution and 
stirred at room temperature for 72 h.  Workup was done as directed to yield 11 
(Novozym-435- 150 mg, yield 90%, [α]25D =  -5.0o (CHCl3, c = 0.01); AYS- 150 mg, 
yield 54%) as a light amber viscous liquid which was purified using ethyl acetate : 
hexane (30:70) as the eluent in chromatographic separation; IR υ 2929, 2846, 1754, 1362, 
1164, 1058, 1021 cm-1. HRESIMS m/z: 1014.5399 [M + Na]+ (calcd for C51H82O20, 
1014.5400). 
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Synthesis of butyl 17-L-([2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-
octadecenoate (12). 
In a 50ml round bottomed flask was added 0.1g (0.153 Mmol) of 5 and dissolved in dry 
THF (3 ml).  To this solution, 0.1g of Novozym-435 was added followed by .057g (.077 
mmol) of n-butanol and the reaction was stirred at 40oC for 72 h. The reaction mixture 
was then filtered over a celite bed and concentrated by rotoevaporation. The resulting 
crude product was purified by silica gel column chromatography using a 35:65 ethyl 
acetate: hexane mixture as eluent to afford 12 (0.103g, yield = 95%); IR υ 3328, 3248, 
2921, 2846, 1749, 1258, 1078, 1011, 813 cm-1; HRESIMS m/z: 678.4195 [M + Na]+ 
(calcd for C34H62O13, 678.4190). 1H- NMR (250 MHz, CD3OD) δ 0.84 (3H, t, J = 7.5 Hz, 
-O(CH2)3CH3), 1.21 (16H, brs, H- 4-7,12-14,16), 1.21 (4H, brs, -OCH2(CH2)2CH3), 1.50 
(4H, bs, H-3,15), 1.93 (4H, bs, H-8 and -11), 2.20 (2H, t, J = 7.5 Hz, H-2), 3.16 (4H, m, 
H-2″,-4″,-4′, and -5′), 3.34 (3H, m, H-3″,H-3′,H-2′), 3.54 (2H, m, H-6′), 3.76 (3H, m, H-
6″ and H-17), 3.96 (2H, t, -OCH2(CH2)2CH3), 4.35 (1H, d, J = 7.5 Hz, H-1′), 4.54 (1H, J 
= 7.5 Hz, H1″) and 5.24 (2H, bs, H-9 and -10);  13C-NMR (62.5 MHz): 14.08, 20.18, 
21.93, 24.83, 26.05, 26.22, 28.09, 28.14, 30.13, 30.23, 30.40, 30.75, 30.82, 30.90, 31.81, 
35.07, 37.79, 62.63, 63.01, 65.19, 68.22, 71.35, 71.68, 75.79, 77.67, 78.17, 78.26, 78.90, 
81.75, 102.70, 104.57, 130.75, 130.89, 175.58. 
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CHAPTER FOUR 
An Enantioselective Synthesis of Imperanene via Lipase-Catalyzed Asymmetrization of 
a 1,3-Diol 
 
4.1 General Introduction 
 
Imperanene (1), a phenolic compound of the rare C6-C4-C6 class of natural 
products, has been isolated from Imperata cylindrica1 and shown to possess platelet 
aggregation inhibitory activity2 making it a suitable candidate in the search for platelet 
aggregation inhibitors for the treatment of disease such as stroke. The rhizomes of I. 
cylindrical have been used in Chinese medicine as a diuretic and anti-inflammatory 
agent3-5, but only few studies concerning the chemical constituent of this plant have been 
reported6-9.  
O
HO
O
HO
OH
1  
Figure 4-1. Structure of Imperanene, a novel phenolic compound from I. cyclidrica. 
While the Imperanene was isolated as a single (+) isomer, its absolute 
stereochemistry was not reported. Shattuck et al10 have since established, through 
comparison of optical rotation data, the natural product to be the (S)-enantiomer. 
 
4.2 Synthetic Approaches to the Synthesis of Imperanene 
To date, four different synthetic approaches of imperanene have been reported. 
Shattuck et al10 employed the Ender’s RAMP/SAMP chiral auxiliary method toward the 
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asymmetric synthesis of both enantiomers of imperanene (1) in an eight-step synthesis 
with enantiomeric excesses of 82-90%. The key step of asymmetric induction utilizes 
Ender’s method with (S)-1-amino-2-methoxy-methylpyrrolidine (SAMP) or (R)-1-amino-
2-methoxy-methylpyrrolidine (RAMP), the chiral auxiliaries used for enantiofacial 
selectivities of alkylation with benzyl chloromethyl ether (Scheme 4-1). The chiral 
auxiliaries were made to react with an aldehyde to form a hydrazone capable of being 
alkylated. Benzyl chloromethyl ether, the alkylating agent used in the Ender’s method, 
introduced a one-carbon benzyl-protected alcohol in a single step. Subsequent oxidation 
with ozone, followed by Wittig coupling gave both protected enantiomers of imperanene 
(1), which were then deprotected to give the desired products.  
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Scheme 4-1 Key step in Shattuck’s synthesis of imperanene utilizing Ender’s method. 
Legend: (a) SAMP, 0oC to rt, 20h, 84%; (b) RAMP, 0oC to rt, 20h, 82%; (c) (i) LDA, 
0oC, 5.5h; (ii) benzyl chloromethyl ether, -120oC for 20 min, then rt for 20h (77% for 
pathway (a), 75% for (b)). 
 
  In another reported synthesis, Eklund et al11 used a semisynthetic method for the 
synthesis of the (R)-(–)-enantiomer of imperanene (1) starting from hydroxymatairesinol, 
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a natural lignan from the Norway spruce. The semisynthetic method is very efficient but 
is not amenable to the synthesis of the natural enantiomer or its structural analogs. The 
key step in Eklund’s synthetic pathway was the synthesis of the a carboxylic acid 
intermediate using hydroxymatairesinol as starting material (Scheme 4.2) 
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Scheme 4-2 Key step in Eklund’s synthesis of imperanene using hydromatairesinol. (a) 
NaOH (0.6 M), 80oC, 2.5h. 
 
  
The resulting carboxylic acid was then esterified to yield the methyl ester by 
refluxing in acidified methanol, which was reduced with LiAlH4 to afford (–)-imperanene 
with a high enantiomeric purity (ee ~ 90%) and overall yield of 60%.  
Doyle et al12 reported the synthesis of S-(+)-imperanene by use of regio- and 
enantioselective intramolecular carbon-hydrogen insertion reactions catalyzed by chiral 
dirhodium(II) carboxamidates. The key step in Doyle’s synthetic approach used Rh2(4S-
MPPIM)4 and Rh2(4R-MPPIM)4 to give both enantiomeric forms of the 3-benzyl-δ-
butyrolactone products (Scheme 4.3). Other rhodium catalysts were screened, but only 
the Rh2(MPPIM)4 catalysts led to enantioselection of greater than 20:1. This is due 
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primarily to the increased steric interactions of ligands with the reacting carbine, which 
restricts available conformations and direct product formation. The use of the Rh2(4S-
MPPIM)4 catalyst gave the highest enantiomeric excess of the S-configured lactone 
product (93%).  
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(b)
(c)
Rh2L4, CH2Cl2
N
N COOMe
OPh
O
RhRh
Rh2(4S-MPPIM)4  
Scheme 4-3. Key step in Doyle’s synthesis of imperanene using chiral dirhodium(II) 
carboxamidates. (a) Rh2(4S-MPPIM)4, CH2Cl2, 68%; (b) DIBAL-H, 95%; (c) aryllithium, 
THF, -78oC to r.t., 74%. 
 
 The final reported synthesis of imperanene (1) was reported by Davies et al13 
who established the efficient C-H activation of primary benzylic positions by means of 
rhodium carbenoid induced intermolecular C-H insertion toward the synthesis of (+)-
imperanene and (–)-conidendrin (Scheme 4-4).  
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Scheme 4-4. Key step in Davies’ synthesis of imperanene by intermolecular C-H 
insertion. (a) (i) LAH, -40oC; (ii) TBAF, rt, 87%. 
  
The total synthesis of (+)-imperanene by Davies et al. is summarized in Scheme 
4-4. Rh2(R-DOSP)4-catalyzed decomposition of α-diazo methyl ester in the presence of 
the very electron-rich aromatic at 50°C generates the C–H activation product (S) in 43% 
yield and 91% ee. Lithium aluminum hydride reduction of (S) followed by silyl 
deprotection generates (+)-imperanene in 87% yield. The specific rotation was in 
agreement with the literature value and demonstrated that Rh2(R-DOSP)4 generates the S 
configured C–H insertion product. Interestingly, all synthetic methods described above 
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required the use of a chiral auxiliary or an organometallic catalyst.  The semisynthetic 
method is very efficient but is not amenable to synthesis of the natural enantiomer or its 
structural analogs. 
 
4.3 Synthesis of S and R imperanene by Lipase-catalyzed Asymmetrization 
In our synthesis of imperanene, we envisaged a divergent-convergent synthetic 
strategy to imperanene starting from vanillin, which can be converted to a 1,3-diol (8) 
and the Wittig reagent (6) (Scheme 4-5).  
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Scheme 4-5. Retrosynthetic analysis of Imperanene. 
 
The 1,3-diol is a key intermediate as it is prochiral and can be converted to an 
enantiomerically pure intermediate (B) (Scheme 4-5) in high yield. Thus diverging from 
a commercially inexpensive starting material (vanillin), the two pieces of the carbon 
skeleton of Imperanene would be obtained. (S)-(+)-Imperanene would be readily derived 
through a Wittig coupling reaction of the aldehyde obtained from the S enantiomer of B 
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with the ylide generated from A.  Similarly, the (R)-(–) enantiomer would be derived 
from the R enantiomer of B. The highlight of this strategy is the enantiocontrol exhibited 
by the biocatalyst during enzymatic acetylation of the prochiral 1,3 diol. 
Asymmetrization of prochiral diols make very useful synthetic intermediates since the 
maximum feasible yield upon lipase-catalyzed transformation is not limited to 50%, as 
what happens when resolving racemates.14 
The choice of lipases as biocatalyst for the asymmetrization of the prochiral 1, 3-
diol was based upon their ability to assume a variety of conformations to accommodate 
substrates of varying sizes and complexities, providing one of the most useful and 
versatile biocatalytic methods in asymmetric synthesis and resolution of organic 
substrates with high efficiency and selectivity.15 Furthermore, the lipase used herein was 
recyclable and was reused without significant lost in activity. 
Our strategy for the synthesis of imperanene began with the tosylation of vanillin 
(2) with tosyl chloride affording the tosylated aldehyde (3) in 95% yield (Scheme 4-6). 
The choice of the protecting group turned out to be quite important. Other protecting 
groups such as TBDMS, Bn and PMB were initially utilized, but they proved to be 
liabilities during the course of the subsequent reactions often resulting in low yielding or 
failed reactions. The benzyl group in particular was an excellent protecting group but the 
difficulties of its deprotection in the presence of a carbon-carbon double bond made this 
approach unrealistic in the overall synthetic scheme. Subsequent reduction with sodium 
borohydride yielded the alcohol (4) in 99% yield which was readily brominated using 
phosphorus tribromide to afford the bromide (5) quantitatively.16 It is important to note 
that the first four steps were readily amendable to large scales; high yields were achieved 
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and no purifications by wet column chromatography were required. Purifications were 
easily accomplished by recrystallization. 
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Scheme 4-6.  Synthesis of Wittig Reagent starting from vanillin. Conditions: (i) tosyl 
chloride, K2CO3, acetone, reflux, 24h, 95%; (ii) NaBH4, MeOH, 0oC, 8h, 99%; (iii) PBr3, 
ether, r.t., 3h, 98%; (iv) triphenylphosphine, toluene, reflux, 24h, 97%; (v) 
diethylmalonate, NaH, 0oC, 8h, 88%. 
 
The bromide (5) served as the intermediate for the divergent synthesis of the 
triphenylphosphonium bromide salt (6) (yield = 97%) which was synthesized by 
refluxing 5 with triphenylphosphine in toluene for 24 hours and for the symmetrical 
alkylation of diethylmalonate affording the monoalkylated diethylmalonate (7) (yield = 
 118
88%) which was easily separated from the dialkylated product (5-10% yield) by column 
chromatography. 
Reduction of the alkylated diethylmalonate (7) to the prochiral 1,3-diol (8) was 
accomplished using NaBH :LiCl (4:4) in methanol:ether (1:3) (Scheme 4-7).4 17 The 
resulting diol was then selectively acylated using vinyl acetate as the acylating agent in 
the presence of lipase form Pseudomonas cepacia (Amano lipase PS-30). A systematic 
screening of a number of different lipases available in our laboratories led us to the most 
efficient route through use of the lipase PS-30.  
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Scheme 4-7. Synthesis of R-aldehyde through asymmetrization of a 1,3-diol. (i) NaBH4, 
LiCl, MeOH:ether (1:3), 0oC, 24h, 87%; (ii) vinyl acetate, PS-30, 40oC, 48h, 90%; (iii) 
Dess-Martin periodinane, CH2Cl2, r.t., 6h, 75%. 
 
The reaction gave the R-(+)-monoacetate in good yield18 with high 
enantioselectivity. The enantiopurity of the product acetate was calculated from its H-1
NMR spectra acquired in the presence of (+)-Eu(tfc)3, a chiral shift reagent (Figure 4-2). 
The resonance signal of the methoxy and acetoxy protons in the racemic mixture, singlets 
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in absence of the chiral shift reagent, was split into a set of two signals of equal intensity 
for the two enantiomers in the presence of (+)-Eu(tfc)3.12 The product monoacetate (9) 
obtained by lipase desymmetrization reveals a singlet for both the methoxy and acetoxy 
protons in the presence of (+)-Eu(tfc)3. The enantiomeric excess was determined from the 
1H-NMR spectrum recorded in the presence of the (+)-Eu(tfc)3 using the following 
equation: ee = [(R)-(S)]/[(R)+(S)]x 100%. 
The enantiomerically enriched monoacetate was oxidized to the aldehyde (10) 
which was particularly sensitive to the choice of oxidizing agent used. Oxidation with 
pyridinium chlorochromate (PCC) or with Parikh-Doering reagent (SO3·pyridine) 
proceeded with β-elimination of the β-acetoxy aldehyde to give the α,β-unsaturated 
aldehyde. Dess-Martin periodinane in dry dichloromethane at 0oC gave the maximum 
yield of the desired product will minimal side reaction; however, it important to note that 
if the reaction proceeded for longer than six hours, the yield of the eliminated product 
increased. Due to its instability, the aldehyde was taken directly to the next step without 
further purification. 
The final assembly of R-(–)-imperanene began with the coupling of aldehyde 10 
with Wittig reagent 6 that was synthesized in Scheme 4-6. The trans-pertosylated 
imperanene (11) was the favored diastereomer of the product alkene (yield = 88%, a 9:1 
diastereomeric ratio) (Scheme 4-8).19 The isomers were separated by wet column 
chromatography over silica gel. Global deprotection of the p-tosyl and acetyl protecting 
groups was achieved by refluxing isomer 11 in ethanolic KOH for 3 hr followed by 
chromatographic purification to yield R-(–)-imperanene in 60% yield. The specific  
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Figure 4-2. Determination of enantiomeric excess of R-(+)-monoacetate (9). 
 
 rotation value of the product matched with that of the R-(–)-imperanene reported in the 
literature ([α]25D = -98.2o (c = 0.011 g/ml, CHCl3)).20
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Scheme 4-8. Synthesis of R-(–)-imperanene through the coupling of aldehyde 10 with 
Wittig reagent 6. Conditions: (i) 6, n-butyl lithium, 0oC, 24h, 88%; (ii) KOH, ethanol, 
reflux, 3hr, 60%. 
 
To synthesize the S-(+)-imperanene, inversion of stereochemistry in the 
monoacetate was accomplished after the enantiopure monoacetate (9) was tosylated with 
tosyl chloride in dichloromethane using triethylamine: DMAP to furnish 12 (yield =93%) 
(Scheme 4-9). Deacetylation of 12 using K2CO3 in methanol gave the mono-ol (13) in 
86% yield which was oxidized under conditions previously stated to give the desired 
aldehyde 14. The aldehyde (14) proved to be more stable that it’s acetylated counterpart 
(10). This stability is probably due to steric encumbrance of the β-tosyl group thus 
suppressing elimination of the α-proton.  Similarly, the final assembly of S-(+)-
imperanene began with the coupling of aldehyde 14 with the Wittig reagent 6 to give 15 
(yield = 72%), in a diastereomeric ratio 7:1 in favor of the trans- stereoisomer. Separation 
of diastereomers was accomplished via wet column chromatography and removal of the 
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p-tosyl protecting groups in refluxing ethanolic KOH gave S-(+)-imperanene in 56% 
yield ([α]25D = + 104o (c = 0.01 g/ml, CHCl3)).19  
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Scheme 4-9. Synthesis of S-(+)-imperanene through stereochemical inversion of the 
enantiorich monoaceate (9). Conditions: (i) tosyl chloride, triethylamine, DMAP, dry 
CH2Cl2, 0oC, 93%; (ii) K2CO3, MeOH, 0oC, 87%; (iii) Dess-Martin periodane, CH2Cl2, 
r.t., 6h, 83%; (iv) 6, n-butyllithium, THF, 0oC, 80%; (v) KOH, ethanol, reflux, 3h, 56%. 
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In conclusion, enantioselective syntheses of both S-(+)-and R-(–)-imperanene 
have been demonstrated starting from vanillin with overall yields of 19% and 24%, 
respectively. In the core reaction, PS-30 served as the biocatalyst for asymmetrization of 
the prochiral diol (8) providing the monoacetate (9) in enantiomeric excesses of >97%. 
The specific rotation values are in agreement with reported literature values.20
 
4.4 Stereopreference of the Lipase PS-30. 
Modeling experiments21-23 have indicated that Pseudomonas cepacia has a 
stereochemical preference for the (R)-substrate over the (S)-substrate but its 
stereoselectivity seems to be dependent on the chemical nature and/or physical state of 
the substrate, as has been observed for other lipases.24 The stereochemical outcome from 
the PS-30-catalyzed formation of the monoacetate 9 (Scheme 4-7) does supported the 
stereochemical preference for the R-substrate. The stereopreference of the lipase PS-30 
R-enantiomer was rationalized using a known active site model (Figure 4-3) for the 
lipase as described by Zuegg et al.21 While the hydrogen at the asymmetric center of both 
enantiomers is directed towards the same site (referred to as H-alignment), the medium 
sized group (the acetate function) and the large group (the tosyl function) trade places. 
This allows the medium-sized group to fit into the smaller hydrophobic pocket in the 
favored enantiomer whereas the larger-sized group is made to accommodate the smaller 
hydrophobic pocket in the disfavored enantiomer. 
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Figure 4-3. Schematic Representations of the Orientation of Favored (R) and Disfavored 
(S) Enantiomer in Active Site of the Lipase PS-30. M = medium, L = large. 
 
 
 
 
 
 
 
 
 
 125
4.5 Experimental Section 
Lipases PS-30 and AYS were generous gifts from Amano Enzymes and 
Novozym-435 was donated by Novo Nordisk. 1H-NMR and 13C-NMR spectra were 
recorded on a Bruker 250 MHz spectrometer (Appendix C) in CDCl3 with TMS as the 
standard. Optical rotations were measured with a Rudolph Research Analytical AutoPol 
IV Automatic polarimeter. Thin-Layer chromatography (TLC) was performed on glass 
plates coated with 0.25mm thickness of silica-gel. All solvents were dried and distilled 
prior to use and organic solvent extracts dried over Na2SO4. 
 
4-Formyl-2-methoxyphenyl 4-methylbenzenesulfonate (3). To a solution of vanillin 
(100 g, 657 mmol) dissolved in dry acetone (500 ml) was added anhydrous K2CO3 (182 
g, 1314 mmol) and the mixture allowed stirring for 10 minutes at room temperature. To 
the solution was added tosyl chloride (251 g, 1314 mmol) and the mixture refluxed for 24 
hours. The solution was cooled to room temperature, filtered, and concentrated in vacuo. 
To the resulting solid was added hexane, the solution was warmed, then cooled to room 
temperature. The solid was vacuum-filtered and the solid washed with cold hexane to 
afford an off-white solid (191.5 g, 657.2 mmol, 95%). 1H-NMR (250MHz, CDCl3) δ: 
2.46 (s, 3H, Ph-CH3), 3.63 (s, 3H, -OCH3), 7.28-7.77 (comp, 7H), 9.93 (s, 1H, C(O)H). 
13C-NMR (62.5 MHz, CDCl3) δ: 21.7, 55.7, 110.9, 124.3, 124.5, 128.5, 129.5, 132.7, 
135.6, 142.9, 145.5, 152.5, 190.9. 
 
4-(Hydroxymethyl)-2-methoxyphenyl 4-methylbenzenesulfonate (4). To a solution of 
protected vanillin 3 (75 g, 245 mmol) in dry methanol (250 ml) cooled at 0oC was added 
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sodium borohydride (23 g, 612 mmol) portionwise over a 2 hr period. The reaction was 
brought to room temperature and allowed to stir for a further 12 hours. The mixture was 
concentrated under reduced pressure and to the resulting solid was added ethyl acetate 
(400 ml) followed by a solution of ammonium chloride (200 ml). The solution was 
extracted, the organic layer dried over sodium sulfate and concentrated under reduced 
pressure. Acetone was added to the resulting solid, cooled to 0oC and vacuum-filtered to 
afford a white solid (74.5 g, 245 mmol, 99%), m.p. 84-87oC. 1H-NMR (250MHz, CDCl3) 
δ: 2.44 (s, 3H, Ph-CH3), 3.54 (s, 3H, -OCH3), 4.63 (s, 2H, -CH2OH), 6.81-7.09 (comp, 
3H), 7.28-7.74 (dd, 4H, J = 8.2, 8.2 Hz, -OTs). 13C-NMR (62.5 MHz, CDCl3) δ: 21.6, 
55.4, 64.4, 110.9, 118.5, 123.7, 128.5, 129.3, 133.0, 137.3, 141.2, 145.0, 151.7. 
 
4-(Bromomethyl)-2-methoxyphenyl 4-methylbenzenesulfonate (5). To a solution of 
the alcohol 4 (36 g, 117 mmol) in dry ether (250 ml) was added phosphorus tribromide 
(47 g, 175 mmol) dissolved in dry ether (50 ml) and the reaction allowed to stir at room 
temperature for 45 minutes. The reaction was cooled to 0oC and ice water (approximately 
100ml) was carefully added over a 30 minute period. The mixture was extracted and the 
organic layer dried over sodium sulfate and concentrated under reduced pressure. Hexane 
(100 ml) was added to the resulting solid and vacuum-filtered to afford an off-white solid 
(42.5g, 117 mmol, 98%), m.p. 69-71oC. 1H-NMR (250MHz, CDCl3) δ: 2.45 (s, 3H, Ph-
CH3), 3.57 (s, 3H, -OCH3), 4.42 (s, 2H, -CH2Br), 6.86-7.09 (comp, 3H), 7.27-7.76 (dd, 
4H, J = 8.2, 8.2 Hz, -OTs). 13C-NMR (62.5 MHz, CDCl3) δ: 21.7, 32.7, 55.5, 113.2, 
121.1, 124.0, 128.5, 129.4, 133.0, 137.7, 138.1, 145.1, 151.8. 
 
 127
2-Methoxy-4-(triphenylphosphinomethyl bromide)phenyl 4-methylbenzenesulfonate 
(6). To a solution of the bromide 5 (25 g, 67 mmol) in dry toluene was added freshly 
recrystallized triphenylphosphine (26 g, 101 mmol) and the solution refluxed for 24 
hours. The mixture was cooled to room temperature, filtered under reduced pressure, and 
washed with dry ether to afford a white solid (41.5g, 67.3 mmol, 97%), 235-238oC. 1H- 
NMR (250MHz, DMSO-d6) δ: 2.39 (s, 3H, Ph-CH3), 3.02 (s, 3H, -OCH3), 5.26 (d, 2H, J 
= 15.6 Hz, Ph-CH2), 6.56-6.99 (comp, 3H), 7.39-7.93 (comp, 19H). 13C-NMR (62.5 
MHz, DMSO-d6) δ: 21.2, 28.3, 55.2, 115.9, 116.8, 118.2, 123.2, 123.8, 128.3, 128.6, 
129.7, 130.0, 130.2, 131.6, 134.1, 134.2, 135.2, 137.2, 145.7, 150.8. 
 
Diethyl 2-(3-methoxy-4-(tosyloxy)benzyl)malonate (7). To a solution of distilled 
diethyl malonate (19 g, 121 mmol) in dry THF (150 ml) at 0oC was added sodium 
hydride (2.9 g, 121 mmol) portionwise under a nitrogen atmosphere. The reaction was 
allowed to stir for 20 minutes and a solution of bromide 5 (30 g, 81 mmol) in dry THF 
(100 ml) was added dropwise over a 90 minute period. The solution was warmed to room 
temperature and allowed to stir for a further 12 hours. The solution was concentrated 
under reduced pressure and the viscous liquid taken up in ethyl acetate (400 ml) and 
extracted with aqueous sodium chloride (250 ml). The organic layer was dried over 
sodium sulfate and concentrated. The product was purified by silica gel chromatography 
using a gradient eluent of ethyl acetate: hexane (2:8) followed by ethyl acetate: heaxne 
(3:7) to afford 7 (33g, 81 mmol, 91%) as light yellow viscous oil. 1H-NMR (250MHz, 
CDCl3) δ: 1.21 (t, 6H, J = 7.1 Hz, -OCH2CH3), 2.44 (s, 3H, Ph-CH3), 3.17 (d, 2H, J = 7.8 
Hz, -CH2CH), 3.53 (s, 3H, -OCH3), 3.60 (t, 1H, J = 7.8 Hz, -CH2CH), 4.16 (q, 4H, J = 
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7.1 Hz, -OCH2CH3), 6.69-7.04 (comp, 3H), 7.28-7.74 (dd, 4H, J = 8.2 Hz, OTs). 13C- 
NMR (62.5 MHz, CDCl3) δ: 13.9, 21.6, 34.4, 53.5, 55.4, 61.5, 113.2, 120.8, 123.8, 128.5, 
129.2, 133.1, 137.0, 138.1, 145.0, 151.5, 168.6. 
 
4-(3-Hydroxy-2-(hydroxymethyl)propyl)-2-methoxyphenyl-4-methylbenzene 
sulfonate (8).17 To a solution of 7 (20 g, 44 mmol) in methanol:ether (1:3) cooled at 0oC 
was added lithium chloride (8 g, 178 mmol) and the reaction stirred for an additional 10 
minutes. Sodium borohydride (6.7 g, 178 mmol) was then added portionwise over a 30 
minute period and the reaction warmed to room temperature and allowed to stir for a 
further 8 hours. The solution was concentrated, the residue taken up in ethyl acetate (400 
ml) and extracted with aqueous ammonium chloride solution (150 ml). The organic layer 
was dried over sodium sulfate and the resulting product was purified by silica gel 
chromatography using ethyl acetate as the eluent affording 6 as a colorless viscous liquid. 
1H-NMR (250MHz, CDCl3) δ: 2.20 (m, 1H, -CH2CH), 2.44 (s, 3H, Ph-CH3),  2.54 (d, 
2H, J = 7.6 Hz, -CH2CH), 3.55 (s, 3H, -OCH3), 3.72 (dd, 2H, J = 10 Hz and 3 Hz, -
CH2OH), 3.98 (dd, 2H, J = 10 Hz and 3 Hz, -CH2OH), 6.61-6.68 (comp, 3H), 7.27-7.76 
(dd, 4H, J = 8.2 Hz, OTs). 13C-NMR (62.5 MHz, CDCl3) δ: 14.1, 21.6, 34.0, 37.8, 55.5, 
60.4, 66.6, 112.9, 120.7, 123.9, 128.5, 129.3, 133.1, 136.9, 138.7, 145.0, 151.7. 
 
2-(Hydroxymethyl)-3-(3-methoxy-4-(tosyloxy)phenyl)propyl acetate (9). To a 
solution of 8 (10 g, 27 mmol) in dry THF (30 ml) was added PS-30 (5g) followed by 
vinyl acetate (3.5 g, 41 mmol). The reaction was allowed to stir at 40oC for 48 hours and 
the reaction was filtered under vacuum with subsequent concentration of the filtrate. The 
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product was purified by wet column chromatography using ethyl acetate: hexane (2:1) to 
afford a clear viscous liquid (7.5 g, 27 mmol, 67%). 1H-NMR (250MHz, CDCl3) δ: 1.85 
(m, 1H, -CH2CH), 2.08 (s, 3H, -C(O)CH3), 2.44 (s, 3H, Ph-CH3),  2.54 (dd, 2H, J = 7.6 
Hz and 18.9 Hz, -CH2CH), 3.55 (m, 5H, -OCH3, -OCH2OH), 4.06 (dd, 2H, J = 11.3 Hz 
and 4.8 Hz, -CH2C(O)CH3), 6.65-6.71 (comp, 3H), 7.27-7.76 (dd, 4H, J = 8.2 Hz, OTs). 
13C-NMR (62.5 MHz, CDCl3) δ: 20.6, 21.3, 34.3, 38.7, 55.5, 63.5, 113.1, 120.9, 124.0, 
128.5, 129.3, 133.1, 136.7, 139.2, 145.6, 151.6, 171.0. 
 
2-Formyl-3-(3-methoxy-4-(tosyloxy)phenyl)propyl acetate (10). To a solution of 9 (1 
g, 2.4 mmol) in dry dichloromethane (30 ml) at 0oC was added Dess-Martin periodinane 
(5ml, 15%w/v). The reaction was allowed to stir at 0oC for a further 90 minutes then 
allowed to warm to room temperature and stirred for an additional 2 hours. A solution of 
sodium thiosulfate (15ml) was added and the solution stirred for an additional 15 
minutes, then vacuum-filtered over celite. An additional 30 ml of dichloromethane was 
added and extracted with aqueous sodium chloride (20 ml). The organic layer was dried 
over sodium sulfate, concentrated, and the product (amber liquid, 0.750 g, 2.4 mmol, 
75%) used immediately in the next reaction without further purification. 1H-NMR 
(250MHz, CDCl3) δ: 2.04 (s, 3H, -C(O)CH3), 2.45 (s, 3H, Ph-CH3),  2.77 (dd, 2H, J = 7.8 
Hz and 13.6 Hz, -CH2CH), 2.91 (m, 1H, -CH2CH), 3.53 (s, 3H, -OCH3), 4.2 (dd, 2H, J = 
11.3 Hz and 4.8 Hz, -CH2C(O)CH3), 6.65-6.71 (comp, 3H), 7.27-7.76 (dd, 4H, J = 8.2 
Hz, OTs), 9.66 (s, 1H, -C(O)H). 
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(E)-2-(3-methoxy-4-(tosyloxy)benzyl)-4-(3-methoxy-4-(tosyloxy)phenyl)but-3-enyl 
acetate (11). To a solution of the Wittig reagent (9.7 g, 15 mmol) 6 in dry THF under a 
nitrogen atmosphere at 0oC was added n-butyllithium (0.98 g, 15 mmol). The reaction 
was allowed to stir for an additional 30 minutes and a solution of the aldehyde 9 (2.5g, 
6.2 mmol) in dry THF (10 ml) was added to the sanguineous solution at 0oC. The reaction 
was allowed to warm to room temperature and stirred for an additional 19 hours. The 
solution was then concentrated, and the residue taken up in ethyl acetate (50 ml) and 
extracted with brine (20 ml). Purification over wet silica chromatography using ethyl 
acetate: hexane (2:8) provided compound 11 as a viscous, amber liquid (3.58g, 6.15 
mmol, 88%). 1H-NMR (250MHz, CDCl3) δ: 1.98 (s, 3H, C(O)CH3), 2.43 (s, 6H, Ph-
CH3), 2.61 (m, 3H, Ph-CH2-CH-), 3.37 (s, 3H, -OCH3), 3.44 (s, 3H, -OCH3), 4.01 (m, 
2H, -CH2OAc), 5.84 (dd, 1H, J = 7.9, 15.8 Hz), 6.27 (d, 1H, J = 15.8 Hz), 6.33-7.15 
(comp, 6H), 7.19-7.70 (comp, 8H); 13C-NMR (62.5 MHz, CDCl3) δ: 14.1, 21.6, 37.8, 
43.8, 55.5, 60.5, 66.2, 110.0, 113.3, 118.2, 121.0, 123.5, 124.0, 128.5, 129.3, 130.6, 
131.0, 133.0, 136.3, 136.7, 137.1, 139.2, 145.0, 151.3, 151.6, 170.5. 
 
3-(3-Methoxy-4-(tosyloxy)phenyl)-2-((tosyloxy)methyl)propyl acetate (12). To a 
solution of the monoacetate 9 (2.17 g, 5.31 mmol) in dry dichloromethane (30 ml) was 
added triethyl amine (0.81g, 8 mmol) and DMAP (100mg) at 0oC. Tosyl chloride (1.52 g, 
8.0 mmol) was then added and allowed to stir at r.t. for 8 hours. The solution was then 
concentrated and ethyl ether was added and the solution filtered. The filtrate was 
concentrated under reduced pressure and purified by flash column chromatography using 
EA/hexane (4:6) to afford a viscous colorless liquid (2.79 g, 5.31 mmol, 93%). 1H-NMR 
 131
(250MHz, CDCl3) δ: 1.88 (s, 3H, C(O)CH3), 2.45 (m, 1H, CH), 2.38 (s, 3H, Ph-CH3), 
2.39 (s, 3H, Ph-CH3), 2.54 (d, 2H, J = 7.4 Hz, Ph-CH2), 3.45 (s, 3H, -OCH3), 3.85 (m, 
4H, -CH2OAc, -CH2OTs), 6.50-7.12 (comp, 3H, -Ph), 7.25-7.77 (m, 8H, -OTs); 13C-
NMR (62.5 MHz, CDCl3) δ: 20.6, 21.6, 33.7, 39.3, 55.5, 62.9, 68.5, 113.3, 120.8, 124.0, 
127.8, 128.5, 129.3, 129.9, 132.5, 133.1, 145.0, 151.7, 170.5. 
 
3-(3-Methoxy-4-(tosyloxy)phenyl)-2-(hydroxymethyl)-1-(tosyloxy)propane (13). To a 
solution of the monoacetate 12 (2.5 g, 4.4 mmol) in dry methanol (20 ml) was added 
anhydrous potassium carbonate (1.2 g, 8.8 mmol). The reaction was allowed to stir at 
room temperature for 3 hours upon which it was concentrated and purified by flash 
column chromatography using ethyl acetate: hexane (4:6) affording a viscous colorless 
liquid 13 (2.0 g, 4.4 mmol, 86%). 1H-NMR (250MHz, CDCl3) δ: 1.98 (m, 1H, CH), 2.37 
(s, 6H, Ph-CH3), 2.52 (dd, 2H, J = 6.3, 5.9 Hz, Ph-CH2), 3.44 (s, 3H, -OCH3),  3.47 (m, 
2H, -CH2OH), 3.94 (m, 2H, -CH2OTs), 6.53-6.94 (comp, 3H), 7.19-7.70 (comp, 8H); 
13C-NMR (62.5 MHz, CDCl3) δ: 21.6, 33.4, 42.4, 55.5, 69.2, 113.3, 120.9, 127.8, 128.5, 
129.3, 132.6, 133.2, 136.8, 139.0, 145.0, 151.6.  
 
3-(3-Methoxy-4-(tosyloxy)phenyl)-2-((tosyloxy)methyl)propanal (14). To a solution of 
13 (1.5 g, 2.4 mmol) in dry dichloromethane (30 ml) at 0oC was added Dess-Martin 
periodinane (5 ml, 15%w/v). The reaction was allowed to stir at 0oC for a further 90 
minutes then allowed to warm to room temperature and stirred for an additional 2 hours. 
A solution of sodium thiosulfate (15 ml) was added and the solution stirred for an 
additional 15 minutes, then vacuum-filtered over celite. An additional 30 ml of 
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dichloromethane was added and extracted with aqueous sodium chloride (20 ml). The 
organic layer was dried over sodium sulfate, concentrated, and the product 14 (amber 
liquid, 1.25 g, 2.88 mmol, 83%) used immediately in the next reaction without further 
purification. 1H-NMR (250MHz, CDCl3) δ: 2.45 (s, 6H, Ph-CH3),  2.77 (dd, 2H, J = 7.8 
Hz and 13.6 Hz, -CH2CH), 2.97 (m, 1H, -CH2CH), 3.45 (s, 3H, -OCH3), 4.2 (dd, 2H, J = 
11.3 Hz and 4.8 Hz, -CH2OTs), 6.47-6.91 (comp, 3H), 7.13-8.25 (m, 8H, -OTs), 9.60 (s, 
1H, -C(O)H) 
 
Pertosylated Imperanene (15). To a solution of the Wittig reagent (3.66 g, 5.78 mmol) 6 
in dry THF under a nitrogen atmosphere at 0oC was added n-butyl lithium (0.37 g, 5.8 
mmol). The reaction was allowed to stir for an additional 30 minutes and a solution of the 
aldehyde 14 (1 g, 2 mmol) in dry THF (10 ml) was added to the sanguineous solution at 
0oC. The reaction was allowed to warm to room temperature and stirred for an additional 
19 hours. The solution was then concentrated, and the residue taken up in ethyl acetate 
(50 ml) and extracted with brine (20 ml) to afford  a viscous, amber liquid 15 (1.1 g, 1.93 
mmol, 72%) which was taken onto the next step without further purification. 1H-NMR 
(250MHz, CDCl3) 2.44 (s, 9H, Ph-CH3), 2.54 (m, 3H, Ph-CH2-CH-), 3.35 (s, 3H, -
OCH3), 3.45 (s, 3H, -OCH3), 3.87 (m, 2H, -CH2OTs), 5.84 (dd, 1H, J = 7.9, 15.8 Hz), 
6.27 (d, 1H, J = 15.8 Hz), 6.49-7.01 (comp, 6H), 7.1-7.75 (m, 12H, -OTs); 13C-NMR 
(62.5 MHz, CDCl3) δ: 21.6, 37.2, 43.8, 55.5, 71.5, 110.2, 112.6, 113.5, 118.3, 120.0, 
121.1, 123.8, 124.0, 127.8, 128.5, 129.0, 129.3, 129.9, 131.7, 132.5, 133.1, 136.7, 136.8, 
137.7, 138.5, 145.1, 151.5, 151.7. 
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Imperanene (1). To a solution of 11 or 15 dissolved in ethanol was added aqueous 
potassium hydroxide solution. The mixture was brought to reflux for 3 hours after which 
they were concentrated under vacuum. The viscous liquid was taken up in ethyl acetate 
then extracted with brine. The organic layer was dried over sodium sulfate and 
concentrated. Purification by flash column chromatography using ethyl acetate: hexane 
(15:85) provided the R (60%) and S (56%) isomers, respectively. 1H-NMR (250MHz, 
CDCl3) δ: 2.61 (m, 3H, Ph-CH2-CH-), 3.48 (m, 2H, -CH2OH), 3.74 (s, 3H, -OCH3), 3.80 
(s, 3H, -OCH3), 5.51-5.65 (comp, 2H, Ph-OH), 5.84 (dd, 1H, J = 7.9, 15.8 Hz), 6.27 (d, 
1H, J = 15.8 Hz), 6.59-6.76 (comp, 6H). 13C-NMR (62.5 MHz, CDCl3) δ: 37.6, 47.6, 
55.8, 65.2, 108.2, 111.7, 114.1, 114.4, 119.7, 121.8, 128.3, 129.7, 131.5, 132.1, 143.8, 
145.2, 146.3, 146.6. 
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APPENDIX A 
 
Spectroscopic data for compounds of Chapter 2 
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Figure A-1. 1H and 13C-NMR Spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-
phenylazetidin-2-one. 
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Figure A-2. 1H and 13C-NMR Spectra of 3-Hydroxy-1-(4-methoxyphenyl)-4-
phenylazetidin-2-one. 
 
 
 
 
 138
 
 
 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
N
O
AcO
PMP(2)
 
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
ppm  
 
 
 
 
 
 
Figure A-3. 1H and 13C-NMR Spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-(2-
phenylethyenyl)azetidin-2-one. 
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Figure A-4. 1H and 13C-NMR Spectra of 3-Hydroxy-1-(4-methoxyphenyl)-4-(2-
phenylethyenyl)azetidin-2-one. 
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Figure A-5. 1H-NMR Spectrum of 3-Acetoxy-1-(4-methoxyphenyl)-4-
(phenylethynyl)azetidin-2-one. 
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Figure A-6. 1H and 13C-NMR Spectra of 3-Hydroxy-1-(4-methoxyphenyl)-4-
(phenylethynyl)azetidin-2-one. 
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Figure A-7. 1H and 13C-NMR Spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-thiophen-2-
ylazetidin-2-one. 
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Figure A-8. 1H and 13C-NMR Spectra of 3-Hydroxy-1-(4-methoxyphenyl)-4-thiophen-2-
ylazetidin-2-one. 
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Figure A-9. 1H and 13C-NMR Spectra of 3-Acetoxy-1, 4-bis-(4-methoxyphenyl)azetidin-
2-one. 
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Figure A-10. 1H and 13C-NMR Spectra of 3-Hydroxy-1,4-bis-(4-methoxyphenyl)-
azetidin-2-one. 
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Figure A-11. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(4-methoxycarbonylphenyl)-1-
(4-methoxyphenyl)azetidin-2-one. 
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Figure A-12. 1H and 13C-NMR Spectra of 3-Hydroxy-4-(4-methoxycarbonylphenyl)-1-
(4-methoxyphenyl)azetidin-2-one. 
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Figure A-13. 1H and 13C-NMR Spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-
nitrophenyl)azetidin-2-one. 
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Figure A-14. 1H and 13C-NMR Spectra of Cis-3-Hydroxy-1-(4-methoxyphenyl)-4-(4-
nitrophenyl)azetidin-2-one. 
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Figure A-15. 1H and 13C-NMR Spectra of Trans-3-Hydroxy-1-(4-methoxyphenyl)-4-(4-
nitrophenyl)azetidin-2-one. 
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Figure A-16. 1H and 13C-NMR Spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-(3-
nitrophenyl)azetidin-2-one. 
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Figure A-17. 1H and 13C-NMR Spectra of 3-Hydroxy-1-(4-methoxyphenyl)-4-(3-
nitrophenyl)azetidin-2-one. 
 
 
 
 153
 
 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
N
O
AcO
PMP
CN
(9)
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm  
 
 
 
Figure A-18. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(4-cyanophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-19. 1H and 13C-NMR Spectra of 4-(4-Cyanophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-20. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(4-dimethylaminophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-21. 1H and 13C-NMR Spectra of 3-Hydroxy-4-(4-dimethylaminophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-22. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(3-fluorophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-23. 1H and 13C-NMR Spectra of 4-(3-Fluorophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-24. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(4-fluorophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-25. 1H and 13C-NMR Spectra of 4-(4-Fluorophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-26. 1H-NMR Spectrum of 3-Acetoxy-4-(4-chlorophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-27. 1H and 13C-NMR Spectra of 4-(4-Chlorophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-28. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(3-chlorophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-29. 1H and 13C-NMR Spectra of 4-(3-Chlorophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
 
 
 
 
 165
 
 
 
 
 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
NO
O
O
O
CH3
Cl
(15)
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-30. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(2-chlorophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-31. 1H and 13C-NMR Spectra of 4-(2-Chlorophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-32. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(2,4-dichlorophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-33. 1H and 13C-NMR Spectra of 4-(2,4-Dichlorophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-34. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(2-bromophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-35. 1H and 13C-NMR Spectra of  4-(2-Bromophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-36. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(3-bromophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-37. 1H and 13C-NMR Spectra of 4-(3-Bromophenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-38. 1H and 13C-NMR Spectra of 3-Acetoxy-4-(2-iodophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-39. 1H and 13C-NMR Spectra of 3-Hydroxy-4-(2-iodophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-40. 1H-NMR Spectrum of 3-Acetoxy-4-(4-bromophenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-41. 1H and 13C-NMR Spectra of 3-acetoxy-4-(4-trifluoromethylphenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-42. 1H and 13C-NMR Spectra of 4-(4-trifluoromethylphenyl)-3-hydroxy-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-43. 1H and 13C NMR spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-tert-
butyl phenyl)azetidin-2-one. 
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Figure A-44. 1H and 13C-NMR Spectra of 3-Hydroxy-4-(4-tert-butylphenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure A-45. 1H and 13C NMR spectra of 3-Acetoxy-1-(4-methoxyphenyl)-4-(4-
isopropylphenyl)azetidin-2-one. 
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Figure A-46. 1H and 13C-NMR Spectra of 3-Hydroxy-4-(4-isopropylphenyl)-1-(4-
methoxyphenyl)azetidin-2-one. 
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Figure B-1. 1H and 13C-NMR Spectra of Methyl 17-L-([2′-O-β-D-glucopyranosyl-β-D-
glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-2. 1H and 13C-NMR Spectra of Methyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-
2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-3. HRMS Spectrum of Methyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-2′-O-β-
D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-4. 1H and 13C-NMR Spectra of Methyl 17-L-([2″,3′,3″,4′,4″,6′,6″-
heptapropionyloxy-2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-
octadecenoate. 
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Figure B-5. 1H and 13C-NMR Spectra of n-Butyl 17-L-([2″,3′,3″,4′,4″,6′,6″-
heptaacetoxy-2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-6. HRMS Spectrum of n-Butyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptaacetoxy-2′-O-β-
D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
 
 
 188
 
 
 
 
 
 
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
O
RO
RO
RO
O
OO
RO
RO
RO
O
O
RO
R1
(7)
R = CH3C(O), 
R1 = isobutyl
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
 
 
 
 
 
 
 
Figure B-7. 1H and 13C-NMR Spectra of Isobutyl 17-L-([2″,3′,3″,4′,4″,6′,6″-
heptaacetoxy-2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-8. 1H and 13C-NMR Spectra of Isobutyl 17-L-([2″,3′,3″,4′,4″,6′,6″-
heptaacetoxy-2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-9. 1H and 13C-NMR Spectra of n-Butyl 17-L-([2″,3′,3″,4′,4″,6′,6″-
heptapropionyloxy-2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-
octadecenoate. 
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Figure B-10. HRMS Spectrum of n-Butyl 17-L-([2″,3′,3″,4′,4″,6′,6″-heptapropionyloxy-
2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-11. 1H and 13C-NMR Spectra of Isobutyl 17-L-([2″,3′,3″,4′,4″,6′,6″-
heptapropionyloxy-2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-
octadecenoate. 
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Figure B-12. 1H and 13C-NMR Spectra of 17-L-([2″,3′,3″,4′,4″,6′,6″-Heptaacetoxy-2′-O-
β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoic acid. 
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Figure B-13. HRMS Spectrum of 17-L-([2″,3′,3″,4′,4″,6′,6″-Heptaacetoxy-2′-O-β-D-
glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoic acid. 
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Figure B-14. 1H and 13C-NMR Spectra of 2″,3′,3″,4′,4″,6′,6″-Heptapropionyloxy-17-L-
([2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoic acid. 
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Figure B-15. HRMS Spectrum of 2″,3′,3″,4′,4″,6′,6″-Heptapropionyloxy-17-L-([2′-O-β-
D-glucopyranosyl-β-D-glucopyranosyl]-oxy)-cis-9-octadecenoic acid. 
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Figure B-16. 1H and 13C-NMR Spectra of Butyl 17-L-([2′-O-β-D-glucopyranosyl-β-D-
glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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Figure B-17. HRMS Spectrum of Butyl 17-L-([2′-O-β-D-glucopyranosyl-β-D-
glucopyranosyl]-oxy)-cis-9-octadecenoate. 
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APPENDIX C 
 
Spectroscopic data for compounds of Chapter 4 
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Figure C-1. 1H and 13C-NMR Spectra of 4-Formyl-2-methoxyphenyl 4-
methylbenzenesulfonate. 
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Figure C-2. 1H and 13C-NMR Spectra of 4-(Hydroxymethyl)-2-methoxyphenyl 4-
methylbenzenesulfonate. 
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Figure C-3. 1H and 13C-NMR Spectra of 4-(Bromomethyl)-2-methoxyphenyl 4-
methylbenzenesulfonate. 
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Figure C-4. 1H and 13C-NMR Spectra of 2-Methoxy-4-(triphenylphosphinomethyl 
bromide)phenyl 4-methylbenzenesulfonate. 
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Figure C-5. 1H and 13C-NMR Spectra of Diethyl 2-(3-methoxy-4-
(tosyloxy)benzyl)malonate. 
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Figure C-6. 1H and 13C-NMR Spectra of 4-(3-Hydroxy-2-(hydroxymethyl)propyl)-2-
methoxyphenyl 4-methylbenzenesulfonate. 
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Figure C-7. 1H and 13C-NMR Spectra of 2-(Hydroxymethyl)-3-(3-methoxy-4-
(tosyloxy)phenyl)propyl acetate. 
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Figure C-8. 1H and 13C-NMR Spectra of (E)-2-(3-Methoxy-4-(tosyloxy)benzyl)-4-(3-
methoxy-4-(tosyloxy)phenyl)but-3-enyl acetate. 
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Figure C-9. 1H and 13C-NMR Spectra of 3-(3-Methoxy-4-(tosyloxy)phenyl)-2-
((tosyloxy)methyl)propyl acetate. 
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Figure C-10. 1H and 13C-NMR Spectra of 3-(3-Methoxy-4-(tosyloxy)phenyl)-2-
(hydroxymethyl)-1-(tosyloxy)propane. 
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Figure C-11. 1H Spectrum of 3-(3-Methoxy-4-(tosyloxy)phenyl)-2-
((tosyloxy)methyl)propanal. 
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Figure C-12. 1H Spectrum of Pertosylated Imperanene. 
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Figure C-13. 1H and 13C-NMR Spectra of Imperanene. 
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